中井 正人 (ナカイ マサト)

北海道大学病院 内科助教

研究者基本情報

■ 学位
  • 博士(医学), 北海道大学
■ URL
researchmap URL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究キーワード
  • 肝性腹水
  • 肝性脳症
  • 栄養
  • 門脈圧亢進症
研究分野
  • ライフサイエンス, 消化器内科学
■ 担当教育組織

研究活動情報

■ 論文
  • Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
    Goki Suda; Takuya Sho; Tamami Abe; Masashi Ninomiya; Kei Endo; Yudai Fujiwara; Hiroshi Numao; Go Igarashi; Mio Tsuruoka; Chikara Iino; Kenta Yoshida; Satoshi Sato; Masato Nakai; Masatsugu Ohara; Takashi Kitagataya; Tomohiro Katsumi; Keita Maki; Wataru Sato; Shinichiro Minami; Kazumichi Abe; Masashi Fujita; Yoshiya Yamamoto; Masaru Baba; Takashi Meguro; Takayoshi Oikawa; Nobukazu Tanabe; Yoshiyuki Ueno; Naoya Sakamoto; Hidekatsu Kuroda
    JHEP reports : innovation in hepatology, 101988, 101988, 2026年08月11日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND & AIMS: Atezolizumab plus bevacizumab (Atezo/Bev) is considered standard first-line therapy for unresectable hepatocellular carcinoma (HCC), yet reasons for treatment discontinuation vary, and conventional survival endpoints do not capture the time-varying probability of each cause. This multicentre retrospective study aimed to quantify the cause-specific discontinuation and its predictors. METHODS: We analysed 685 consecutive patients treated with Atezo/Bev (10 excluded). Time to discontinuation was defined from treatment initiation to cessation and right-censored at last follow-up if ongoing. Discontinuation reasons were categorized as progressive disease (PD), adverse event (AE)-driven discontinuation (treatment-related AEs without hepatic decompensation), hepatic dysfunction-driven discontinuation (decompensation irrespective of mechanism), response/strategy change, and other causes. Cumulative incidence functions (CIFs) were estimated, and cause-specific Cox models were fitted with multiple imputation. RESULTS: Discontinuation causes included PD (n=334), AE (n=125), hepatic dysfunction (n=48), response/strategy change (n=44), and other causes (n=35); 99 were censored. One-year CIFs were 0.394, 0.153, 0.056, 0.042, and 0.041, respectively. Baseline AFP predicted PD-driven discontinuation (HR 1.18 per log10[AFP+1]; p=3.95×10-5). AE-driven discontinuation was independently associated with age (HR 1.03/year), ECOG performance status ≥1 (HR 1.82), and ALBI (HR 1.07 per 0.1 increase; p=7.43×10-4). Hepatic dysfunction-driven discontinuation was strongly associated with age (HR 1.07/year; p=4.28×10-4) and ALBI (HR 1.29 per 0.1 increase; p=8.65×10-13). AFP (<400 vs ≥400 ng/mL) × mALBI (1/2a vs 2b/3) defined four strata. Low AFP/poor mALBI showed the highest 1-year toxicity-related discontinuation (CIF 0.339), whereas high AFP/good mALBI showed predominantly PD-driven discontinuation (CIF 0.520). CONCLUSIONS: Four clinically defined risk strata based on AFP and mALBI differentiated distinct patterns of treatment discontinuation, capturing both PD and toxicity-pathways. This framework may support risk-adapted monitoring and early treatment optimisation, but external validation is warranted. IMPACT AND IMPLICATIONS: Atezolizumab plus bevacizumab is a standard first-line regimen for unresectable HCC, yet discontinuation occurs for multiple reasons that are not captured by conventional survival summaries. Analysis of a large multicentre cohort revealed distinct patterns of treatment discontinuation along with clinical predictors. Baseline AFP primarily forecasted PD-driven discontinuation, whereas baseline liver function (ALBI) and older age dominated the risk of AE and hepatic decompensation. An AFP×mALBI matrix separated patients into distinct discontinuation pathways, identifying a low-AFP/poor-mALBI subgroup with high early toxicity-related discontinuation and a high-AFP/preserved-mALBI subgroup with predominantly PD-driven discontinuation. Since this framework has not yet been externally validated, it should be regarded as hypothesis-generating. Nevertheless, it may help clinicians consider risk-adapted monitoring, toxicity preparedness, and supportive care according to the dominant discontinuation risk.
  • Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.
    Akimitsu Meno; Masatsugu Ohara; Goki Suda; Takuya Sho; Osamu Maehara; Naohiro Yasuura; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Shunsuke Ohnishi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    Hepatology international, 2026年07月06日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: /purpose. Although atezolizumab-bevacizumab is approved for unresectable hepatocellular carcinoma (HCC), only a subset of patients attains a durable response (DR). Non-invasive predictors of long-term benefit are lacking. We aimed to assess whether baseline circulating cell-free DNA (cfDNA) quantity combined with cfDNA-derived genetic and methylation profiling could predict prognosis and DR. METHODS: We retrospectively analyzed 55 patients with HCC. Baseline cfDNA was dichotomized at the median to evaluate associations with overall survival (OS) and treatment response (objective response rate [ORR], disease control rate [DCR], and DR). In a discovery cohort (n = 17), targeted mutation and methylation profiling on baseline and progression cfDNA was performed. Candidate CpGs were identified by intersecting baseline differential methylation with longitudinal changes, and top hits were validated in an independent cohort (n = 32). RESULTS: High-cfDNA independently predicted shorter OS (median 13.0 vs. 33.1 months; p = 0.0015) but not ORR, DCR, or DR. Mutation analysis yielded no predictive markers. Integrative methylation profiling identified a locus in CD86 (Chr3:121,795,811) (area under the curve [AUC], 0.903 in discovery); baseline methylation here was associated with DR with an AUC of 0.806 in validation. Patients with high CD86 methylation exhibited higher DR rates and prolonged progression-free survival. Multivariate logistic regression analysis confirmed that high CD86 methylation was independently associated with DR (odds ratio: 6.96, 95% confidence interval: 1.70-28.50; p = 0.0071). CONCLUSIONS: Baseline cfDNA quantity and cfDNA-derived CD86 methylation were associated with clinical outcomes in patients with unresectable HCC treated with atezolizumab-bevacizumab. Prospective validation in larger independent cohorts is warranted before clinical implementation.
  • Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.
    Naohiro Yasuura; Goki Suda; Masatsugu Ohara; Daisuke Yokoyama; Takatsugu Tanaka; Akimitsu Meno; Takuya Sho; Risako Kohya; Ruixin Deng; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Tatsuhiko Kakisaka; Akinobu Taketomi; Naoya Sakamoto
    Journal of gastroenterology, 2026年06月26日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD) are emerging hepatocellular carcinoma (HCC) etiologies. Prior-HBV-infection (pHBV) has been linked to HCC in HBsAg-negative populations, but phenotype-specific effects across steatotic liver disease (SLD) remain unclear. We examined whether pHBV modifies 5-year HCC risk by SLD etiology. METHODS: We analyzed 623 of 1116 patients with hepatic steatosis managed at a single center (2009-2024). pHBV was defined as HBsAg- and HBV DNA-negative status with anti-HBc and/or anti-HBs positivity. The primary endpoint was the 5-year cumulative HCC incidence. Kaplan-Meier, PSM, IPTW, and Cox interaction models were used. RESULTS: pHBV was present in 152 patients (24.4%). Overall, pHBV was not associated with 5-year HCC after PSM (150 pairs; 6.58% vs. 5.60%; log-rank P = 0.701) or IPTW (3.80% vs. 4.27%; HR 0.97, 95% CI 0.37-2.54; P = 0.874). In MASLD/cryptogenic SLD, pHBV was associated with lower HCC incidence (PSM 1.32% vs. 9.53%, P = 0.027; IPTW 0.86% vs. 4.35%, P = 0.048). In ALD/MetALD, pHBV showed a borderline higher incidence (PSM 16.17% vs. 3.45%, P = 0.053; IPTW 12.78% vs. 3.99%, P = 0.073). Interaction analyses supported heterogeneity across etiologies (IPTW HR 12.96, P = 0.024; PSM HR 25.87, P = 0.034, Cox HR 7.83, P = 0.057). CONCLUSIONS: In HBsAg-negative SLD, the association between pHBV and HCC risk appears to differ according to alcohol involvement, with a potentially increased HCC risk in ALD/MetALD and a lower observed HCC incidence in MASLD/cryptogenic disease that requires cautious interpretation.
  • HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.
    Daisuke Yokoyama; Goki Suda; Masatsugu Ohara; Takatsugu Tanaka; Shoichi Kitano; Osamu Maehara; Ruixin Deng; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
    Virology journal, 2026年06月19日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Early decline in HBsAg levels during nucleos(t)ide-analog (NA) therapy predicts subsequent HBsAg loss, but stratification tools are limited. We assessed whether a novel baseline HBV biomarker-the HBsAg glycan-isomer (HBsAgGi)-predicts 12-month HBsAg decline. METHODS: We retrospectively analysed genotype C chronic hepatitis B patients who initiated entecavir, tenofovir-disoproxil-fumarate, or tenofovir-alafenamide and had serum available for HBsAgGi measurement. Early decliners were defined as those with ≥ 0.10 log10 IU/mL HBsAg reduction after 1 year. Baseline clinical and virological parameters were compared between decliners and non-decliners and within HBsAg < 3,000 and ≥ 3,000 IU/mL strata. RESULTS: Of 201 screened individuals, 106 had samples for HBsAgGi testing. In this cohort, HBsAg levels continued to fall annually over 5 years in early decliners, whereas non-decliners showed almost no long-term HBsAg reduction. In univariate analyses, higher baseline HBsAg, HBV DNA, HBeAg-positivity, and HBcrAg were associated with 1-year HBsAg decline, whereas HBsAgGi was not; none remained significant in multivariable models. However, among patients with baseline HBsAg < 3,000 IU/mL, HBsAgGi alone differentiated decliners from non-decliners. After adjustment for baseline HBsAg and HBcrAg, lower HBsAgGi remained independently associated with ≥ 0.10 log10 IU/mL HBsAg decline at 1 year. In patients with baseline HBsAg ≥ 3,000 IU/mL, decliners had higher rates of HBeAg positivity and higher baseline HBsAg and HBcrAg. Traditional HBV markers were tightly correlated, whereas HBsAgGi showed only weak-to-modest correlations. CONCLUSIONS: Baseline HBsAgGi adds prognostic value in patients with low HBsAg, identifying those more likely to achieve on-therapy HBsAg decline and potentially informing selection for intensified or combination HBV therapies.
  • Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.
    Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Daisuke Yokoyama; Shoichi Kitano; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
    Journal of cachexia, sarcopenia and muscle, 17, 3, e70305, 2026年06月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Cachexia and sarcopenia are prevalent, inflammation-linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined. In this study, we evaluated the prevalence, clinical features and prognostic impact of cachexia and sarcopenia-alone and combined-in chronic liver disease. METHODS: We retrospectively screened 776 patients with liver cirrhosis (LC) and/or hepatocellular carcinoma (HCC) at Hokkaido University Hospital (August 2014-May 2025). The inclusion criteria were grip strength, CT-based muscle mass and complete clinical data, yielding 307 patients; 469 did not meet one of the inclusion criteria. Cachexia was determined following the Asian Working Group for Cachexia criteria, and sarcopenia was determined following Japan Society of Hepatology guidelines. Patients were grouped as no cachexia/sarcopenia, cachexia only, sarcopenia only or cachexia+sarcopenia. The outcomes were overall survival, time to liver-related events and time to readmission (Kaplan-Meier and Cox-proportional models). RESULTS: Among 776 patients, 307 were included in the final-analysis. Of 307 patients, 206 (67.1%) were male, the median age was 70 years (range, 19-90 years), 262 patients (85.3%) had LC and 188 patients (61.2%) had HCC. The patients were grouped as no cachexia/sarcopenia (213; 69.4%), cachexia only (54; 17.6%), sarcopenia only (17; 5.5%) and cachexia+sarcopenia (23; 7.5%). The combined group compared with the others had the lowest body mass index, psoas-muscle-index and grip strength (all p < 0.001). Overall survival (OS), liver-related events, LC progression and readmissions were compared between 246 patients with and without cachexia or sarcopenia, after excluding those who visited the hospital on or after July 2023 and had ≤ 3 months of follow-up. OS was shorter in the cachexia only (median 61.8 [95% CI 40.90-not reached (NR)] months, p = 0.046) and cachexia+sarcopenia (median 59.6 [95% CI 14.26-NR] months, p = 0.027) groups than in the no cachexia/sarcopenia group. Multivariable analysis showed that cachexia+sarcopenia (hazard ratio 2.48, p = 0.010), HCC (hazard ratio 3.40, p < 0.001) and diabetes mellitus (hazard ratio 1.80, p = 0.013) independently predicted mortality. The combined group compared with the other groups had a shorter time to liver-related events and readmission. CONCLUSIONS: The coexistence of cachexia and sarcopenia-rather than either alone-can be used as an indicator for identifying patients with chronic liver disease at the highest risk of poor outcomes. Concurrent assessment and early, targeted interventions may improve outcomes in this population.
  • Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.
    Goki Suda; Masatsugu Ohara; Masaru Baba; Yoshiya Yamamoto; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Hidetaka Hosono; Daisuke Yokoyama; Shoichi Kitano; Takatsugu Tanaka; Akimitsu Meno; Naohiro Yasuura; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Osamu Maehara; Shunsuke Ohnishi; Takaaki Izumi; Ren Yamada; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Izumi Tsunematsu; Naoya Sakamoto
    The Journal of infection, 92, 4, 106715, 106715, 2026年04月, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: Our prior interim report remains the only prospective study evaluating tenofovir alafenamide (TAF) for HBV reactivation prevention, with prophylaxis assessed up to 12 months. Herein, we report the final 24-month follow-up results. METHODS: This multicentre prospective-study enrolled HBV carriers who received prophylactic TAF before antineoplastic or immunosuppressive therapy and patients with resolved HBV infection who developed reactivation and received TAF as reactivation-related hepatitis prophylaxis. We examined TAF effectiveness at 12 and 24 months. The primary endpoints were HBV reactivation and reactivation-related hepatitis. RESULTS: Of 191 enrolled patients, 150 and 127 were evaluable at 12 and 24 months, respectively. At 12 months, no HBV reactivation, HBV reactivation-related hepatitis, or therapy interruption occurred. Between months 12-24, four patients discontinued TAF. None of the remaining patients experienced HBV reactivation, HBV reactivation-related-hepatitis, or treatment interruption. Virologic relapse occurred in one of two patients with TAF discontinuation after anticancer/immunosuppressive therapy completion; TAF re-initiation enabled biochemical hepatitis prevention and viral suppression. Neither patient who switched to entecavir experienced reactivation. No patients on high-risk regimens developed reactivation, reactivation-related hepatitis, or treatment interruption. No patient discontinued therapy for TAF-related adverse events. CONCLUSIONS: Over 24 months, TAF demonstrated effectiveness in preventing HBV reactivation and reactivation-related hepatitis.
  • Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC.
    Goki Suda; Masatsugu Ohara; Masato Nakai; Takuya Sho; Naoya Sakamoto
    European journal of cancer (Oxford, England : 1990), 237, 116580, 116580, 2026年03月26日, [国際誌]
    英語
  • Guidance for Liver Rehabilitation in Chronic Liver Disease.
    Shuji Terai; Hiroteru Kamimura; Yoichi Hiasa; Norio Akuta; Toru Ishikawa; Yuichiro Eguchi; Hironao Okubo; Takumi Kawaguchi; Miwa Kawanaka; Tatsuo Kanda; Masaaki Korenaga; Ryotaro Sakamori; Masahito Shimizu; Yoshio Sumida; Ryosuke Tateishi; Atsushi Tanaka; Naoki Tanaka; Yasuo Tanaka; Yuki Tahata; Masato Nakai; Tadashi Namisaki; Takashi Nishimura; Atsushi Hiraoka; Takeshi Matsui; Nami Mori; Akio Moriya; Tetsuo Takehara
    Hepatology research : the official journal of the Japan Society of Hepatology, 56, 3, 279, 291, 2026年03月, [国際誌]
    英語, 研究論文(学術雑誌), In April 2023, the Japan Society of Hepatology published its official guidelines on liver rehabilitation for chronic liver disease. In this article, we summarize the current evidence on the role of liver rehabilitation in slowing the progression of chronic liver disease, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), liver cirrhosis, and hepatocellular carcinoma (HCC). Specifically, we outline the following: (1) the definition of liver rehabilitation and its target population; (2) exercise therapy in liver rehabilitation according to disease state; (3) considerations for patients with complications; (4) nutritional therapy in liver rehabilitation; and (5) potential economic benefits. Liver rehabilitation represents a novel therapeutic approach for patients with chronic liver disease, and this guidance aims to promote high-quality clinical research and strengthen the evidence base for its application.
  • Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.
    Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
    Frontiers in nutrition, 13, 1730695, 1730695, 2026年, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Cachexia is associated with poor prognosis in chronic liver disease (CLD), yet robust predictors remain poorly defined. This study examined clinical factors and serum biomarkers associated with cachexia in patients with CLD. METHODS: We analyzed 356 of 526 patients with CLD who had complete cachexia assessment and available stored serum samples. In a discovery cohort (n = 240; Aug 2014-Jun 2023), serum fibroblast growth factor 21 (FGF21), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured. Multivariable logistic regression and receiver operating characteristic analyses were used to identify independent predictors and optimal cutoff values. Findings were subsequently evaluated in an independent validation cohort (n = 116; Jul 2023-May 2025). RESULTS: Median age was 68 years (range 19-90), 65.8% of participants were male, and 24.6% had cachexia, which independently predicted worse overall survival (hazard ratio 1.64; 95% CI 1.03-2.62; p = 0.038). Patients with cachexia had higher serum FGF21 concentrations than those without cachexia (median, 292 vs. 177 pg./mL; p = 0.002), whereas IL-6 and TNF-α levels did not differ significantly between groups. FGF21 was the only biomarker independently associated with cachexia (odds ratio, 1.71; 95% CI, 1.10-2.66; p = 0.016). Advanced Child-Pugh class and platelet count were identified as additional independent clinical predictors. CONCLUSION: Serum FGF21 independently predicts cachexia in CLD and may facilitate earlier identification of at-risk patients, enabling timely intervention to improve clinical outcomes.
  • Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.
    Masato Nakai; Masatsugu Ohara; Daisuke Yokoyama; Shoichi Kitano; Takatsugu Tanaka; Naohiro Yasuura; Akimitsu Meno; Takashi Kitagataya; Takuya Sho; Goki Suda; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 2025年12月13日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), AIM: In patients with decompensated liver cirrhosis, water retention often leads to complications such as acute kidney injury and poor prognosis. Soluble CD14 (sCD14), a marker of bacterial translocation, may have clinical relevance in this setting. Therefore, we aimed to investigate the prognostic value of sCD14 in patients with decompensated liver cirrhosis and water retention, and to determine its association with diuretic responsiveness, acute kidney injury development, and short-term mortality. METHODS: We retrospectively analyzed 134 patients with decompensated liver cirrhosis and refractory fluid retention treated with tolvaptan. Associations between serum sCD14 levels and diuretic response, acute kidney injury development, and liver-related mortality were evaluated. sCD14 was compared with other bacterial translocation markers (soluble CD163 and mannose receptor) in a subset excluding patients with advanced hepatocellular carcinoma. RESULTS: Lower sCD14 levels were associated with improved short- and long-term diuretic responses and a lower acute kidney injury incidence. Patients with sCD14 ≤ 2340 pg/mL had significantly better liver-related survival than those with higher levels (median survival time: 24.5 vs. 4.8 months, respectively; p < 0.01). In the multivariate analysis, sCD14 > 2340 pg/mL independently predicted liver-related mortality (hazard ratio = 2.71, p < 0.01). Compared with sCD163 and mannose receptor, sCD14 demonstrated superior prognostic value. Concomitant rifaximin use was significantly associated with lower sCD14 levels. CONCLUSIONS: sCD14 is a potential biomarker for predicting prognosis, diuretic response, and acute kidney injury development in patients with decompensated liver cirrhosis and water retention. Its predictive capacity surpasses that of other bacterial translocation markers and may be influenced by administering therapeutic interventions, including rifaximin.
  • Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.
    Goki Suda; Masaru Baba; Yoshiya Yamamoto; Sonoe Yoshida; Tetsuhito Muranaka; Takashi Meguro; Katsumi Terashita; Jun Ito; Tomoe Kobayashi; Takaaki Izumi; Tomofumi Takagi; Shunichi Hosoda; Ren Yamada; Qingjie Fu; Zijian Yang; Daisuke Yokoyama; Takatsugu Tanaka; Akimitsu Meno; Naohiro Yasuura; Takashi Kitagataya; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto
    Scientific reports, 15, 1, 42628, 42628, 2025年11月28日, [国際誌]
    英語, 研究論文(学術雑誌), Simplified ("minimal monitoring") pathways can expand access to direct-acting antivirals (DAAs) by reducing visit burden. In Japan, where hepatitis C virus (HCV) patients are among the oldest worldwide, whether DAA regimens can be delivered safely and effectively with fewer visits remains unclear, and real-world outcomes with sofosbuvir/velpatasvir are scarce. We evaluated effectiveness, safety, and visit frequency in a multicenter cohort. Sixty patients with HCV-infection, with or without compensated liver cirrhosis, received 12 weeks of sofosbuvir/velpatasvir with follow-up to sustained virologic response at 12 weeks post-treatment (SVR12). The visit number was set with no schedule and analyzed post hoc (≤ 3 vs. ≥4 visits). There were 1-8 outpatient visits (median 3). SVR12 was 96.7% by intention-to-treat (ITT; 58/60; 95% CI, 88.6-99.6) and 100% per protocol (57/57; 95% CI, 90.0-100.0). Cure rates were comparable (ITT 95.8-97.2% for ≤ 3 vs. ≥4 visits; p = 1.00; PP 100% in both). Sofosbuvir/velpatasvir was well-tolerated: adverse events were recorded in 10%, none grade ≥ 3, no treatment-related serious events, and no toxicity-related discontinuations. Two patients were lost to follow-up; one who discontinued treatment achieved SVR12. This is the first Japanese real-world evaluation of DAA under simplified monitoring and supports low-burden pathways with high efficacy and safety.
  • Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.
    Takashi Kitagataya; Goki Suda; Takatsugu Tanaka; Shoichi Kitano; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Qingjie Fu; Shunichi Hosoda; Sonoe Yoshida; Osamu Maehara; Shunsuke Ohnishi; Masatsugu Ohara; Masato Nakai; Takuya Sho; Kosuke Nakamura; Suguru Ishizaka; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 55, 10, 1367, 1375, 2025年10月, [国際誌]
    英語, 研究論文(学術雑誌), AIM: Cirrhotic cardiomyopathy (CCM) is a significant complication of liver cirrhosis; however, its prevalence and impact in Asian populations remain unclear. The aim of this study was to assess the prevalence of CCM in Japanese patients with liver cirrhosis and to evaluate its impact on clinical outcomes. METHODS: In this retrospective study, 80 patients with liver cirrhosis confirmed using transient elastography (liver stiffness ≥ 12.5 kPa) were included. Study was performed at Hokkaido University Hospital between January 2014 and April 2024. CCM was diagnosed using the 2019 Cirrhotic Cardiomyopathy Consortium criteria. Subsequently, patient characteristics, survival, and the incidences of decompensation and cardiovascular events were analyzed. RESULTS: The prevalence of CCM was 46.3% (37/80), with 78.4% of patients with CCM showing isolated systolic dysfunction based on global longitudinal strain. Patients with CCM were significantly older, had lower serum ammonia and bilirubin levels, and had higher platelet counts. CCM was associated with a significantly higher incidence of decompensation events (hazard ratio 3.97, 95% confidence interval 1.64-9.61, p = 0.003) and was an independent risk factor for decompensation in the multivariate analysis (hazard ratio 3.24, 95% confidence interval 1.29-8.11, p = 0.012). Patients with and without CCM showed no significant differences in overall survival or cardiovascular events. CONCLUSIONS: CCM is prevalent among Japanese patients with liver cirrhosis and is associated with an increased risk of hepatic decompensation. These findings highlight the importance of cardiac evaluation in patients with cirrhosis and suggest that CCM should be considered in the management of liver cirrhosis to improve patient outcomes.
  • Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.
    Goki Suda; Masaya Sugiyama; Hayato Hikita; Akira Nishio; Tomohide Tatsumi; Tetsuo Takehara; Miyako Murakawa; Mina Nakagawa; Yasuhiro Asahina; Masashi Mizokami; Tatsuhiko Kakisaka; Yuzuru Sakamoto; Akinobu Taketomi; Koji Miyanishi; Yoshiyuki Ueno; Hiroaki Haga; Shinya Maekawa; Nobuyuki Enomoto; Masayuki Kurosaki; Motoyuki Kohjima; Makoto Nakamuta; Yasuhito Tanaka; Yoshiya Yamamoto; Masaru Baba; Hisatoshi Hanamatsu; Jun-Ichi Furukawa; Masatsugu Ohara; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto
    Biomarker research, 13, 1, 113, 113, 2025年09月24日, [国際誌]
    英語, A subset of patients still develops hepatocellular carcinoma (HCC) even after eradication of the hepatitis-C virus (HCV) by anti-HCV treatment. We conducted a genome-wide association study (GWAS) to identify host genetic factors associated with HCC development following HCV eradication in Japan. In this GWAS (n = 517), the discovery cohort included 118 patients without HCC and 67 who developed HCC following HCV eradication with interferon-based therapy. A genome-wide scan for HCC-associated variants was conducted. An independent cohort of 274 patients without HCC and 58 patients with post-eradication HCC was used for replication. The effects of candidate gene variants were assessed clinically and through in vitro cellular assays. The GWAS identified significant variants associated with HCC development following HCV eradication, including rs4778350, located near the long non-coding RNA Prader-Willi non-protein coding RNA 4 (PWRN4) on chromosome 15. In the combined analysis, rs4778350 remained significantly associated with HCC, showing a high odds ratio of 5.86 (95% CI, 3.63-9.44). The frequency of the A allele in rs4778350 differs across ethnic populations. Multivariate analysis revealed that female sex, high platelet count, and higher serum albumin levels were associated with reduced HCC risk, while fibrosis stage F4 and the AA genotype of rs4778350 were linked to increased risk. The AA genotype of rs4778350 enhanced PWRN4 expression, promoting cell proliferation, migration, and invasion. These findings suggest a role for PWRN4 in hepatocarcinogenesis through its association with rs4778350 in patients achieving HCV eradication.
  • Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Masatsugu Ohara; Goki Suda; Risako Kohya; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shinya Maekawa; Nobuyuki Enomoto; Makoto Chuma; Manabu Morimoto; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Atsumasa Komori; Yuki Kugiyama; Masaru Baba; Akihisa Nakamura; Jun Ito; Ren Yamada; Shunichi Hosoda; Yoshiya Yamamoto; Sonoe Yoshida; Takuya Sho; Takashi Sasaki; Tomoka Yoda; Akimitsu Meno; Naohiro Yasuura; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Koji Ogawa; Naoya Sakamoto
    Hepatology international, 19, 6, 1371, 1381, 2025年08月28日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality. Although the atezolizumab/bevacizumab regimen demonstrated impressive efficacy in the IMbrave150 clinical trial, long-term outcomes, particularly 3-year overall survival (OS), remain unestablished because of limited follow-up. Long-term outcomes have been reported for the tremelimumab/durvalumab combination, highlighting the need for comparable data on atezolizumab/bevacizumab. We aimed to elucidate the 3-year OS in patients with unresectable HCC (uHCC) treated with atezolizumab plus bevacizumab. METHODS: This retrospective multicenter study included patients with uHCC who received atezolizumab/bevacizumab. Among the 506 patients treated at the participating institutions, only those who initiated therapy between October 2020 and January 2022 were included. Comprehensive clinical, laboratory, and imaging data were collected, and the patients were followed up until March 2025. RESULTS: A total of 257 patients were analyzed, with a median follow-up of 48.23 months (range, 36.23-53.60 months). The 2- and 3-year OS rates were 39.2% and 25.3%, respectively. Among patients meeting the IMbrave150 criteria, the 3-year OS rate was 31.6%. Multivariate regression analysis identified baseline alpha-fetoprotein level > 116 ng/mL (odds ratio [OR] 0.41; 95% confidence interval [CI] 0.20-0.84; p = 0.015) and modified albumin-bilirubin grade 1-2a (OR 2.50; 95% CI 1.18-5.32; p = 0.017) as significant factors associated with 3-year OS. CONCLUSIONS: In a real-world setting, the 3-year OS for uHCC patients treated with atezolizumab/bevacizumab was 25.3%, rising to 31.6% among those meeting the IMbrave150 criteria. Survival outcomes underscore the clinical value of atezolizumab/bevacizumab in improving long-term prognosis and guiding first-line treatment decisions for patients with unresectable HCC.
  • 慢性肝疾患におけるTPORAの有効性の検討 脾臓体積に注目して
    中井 正人; 横山 大輔; 田中 崇倫; 北野 翔一; 保浦 直弘; 目野 晃光; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉
    日本門脈圧亢進症学会雑誌, 31, 3, 161, 161, (一社)日本門脈圧亢進症学会, 2025年08月
    日本語
  • Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
    Risako Kohya; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Takuya Sho; Makoto Chuma; Atsumasa Komori; Yuki Kugiyama; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Shinya Maekawa; Nobuyuki Enomoto; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    JHEP reports : innovation in hepatology, 7, 5, 101364, 101364, 2025年05月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND & AIMS: Fibroblast growth factor 21 (FGF21) is a crucial regulator of cell metabolism. Tumour-secreted FGF21 has shown immune-checkpoint factor functions, and high FGF21 levels are associated with a poor prognosis for patients. However, its prognostic value and impact on treatment response in patients with hepatocellular carcinoma (HCC) treated with immune-checkpoint inhibitors (ICIs) remain unclear. Thus, this study investigated the potential of high FGF21 levels as a prognostic marker and whether traditional ICI-based therapy can improve the prognosis of patients with high FGF21 levels. METHODS: In this retrospective multicentre study, patients with unresectable HCC who received atezolizumab/bevacizumab in the NORTE study group (n = 117) were classified into high (≥915 pg/ml; n = 29) and non-high (n = 88) FGF21 groups. For validation, we investigated patients treated with atezolizumab/bevacizumab in an independent cohort (n = 285). Overall survival, progression-free survival, and treatment response were compared between patients with and without high baseline FGF21 levels. RESULTS: The median overall survival (p <0.001) and progression-free survival (p = 0.045) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. Independent cohort analysis validated these results. In the overall cohort, the median progression-free survival (5.75 vs. 8.84 months; p = 0.027) and median overall survival (14.13 vs. 22.08 months; p <0.001) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. The durable response (≥6 months) + complete response rate was significantly decreased in the high FGF21 group (p = 0.045). No patient with a high FGF21 level achieved a complete response, whereas this was achieved in 4.1% (13/319) of patients with non-high FGF21 levels. Multivariate Cox regression analysis identified high baseline serum FGF21 as an independent poor prognostic factor for overall survival (hazard ratio 2.20, p <0.001). CONCLUSIONS: Serum FGF21 may be a robust, non-invasive prognostic and treatment response marker for unresectable HCC treated with atezolizumab/bevacizumab. IMPACT AND IMPLICATIONS: FGF21 has been reported to act as a secreted immune-checkpoint factor, and elevated levels of FGF21 are associated with a poor prognosis in patients with HCC. It is not fully understood whether ICIs can overcome the impact of high FGF21 levels on the shortened prognosis of patients with HCC. In this multicentre retrospective study, patients with HCC and high baseline levels of serum FGF21 who received atezolizumab/bevacizumab treatment exhibited a significantly shorter overall survival and shorter progression-free survival. These findings suggest serum FGF21 as a robust prognostic marker and an indicator of treatment response in unresectable HCC treated with ICI-based therapy. These findings could be crucial for the implementation of personalised treatment strategies for unresectable HCC. However, identifying optimal therapeutic options for patients with unresectable HCC and high serum FGF21 levels remains an urgent and critical clinical issue.
  • Relationship between daily physical activity and muscle cramping in elderly liver cirrhosis patients-A multicenter study.
    Atsushi Hiraoka; Tadashi Namisaki; Masato Nakai; Nagisa Hara; Hirokazu Takahashi; Yuichiro Eguchi; Hideko Ohama; Fujimasa Tada; Naoya Sakamoto; Hitoshi Yoshiji
    Internal medicine (Tokyo, Japan), 64, 19, 2817, 2822, 2025年03月29日, [国内誌]
    英語, 研究論文(学術雑誌), Introduction Sarcopenia is a common secondary muscle-related complication observed in patients with chronic liver disease (CLD), along with muscle cramping. The present study aimed to assess the daily activity levels to explore the relationship between the number of steps taken and muscle cramping in patients with cirrhosis (LC) in Japan. Methods Fifty patients were enrolled (male 25, Child-Pugh A, B=42:8). Daily steps were recorded over six months using a pedometer, and seasonal sub-analyses were performed. Sarcopenia was diagnosed in accordance with the guidelines of the Japan Society of Hepatology. Results The median number of steps per day was 3,881, with no significant seasonal differences. Muscle cramping, reduced handgrip strength and sarcopenia were noted in 66.0%, 34.0% and 23.9% of the patients, respectively. However, no significant relationships were found between muscle cramping, handgrip strength, and the average number of steps per day. Although no significant differences in daily steps were noted in the comparisons of patients with varying degrees of hepatic function or the sarcopenia status, those with muscle cramping had a worse modified ALBI grade (≥2b) than those without (42.4% vs. 5.9%, P=0.009). The median average number of steps per day was not significantly different between the patients with and without muscle cramping (3,673 vs. 4,775, P=0.292). Conclusions The present study revealed that the average number of steps per day in LC patients is low. Although no significant relationship between daily activity and muscle cramping was observed, the establishment of appropriate intervention strategies to maintain daily activity and prevent sarcopenia progression is urgently required.
  • 肝内胆管癌との鑑別に難渋し手術加療にて診断が得られた肝偽リンパ腫の1例
    田中 崇倫; 北潟谷 隆; 北野 翔一; 目野 晃光; 保浦 直弘; 佐々木 貴志; 甲谷 理紗子; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 柿坂 達彦; 種井 善一; 田中 伸哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 136回・130回, 65, 65, 日本消化器病学会-北海道支部, 2025年03月
    日本語
  • 肝線維化・肝発癌における基礎と臨床の融合 慢性B型肝炎症例におけるCAMP-BとPAGE-Bによる発癌リスク評価の検討
    大原 正嗣; 須田 剛生; 保浦 直弘; 目野 晃光; 甲谷 理紗子; 佐々木 貴志; 北潟谷 隆; 中井 正人; 荘 拓也; 坂本 直哉
    日本消化器病学会雑誌, 122, 臨増総会, A212, A212, (一財)日本消化器病学会, 2025年03月
    日本語
  • Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
    Hisatoshi Hanamatsu; Goki Suda; Masatsugu Ohara; Koji Ogawa; Nobuharu Tamaki; Hayato Hikita; Hiroaki Haga; Shinya Maekawa; Masaya Sugiyama; Tatsuhiko Kakisaka; Masato Nakai; Takuya Sho; Nobuaki Miura; Masayuki Kurosaki; Yasuhiro Asahina; Akinobu Taketomi; Yoshiyuki Ueno; Tetsuo Takehara; Takashi Nishikaze; Jun-Ichi Furukawa; Naoya Sakamoto
    Journal of gastroenterology, 60, 4, 456, 468, 2025年01月24日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Advanced liver fibrosis in cases of metabolic dysfunction-associated steatotic liver disease (MASLD) leads to cirrhosis and hepatocellular carcinoma. The current gold standard for liver fibrosis is invasive liver biopsy. Therefore, a less invasive biomarker that accurately reflects the stage of liver fibrosis is highly desirable. METHODS: This study enrolled 269 patients with liver biopsy-proven MASLD. Patients were divided into three groups (F0/1 (n = 41/85), F2 (n = 47), and F3/4 (n = 72/24)) according to fibrosis stage. We performed serum N-glycomics and identified glycan biomarker for fibrosis stage. Moreover, we explored the carrier proteins and developed a sandwich ELISA to measure N-glycosylation changes of carrier protein. RESULTS: Comprehensive N-glycomic analysis revealed significant changes in the expression of A2F bisect and its precursors as fibrosis progressed. The sum of neutral N-glycans carrying bisecting GlcNAc and core Fuc (neutral sum) had a better diagnostic performance to evaluate advanced liver fibrosis (AUC = 0.804) than conventional parameters (FIB4 index, aspartate aminotransferase-to-alanine aminotransferase ratio (AAR), and serum level of Mac-2-binding protein glycol isomer (M2BPGi). The combination of the neutral sum and FIB4 index enhanced diagnostic performance (AUC = 0.840). IgM, IgA, and complement C3 were identified as carrier proteins with A2F bisect N-glycan. A sandwich ELISA based on N-glycans carrying bisecting GlcNAc and IgA showed similar diagnostic performance than the neutral sum. CONCLUSIONS: A2F bisect N-glycan and its precursors are promising candidate biomarkers for advanced fibrosis in MASLD patients. Analysis of these glycan alterations on IgA may have the potential to serve as a novel ELISA diagnostic tool for MASLD in routine clinical practice. CLINICAL TRIAL NUMBER: UMIN000030720.
  • Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
    Zijian Yang; Goki Suda; Takuya Sho; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Qingjie Fu; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Tomoe Kobayashi; Minhu Chen; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 55, 3, 433, 443, 2024年11月25日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear. We aimed to clarify these. METHODS: In this multicenter retrospective study, we screened patients with HCC treated with atezolizumab/bevacizumab. The prognostic impact of grade ≥2 proteinuria was examined in patients with proper clinical data and preserved serum for growth factor analysis. For biomarker analysis predicting proteinuria, baseline serum vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D levels were analyzed. RESULTS: This study included 75 patients, and 32 (42.7%) experienced grade ≥2 proteinuria. No significant differences were observed between those with or without proteinuria, except for aspartate transaminase and alanine transaminase levels. Time-dependent Cox proportional hazards analysis revealed that grade ≥2 proteinuria was significantly associated with better prognosis (hazard ratio 0.221; 95% confidence interval 0.082-0.592; p = 0.003). In biomarker analysis, low baseline serum VEGF-C and VEGF-D levels were significantly associated with proteinuria, and multivariate analysis demonstrated that baseline serum VEGF-D level was significantly associated with grade ≥2 proteinuria (hazard ratio 0.101; 95% confidence interval 0.029-0.357; p < 0.001). CONCLUSIONS: Grade ≥2 proteinuria in patients with unresectable HCC treated with atezolizumab/bevacizumab indicates a better prognosis, and baseline serum VEGF-D levels can help predict its occurrence. These findings can help in managing adverse events and prognosis in advanced HCC treated with atezolizumab/bevacizumab.
  • Brief intervention for chronic liver disease patients with alcohol use disorder in a hepatology outpatient unit: Effects and limitations.
    Nagisa Hara; Atsushi Hiraoka; Masato Nakai; Makoto Shiraki; Tadashi Namisaki; Hisamitsu Miyaaki; Takuro Hisanaga; Hirokazu Takahashi; Hideko Ohama; Fujimasa Tada; Naoya Sakamoto; Kazuhiko Nakao; Taro Takami; Yuichiro Eguchi; Hitoshi Yoshiji
    Hepatology research : the official journal of the Japan Society of Hepatology, 54, 11, 1099, 1105, 2024年11月, [国際誌]
    英語, 研究論文(学術雑誌), AIM: It is not uncommon to encounter outpatients in the hepatology department with harmful alcohol habits. When treating such chronic liver disease (CLD) patients, an adequate intervention method for harm reduction of alcohol use, such as brief intervention (BI) or BI and nalmefene, should be considered. This study aimed to elucidate the clinical effectiveness of BI for CLD patients affected by harmful alcohol use. METHODS: From June 2021 to 2023, 123 Japanese CLD outpatients (hepatitis B virus : hepatitis C virus : alcoholic liver disease : others = 32:18:42:31) with an Alcohol Use Disorders Identification Test (AUDIT) score of ≥8 at the initial interview and a repeat interview with AUDIT 9 months later were enrolled. Clinical features related to patient behavior following the initial AUDIT interview were retrospectively evaluated, and compared between patients without and with BI treatment. RESULTS: For the non-BI and BI groups, baseline AUDIT score (median 10 [interquartile range (IQR) 9-13] vs. 12 [IQR 10-17], p = 0.016) and relative change in AUDIT score (median 0 [IQR -3 to 2] vs. -3 [IQR -7 to 0], p < 0.01) showed significant differences, whereas there was no significant difference between the groups for AUDIT score at the time of the second interview (p = 0.156). Following BI, significant improvements were observed for items 1, 2, 3, 4, 5, 8, and 10 of AUDIT (each p < 0.05). CONCLUSION: Patients with an alcohol use disorder as well as those with alcohol dependency who received BI showed a significant decline in AUDIT score, although the score of the follow-up AUDIT indicated continued alcohol use disorder. In addition to BI, medication with nalmefene should be considered, based on individual factors.
  • 切除不能肝細胞癌に対するレンバチニブ治療後のFGF21の変化と食欲不振の関連性について
    甲谷 理紗子; 須田 剛生; 大原 正嗣; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉
    日本消化器病学会雑誌, 121, 臨増大会, A802, A802, (一財)日本消化器病学会, 2024年10月
    日本語
  • Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
    Naohiro Yasuura; Goki Suda; Masatsugu Ohara; Akimitsu Meno; Takuya Sho; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Tomoya Saitou; Masaya Sugiyama; Takasuke Fukuhara; Masaru Baba; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Akinobu Taketomi; Naoya Sakamoto
    Alimentary pharmacology & therapeutics, 60, 10, 1315, 1324, 2024年09月04日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND AND AIMS: The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these patients remain unclear. We aimed to close these gaps. METHODS: We retrospectively screened patients with newly diagnosed non-HBV-related-HCC (standard HBsAg-test negative) at Hokkaido University. Patients with complete clinical information and preserved serum for hHBsAg+ were included. We evaluated the prevalence, characteristics and prognostic impact of pHBV and hHBsAg+ in non-HBV-related-HCC. RESULTS: A total of 401 non-HBV-related-HCC patients were included (288 with pHBV/113 without pHBV). In non-HBV-related-HCC, pHBV did not affect overall survival (OS). Among non-HBV-related-HCC patients with pHBV, 11.8% (34/288) were hHBsAg+ and had more advanced stages of HCC, higher AFP levels, higher vascular invasion rates, and significantly shorter OS than others (OS: 19.3 vs. 61.4 months, p = 0.012). Comparison of OS among non-HBV-related-HCC patients without pHBV (group 1), those with pHBV and without hHBsAg+ (group 2), and those with pHBV and hHBsAg+ (group 3) revealed significantly shorter OS in group 3 (19.3, 56.6 and 66.4 months in groups 1, 2 and 3, respectively; p = 0.036). Multivariate Cox regression indicated that compared with group 1, only group 3 was significantly and independently associated with shorter OS (HR: 2.044, p = 0.011). Subgroup analysis revealed that this association was particularly evident in non-HBV-related-HCC patients with non-B-non-C aetiology and advanced HCC. CONCLUSIONS: In non-HBV-related-HCC patients, hHBsAg+, not pHBV, is significantly and independently associated with poor prognosis.
  • Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
    Takuya Sho; Goki Suda; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Sonoe Yoshida; Shunichi Hosoda; Koji Ogawa; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Masaru Baba; Yoshiya Yamamoto; Yoko Tsukuda; Takashi Meguro; Ren Yamada; Tomoe Kobayashi; Tomofumi Takagi; Naoya Sakamoto
    Targeted oncology, 19, 5, 769, 778, 2024年09月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: While guidelines recommend immune checkpoint inhibitor (ICI) rechallenge as second-line therapy for unresectable hepatocellular carcinoma (HCC), data supporting this remain limited, particularly regarding a standard regimen for first- and second-line treatments. Tremelimumab/durvalumab was recently approved but data on ICI rechallenge are lacking. OBJECTIVES: The purpose of this study was to evaluate the early efficacy and safety of tremelimumab/durvalumab for HCC as an ICI rechallenge following initial ICI therapy with atezolizumab/bevacizumab. PATIENTS AND METHODS: This multicenter retrospective study included patients with HCC who underwent treatment with tremelimumab/durvalumab, with relevant available clinical information. We evaluated the safety and efficacy of tremelimumab/durvalumab as ICI rechallenge following initial treatment with atezolizumab/bevacizumab. We analyzed the outcomes in patients who underwent tremelimumab/durvalumab as an ICI rechallenge and those who received tremelimumab/durvalumab as their initial ICI therapy RESULT: A total of 45 patients treated with tremelimumab/durvalumab were included, with 55.6% (25/45) undergoing ICI rechallenge. The objective-response and disease-control rates in patients who underwent ICI rechallenge were 14.3% (3/21) and 47.6% (10/21), respectively, similar to those in patients initially treated with tremelimumab/durvalumab. All patients (n = 3) who experienced the best response to progressive disease (PD) with initial atezolizumab/bevacizumab experienced PD during ICI rechallenge. The incidence rates of adverse events were similar between patient groups treated with tremelimumab/durvalumab as ICI rechallenge and initial ICI. Among patients experiencing immune-related adverse events (irAEs) with atezolizumab/bevacizumab, 75% (3/4) encountered similar irAEs during ICI rechallenge. CONCLUSION: Early safety and efficacy profiles of durvalumab/tremelimumab as ICI rechallenge are satisfactory.
  • Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
    Masato Nakai; Kenichi Morikawa; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Masatsugu Ohara; Takuya Sho; Goki Suda; Koji Ogawa; Naoya Sakamoto
    Journal of gastroenterology, 58, 7, 656, 667, 2023年07月, [査読有り], [筆頭著者], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Acute kidney injury (AKI) is associated with liver cirrhosis (LC), water retention, diuretics to treat water retention, and a poor prognosis. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) reportedly predicts a poor prognosis in decompensated LC. This study investigated the usefulness of uNGAL in predicting the short- and long-term effects of tolvaptan (TVP) and the incidence of AKI post-TVP administration. METHODS: Of the LC cases with water retention, 86 with available pre-treatment uNGAL were analyzed. A short-term response was defined as weight loss of ≥ 1.5 kg within the first week; a long-term response was defined as a short-term response without early recurrence. The uNGAL usefulness in predicting the short- and long-term effects of TVP and AKI incidence post-TVP administration was investigated. RESULTS: Short-term effects of TVP were observed in 52 patients. Of these, 15 patients had an early recurrence. In multivariate analysis, significant short-term predictive factors were C-reactive protein (CRP) < 1.4 mg/dl, uNa/K ratio ≥ 3.51, and uNGAL < 50.2 ng/ml. Patients were classified according to these three cut-off values, with short-term response rates of 92.9%, 68.8%, 26.7%, and 0% for 0, 1, 2, and 3 points, respectively. CRP < 0.94 mg/dl and uNGAL < 50.2 ng/ml were significant factors for predicting the long-term response of TVP. The AKI incidence post-TVP was 8.1% (n = 7) and was significantly higher among those with uNGAL ≥ 38.1 ng/mL. CONCLUSION: uNGAL is a useful predictor of the short- and long-term efficacy of TVP and can be useful in predicting AKI incidence post-TVP administration.
  • Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
    Risako Kohya; Goki Suda; Masatsugu Ohara; Takashi Sasaki; Tomoka Yoda; Naofumi Sakurai; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    Cancers, 15, 12, 2023年06月20日, [国際誌]
    英語, 研究論文(学術雑誌), Lenvatinib, used for unresectable hepatocellular carcinoma (HCC), causes appetite loss, but the underlying mechanisms, clinical impact, and predictive factors have been unclear. The endocrine factor FGF21 modulates appetite and is involved in cachexia. We evaluated the association between FGF21 level changes during lenvatinib treatment for unresectable HCC and appetite loss. Sixty-three eligible unresectable HCC patients who started lenvatinib treatment between 2018 and 2021 were included. We analyzed FGF21 levels at baseline; 1, 2, and 4 weeks after lenvatinib initiation, and before the onset of appetite loss. Grade ≥ 2 lenvatinib-induced appetite loss led to liver functional reserve deterioration at disease progression and a poor prognosis. Baseline characteristics and serum FGF21 levels were similar between patients with and without appetite loss. However, the serum FGF21 change rate increased significantly at 4 weeks post-lenvatinib initiation in patients with grade ≥ 2 appetite loss, as compared to those without appetite loss. Similar significant increases in the serum FGF21 level change rate were observed prior to grade ≥ 2 appetite loss onset. This suggests that changes in FGF21 levels can be used to predict patients with a greater risk of marked appetite loss and provides insights into the mechanisms underlying lenvatinib-induced appetite loss in patients with HCC.
  • Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
    Takashi Sasaki; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Naoki Kawagishi; Risako Kohya; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Sho Komukai; Koji Ogawa; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 53, 10, 960, 967, 2023年06月18日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: Although hepatitis delta virus (HDV) coinfection with hepatitis B virus (HBV) is a global health concern, the global prevalence of HDV infections remains unknown due to insufficient data in many countries. In Japan, HDV prevalence has not been updated for over 20 years. We aimed to investigate the recent prevalence of HDV infections in Japan. METHODS: We screened 1264 consecutive patients with HBV infection at Hokkaido University Hospital between 2006 and 2022. Patients' serums were preserved and subsequently tested for HDV antibody (immunoglobulin-G). Available clinical information was collected and analyzed. We compared the changes in liver fibrosis using the Fibrosis-4 (FIB-4) index between propensity-matched patients with and without the evidence of anti-HDV antibodies and corrected for baseline FIB-4 index, nucleoside/nucleotide analog treatment, alcohol intake, sex, HIV coinfection, liver cirrhosis, and age. RESULTS: After excluding patients without properly stored serums and those lacking appropriate clinical information, 601 patients with HBV were included. Of these, 1.7% of patients had detectable anti-HDV antibodies. Patients with anti-HDV antibody serum positivity had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV coinfection than those who demonstrated serum anti-HDV antibody negativity. A propensity-matched longitudinal analysis revealed that liver fibrosis (FIB-4 index) progressed more rapidly in patients with positive results for anti-HDV antibody tests. CONCLUSIONS: The recent prevalence of HDV infections in Japanese patients with HBV was 1.7% (10/601). These patients experienced rapid liver fibrosis progression, highlighting the importance of routine HDV testing.
  • Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
    Shunichi Hosoda; Goki Suda; Takuya Sho; Koji Ogawa; Megumi Kimura; Zijian Yang; Sonoe Yoshida; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
    Liver cancer, 12, 2, 156, 170, 2023年06月, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. METHODS: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, 6 weeks after treatment initiation (early PD; n = 13). Of these, 4 patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. RESULTS: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (<333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs. 227 days; HR: 2.41, 95% CI: 1.22-4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. CONCLUSION: Baseline low serum CXCL9 (<333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
  • Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
    Yoshimasa Tokuchi; Goki Suda; Naoki Kawagishi; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 53, 7, 595, 606, 2023年03月21日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct-acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify long-term changes in the prevalence of fatty liver and hyper-low-density lipoprotein (LDL) cholesterolemia and their associations in patients who achieve successful HCV eradication using DAAs. METHODS: This retrospective study included patients with HCV who achieved sustained virologic response after interferon-free DAA and analyzed the changes in the prevalence of fatty liver diagnosed with controlled attenuation parameter (CAP), hyper-LDL cholesterolemia, and their relationships at baseline (n = 100) and 24 weeks (SVR24, n = 100), 96 weeks (SVR96, n = 100), and 144 weeks (SVR144, n = 90) after DAA. RESULTS: In 100 participants, the prevalence of fatty liver (19% vs. 32%, p = 0.0349) and hyper-LDL cholesterolemia (6% vs. 15%, p = 0.0379) significantly increased without changes in body weight at SVR96. Median total cholesterol, low-density lipoprotein cholesterol (LDL-C), and small-dense-LDL (sdLDL) levels and CAP values were significantly greater at SVR24, SVR96, and SVR144 than at baseline. Baseline CAP values and changes in CAP values were significantly negatively correlated at every observation point: r = -0.5305, p < 0.0001 at SVR24; r = -0.3617, p = 0.0005 at SVR96; and r = -0.4735, p < 0.0001 at SVR144. A similar relationship was observed in cholesterol levels. Unlike at baseline, CAP values were significantly positively correlated with LDL-C and sdLDL-C levels at all observation points after DAAs. CONCLUSIONS: Direct-acting antivirals may cause an increased prevalence of fatty liver accompanying hyper-LDL cholesterolemia without increased body weight. As post-SVR liver steatosis could cause HCC, careful follow-up may be required.
  • Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
    Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
    Cancers, 15, 3, 2023年01月18日, [国際誌]
    英語, 研究論文(学術雑誌), The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated. A total of 4, 9, 19, and 14 patients showed CR, PR, SD, and PD, respectively. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Baseline growth factor levels were similar between patients with or without disease control and those with or without an objective response. Growth factor changes between the baseline and the best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies.
  • Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
    Naoki Kawagishi; Goki Suda; Yoshiya Yamamoto; Masaru Baba; Ken Furuya; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    Viruses, 15, 1, 2023年01月07日, [国際誌]
    英語, 研究論文(学術雑誌), Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34-6.33; p = 0.007) and baseline Ang2 level ≥ 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level ≥ 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs.
  • Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    Goki Suda; Masaru Baba; Yoshiya Yamamoto; Takuya Sho; Koji Ogawa; Megumi Kimura; Shunichi Hosoda; Sonoe Yoshida; Akinori Kubo; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Tomoe Kobayashi; Izumi Tsunematsu; Naoya Sakamoto
    Journal of medical virology, 95, 2, e28452, 2023年01月04日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing HBV reactivation has yet been reported. METHODS: This multicenter prospective study enrolled HBV-carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV-reactivation and received TAF to prevent HBV reactivation-related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation-related hepatitis was evaluated at 6 and 12 months after initiating TAF. RESULTS: Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation-related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous-HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation-related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. CONCLUSION: TAF could effectively prevent HBV reactivation and HBV reactivation-related hepatitis. This article is protected by copyright. All rights reserved.
  • Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test.
    Atsushi Hiraoka; Masato Nakai; Nagisa Hara; Tatsunori Hanai; Tadashi Namisaki; Hisamitsu Miyaaki; Takashi Nakahara; Akira Hiramatsu; Hideko Ohama; Fujimasa Tada; Hirokazu Takahashi; Hiroshi Aikata; Yuichiro Eguchi; Yoichi Hiasa; Hitoshi Yoshiji
    Hepatology research : the official journal of the Japan Society of Hepatology, 53, 1, 43, 50, 2023年01月, [国際誌]
    英語, 研究論文(学術雑誌), AIM: Patients often do not respond truthfully to physicians' interviews concerning alcohol. Few reports regarding the level of alcohol dependence in patients with chronic liver disease (CLD) have been presented. This study aimed to elucidate severity distribution in patients with CLD using the alcohol use disorders identification test (AUDIT). METHODS: From March to June 2022, 2034 Japanese outpatients with CLD, including 415 cases associated with hepatitis C virus, 436 with hepatitis B virus, 173 with alcohol-related liver disease (ARLD), and 1010 with other factors, were interviewed using AUDIT. Clinical features related to alcohol use in these patients were then retrospectively evaluated. RESULTS: In all patients, an AUDIT score 8-14 (harmful use) was noted in 5.8% of hepatitis C virus, 8.9% of hepatitis B virus, 24.3% of ARLD, and 4.4% of other groups, respectively (P < 0.001), while a score ≥15 (dependency) was noted in 3.4%, 3.0%, 27.7%, and 1.9%, respectively (P < 0.001). When the country was divided into regions, the percentages remained similar. Comparisons between patients with and without an AUDIT score ≥8 (n = 1412), performed after exclusion of those without related data (n = 622), showed no significant differences for hepatic reserve function, while those with harmful alcohol use were significantly younger (66 vs. 70 years, P = 0.006) and had a larger percentage of men (80.4% vs. 45.1%, P < 0.001). CONCLUSION: Harmful alcohol and alcohol dependency were observed in approximately 10% of patients with viral or non-viral CLD, after excluding patients with ARLD. Assessment of alcohol intake by use of the AUDIT questionnaire as well as adequate intervention should be considered necessary.
  • Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
    Masatsugu Ohara; Goki Suda; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    Frontiers in nutrition, 10, 1272728, 1272728, 2023年, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: We aimed to assess the prognostic implications of muscle atrophy and high subcutaneous adipose tissue (SAT) radiodensity in patients with hepatocellular carcinoma (HCC). METHODS: In this retrospective study, muscle atrophy was assessed using the psoas muscle index (PMI) obtained from computed tomography. SAT radiodensity was evaluated based on radiodensity measurements. Survival and multivariate analyses were performed to identify factors associated with prognosis. The impact of muscle atrophy and high SAT radiodensity on prognosis was determined through survival analysis. RESULTS: A total of 201 patients (median age: 71 years; 76.6% male) with HCC were included. Liver cirrhosis was observed in 72.6% of patients, and the predominant Child-Pugh grade was A (77.1%). A total of 33.3% of patients exhibited muscle atrophy based on PMI values, whereas 12.9% had high SAT radiodensity. Kaplan-Meier survival analysis demonstrated that patients with muscle atrophy had significantly poorer prognosis than those without muscle atrophy. Patients with high SAT radiodensity had a significantly worse prognosis than those without it. Muscle atrophy, high SAT radiodensity, the Barcelona Clinic Liver Cancer class B, C, or D, and Child-Pugh score ≥ 6 were significantly associated with overall survival. Further classification of patients into four groups based on the presence or absence of muscle atrophy and high SAT radiodensity revealed that patients with both muscle atrophy and high SAT radiodensity had the poorest prognosis. CONCLUSION: Muscle atrophy and high SAT radiodensity are significantly associated with poor prognosis in patients with HCC. Identifying this high-risk subgroup may facilitate the implementation of targeted interventions, including nutritional therapy and exercise, to potentially improve clinical outcomes.
  • Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
    Ren Yamada; Kenichi Morikawa; Kiyohiko Hotta; Daiki Iwami; Tatsu Tanabe; Sachiyo Murai; Nobuo Shinohara; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Megumi Kimura; Koji Yamamoto; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    Journal of viral hepatitis, 29, 11, 976, 985, 2022年11月, [国際誌]
    英語, 研究論文(学術雑誌), Donors with resolved hepatitis B virus (HBV) infection may be a solution for the organ shortage for kidney transplantation (KT). The purpose of this study was to clarify the current state of HBV markers after KT from donors with resolved HBV infection to HBV naïve recipients and the rate of HBV reactivation in recipients with resolved HBV infection. Furthermore, we investigated HBV covalently closed circular DNA (cccDNA) in transplanted organs from donors with resolved HBV infection and the capability of HBV replication in kidney cell lines. We retrospectively analysed the HBV status of 340 consecutive donors and recipients who underwent KT in a single centre. We prospectively measured cccDNA by real-time polymerase chain reaction in kidney biopsy specimens of 32 donors with resolved HBV infection. HBV reactivation was found in three recipients with resolved HBV infection (4.8%, 3/63) after KT. We analysed 45 cases of transplantation from donors with resolved HBV infection to HBV-naive recipients. One case (2.2%, 1/45) became seropositive for hepatitis B core antibody (anti-HBc) and in another case (2.2%, 1/45), HBV-DNA was detected qualitatively in an HBV naive recipient with a donor with resolved HBV infection. In the latter case, cccDNA was measured in the donor kidney during KT. HBV replication was observed in kidney cell lines with HBV plasmid transfection. In conclusion, the risk of reactivation in anti-HBc-positive donors is relatively low. However, post-transplant HBV monitoring should be conducted in all at-risk cases.
  • Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
    Naoki Kawagishi; Goki Suda; Ryotaro Sakamori; Takeshi Matsui; Masahiro Onozawa; Zijian Yang; Sonoe Yoshida; Masatsugu Ohara; Megumi Kimura; Akinori Kubo; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Yoshimasa Tokuchi; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Hajime Sakai; Shunsuke Ohnishi; Masaru Baba; Tetsuo Takehara; Naoya Sakamoto
    Scientific reports, 12, 1, 16800, 16800, 2022年10月07日, [国際誌]
    英語, 研究論文(学術雑誌), De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and DAA. Eleven, 35, and 19 HCV-infected patients with previous HBV infection with HBV reactivation during DAA treatment, previous HBV infection without HBV reactivation during DAA treatment, and without HBV infection resolution receiving DAA treatment, respectively, were enrolled. Clinical data and baseline cytokine levels were analyzed. Low baseline serum interleukin (IL)-1β levels predicted de novo HBV reactivation during DAA treatment (odds ratio: 47.6, 95% confidence interval: 6.94-333.3). HCV-infected patients with the IL-1β gene single nucleotide polymorphism rs16944 AA allele had significantly higher IL-1β levels; no HCV-infected patient with the IL-1β AA allele experienced HBV reactivation during DAA treatment. Compared to HCV-infected patients with HBV infection resolution, non-HCV infected patients with or without HBV reactivation during anti-cancer/immunosuppressive therapy or bone marrow transplantation had remarkably lower baseline IL-1β levels. Low IL-1β levels were not associated with HBV reactivation. IL-1β levels before DAA for HCV-infected patients with resolved HBV infection could predict HBV reactivation during DAA treatment.
  • Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
    Takuya Sho; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Koji Ogawa; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Zijian Yang; Megumi Kimura; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Takuto Miyagishima; Naoya Sakamoto
    Cancers, 14, 16, 2022年08月15日, [国際誌]
    英語, 研究論文(学術雑誌), The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 × 109/L (7/72), Child-Pugh B (9/72), and 2+ proteinuria (8/72). Atezolizumab and bevacizumab therapy was equally effective for patients who did or did not meet the eligibility criteria (PFS, 6.5 vs. 6.9 months, p = 0.765), consistent with subgroup analyses of histories of systemic therapy, platelet counts, Child-Pugh, and proteinuria. Baseline ALBI scores were worse in patients who did not meet the criteria than in those who did and significantly worsened after treatment initiation in patients not meeting the criteria (baseline vs. 12 weeks; 2.35 ± 0.43 vs. -2.18 ± 0.54; p = 0.007). Accordingly, atezolizumab plus bevacizumab was effective for patients not meeting the eligibility criteria of IMbrave150, although careful monitoring for changes in liver functional reserve is needed.
  • Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma.
    Masato Nakai; Kenichi Morikawa; Shunichi Hosoda; Sonoe Yoshida; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Masatsugu Ohara; Takuya Sho; Goki Suda; Koji Ogawa; Naoya Sakamoto
    World journal of hepatology, 14, 7, 1480, 1494, 2022年07月27日, [査読有り], [招待有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC. METHODS: In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative. RESULTS: In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; P < 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients. CONCLUSION: In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC.
  • Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.
    Machiko Umemura; Koji Ogawa; Kenichi Morikawa; Akinori Kubo; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Tomoe Shimazaki; Megumi Kimura; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Kota Ono; Kazumoto Murata; Masaya Sugiyama; Masashi Mizokami; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 52, 7, 586, 596, 2022年07月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND & AIMS: Benefits of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon-lambda3 (IFN-λ3) induction are still not known. This study aimed to investigate the effects of NAs on HBsAg reduction and association with serum IFN-λ3 levels in chronic hepatitis B (CHB) patients. METHODS: A total of 91 patients [51 treated with nucleoside analog entecavir hydrate (ETV) and 40 treated with nucleotide analog adefovir dipivoxil (ADV) or tenofovir disoproxil fumarate (TDF)] with clinically evident CHB (chronic hepatitis, 57; liver cirrhosis, 34) were enrolled in this study. Serum IFN-λ3 levels among patients receiving ETV and ADV/TDF were measured before the initiation of therapy and 1, 3, and 5 years post-therapy. RESULTS: The change (mean ± standard deviation) in serum HBsAg levels from baseline to year five was -0.38 ± 0.46 and -0.84 ± 0.64 log10 IU/ml in ETV and ADV/TDF groups, respectively (p = 0.0004). Higher serum IFN-λ3 levels were observed in ADV/TDF group compared with ETV group during treatment (p < 0.001). Serum IFN-λ3 levels showed negative correlation with HBsAg reduction in ADV/TDF group (r = -0.386, p = 0.038) at week 48. Nucleotide analogs (ADV/TDF) treatment has associated factors with -0.3 log HBsAg decline at 1 year, -0.5 log HBsAg decline at 3 years, and -0.8 log HBsAg decline at 5 years after NAs treatment on multivariate analysis. CONCLUSIONS: Nucleotide analog (ADV/TDF) treatment reduced HBsAg levels greater compared with nucleoside analog (ETV) in parallel with IFN-λ3 induction.
  • Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis.
    Sonoe Yoshida; Goki Suda; Masatsugu Ohara; Megumi Kimura; Zijian Yang; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 52, 7, 603, 613, 2022年03月30日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: A high prevalence of overestimated renal function in patients with liver cirrhosis (LC) has been reported; nonetheless, its impact on prognosis remains unclear. We aimed to evaluate the impact of overestimated renal function on prognosis in patients with LC. METHODS: An overestimated renal function was defined as a >20% increase in the creatinine-based estimated glomerular filtration rate (eGFR), compared with cystatin C-based eGFR. LC patients with conserved serum, who were evaluated for muscle atrophy and had proper clinical information were included, and their prognostic factors were analyzed. RESULTS: A total of 215 consecutive patients with LC were included. The prevalence of overestimated renal function was 29.8% (64/215). Kaplan-Meier survival analysis revealed that patients with overestimated renal function had a poorer prognosis than those without overestimated renal function (hazard ratio [HR]: 2.217 95% confidence interval [CI]: 1.290-3.810; P=0.001). Subgroup analysis showed that overestimated renal function was a significant prognostic factor, irrespective of sex and the presence of hepatocellular carcinoma (HCC). Multivariate Cox regression analyses revealed that overestimated renal function was a significant and independent factor predictive of poor prognosis in the entire cohort (HR: 2.050; 95% CI: 1.041-4.037; P=0.038) and in subgroups classified by Child-Pugh class A (HR: 2.131; 95% CI: 1.019-4.458; P=0.044), Model for End-Stage Liver Disease score <9 (HR: 2.303; 95% CI: 1.038-5.109; P=0.04), and presence of HCC (HR: 2.290; 95% CI: 1.128-4.651; P=0.022). CONCLUSION: Overestimated renal function is a significant and independent prognostic factor in patients with LC. This article is protected by copyright. All rights reserved.
  • The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
    Akihisa Nakamura; Koji Yamamoto; Rei Takeda; Ren Yamada; Akinori Kubo; Kenichi Morikawa; Sayaka Ando; Tomoe Shimazaki; Takaaki Izumi; Machiko Umemura; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Megumi Kimura; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Toshiro Sugiyama; Hiroshi Takeda; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 52, 6, 508, 521, 2022年02月07日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND AND AIMS: Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value only in the diagnosis of the advanced fibrosis stage of NASH. In this study, we evaluated soluble CD14 (sCD14) as a diagnostic marker for discriminating NASH from nonalcoholic fatty liver disease (NAFLD) using an animal model and clinical specimens. METHODS: Serum sCD14 levels were measured in samples derived from mice with diet-induced NASH and patients using an enzyme-linked immunosorbent assay. Our cohort enrolled 126 patients with liver needle biopsy-proven NAFLD. RESULTS: The intestinal defense mechanism in NASH model mice was altered as a consequence of the unique gut environment. Elevated serum levels of sCD14 were observed in mice with diet-induced NASH, and the condition of the liver was exacerbated as a result of exposure to gut-derived endotoxin. We confirmed that the serum sCD14 levels in NAFL patients significantly differed from those in NASH patients. The area under the curve for distinguishing between NAFL and NASH was 0.891. Moreover, we found that serum sCD14 levels were weakly correlated with the inflammation grade based on the NAFLD activity score (NAS), the grade of fibrosis according to the Brunt fibrosis classification, and a positive correlation with the grade of ballooning based on NAS in patients with NAFLD. CONCLUSION: sCD14 could be a useful pathophysiological marker and diagnostic adjunct distinguishing NASH from NAFLD. The use of sCD14 may allow the screening and identification of high-risk groups for NASH development and support early therapeutic interventions.
  • Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
    Masato Nakai; Yoshiya Yamamoto; Masaru Baba; Goki Suda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Ken Furuya; Naoya Sakamoto
    Scientific reports, 12, 1, 1449, 1449, 2022年01月27日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. This study aimed to clarify the non-invasive factors associated with HCC following sustained virological response (SVR) and to identify the low-risk group. 567 patients without history of HCC who achieved SVR at 24 weeks (SVR24) after IFN-free treatment were retrospectively analyzed. The cumulative incidence of HCC and the risk factors were examined using pre-treatment and SVR24 data. The median observation period was 50.2 months. Thirty cases of HCC were observed, and the 4-year cumulative incidence of HCC was 5.9%. In multivariate analysis, significant pre-treatment factors were age ≥ 71 years (hazard ratio [HR]: 3.402) and LSM ≥ 9.2 kPa (HR: 6.328); SVR24 factors were age ≥ 71 years (HR: 2.689) and LSM ≥ 8.4 kPa (HR: 6.642). In cases with age < 71 years and LSM < 8.4 kPa at the time of SVR24, the 4-year cumulative incidence of HCC was as low as 1.1%. Both pre-treatment LSM (≥ 9.2 kPa) and SVR24 LSM (≥ 8.4 kPa) and age (≥ 71 years) are useful in predicting the risk of HCC after SVR with IFN-free treatment. Identification of low-risk individuals may improve the efficiency of follow-up.
  • Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Sonoe Yoshida; Shunichi Hosoda; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
    Cancers, 14, 1, 2022年01月04日, [国際誌]
    英語, 研究論文(学術雑誌), Serum growth factor changes and their effect on prognosis during lenvatinib for unresectable hepatocellular carcinoma (HCC) remain underexplored. The sequential changes in serum growth factors during lenvatinib for unresectable HCC were evaluated in 58 patients using complete clinical data, and preserved serum was used to investigate changes in FGF-19, ANG-2, HGF, VEGF, and EGF. Patients with a complete response (CR), partial response (PR), and stable disease (SD) were evaluated for growth factor changes between the best response and progressive disease (PD) points, classified based on these changes, and evaluated by post progression survival (PPS). A total of 8, 24, 18, and 8 patients showed CR, PR, SD, and PD, respectively. Multivariate analysis revealed that age, relative dose intensity, and baseline ANG-2 were significantly associated with treatment response. Growth factor changes between the best response and PD points revealed that patients could be classified into four groups based on the EGF, ANG-2, and HGF changes. Although patient characteristics at baseline and PD, their response to lenvatinib, and PFS were similar among those groups, patients with an increase in all growth factors had significantly shorter PPS (median PPS was 553, 323, and 316 versus 173 days in groups 1-4 p = 0.032). We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS.
  • 【肝硬変症の診断治療の最新知見】肝硬変に対する次世代治療法 薬剤・再生療法の開発・治験状況
    小川 浩司; 中井 正人; 坂本 直哉
    日本内科学会雑誌, 111, 1, 74, 81, (一社)日本内科学会, 2022年01月
    日本語
  • Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
    Masato Nakai; Goki Suda; Koji Ogawa; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Masatsugu Ohara; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
    PloS one, 17, 7, e0270786, 2022年, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE). However, the usefulness of rifaximin against CHE is not thoroughly investigated in Japanese patients. We aimed to investigate the efficacy of rifaximin against hyperammonemia and CHE in Japan. We observed 102 patients with HE showing hyperammonemia secondary to LC and examined various biochemical and behavioral parameters following rifaximin treatment. CHE was diagnosed when the patients exhibited two or more abnormal neuropsychological test (NPT) scores but did not indicate OHE symptoms. In the 102 cases, a significant therapeutic effect of rifaximin on hyperammonemia was observed from 2 to 48 weeks after starting treatment. Excluding 10 patients diagnosed with OHE upon starting rifaximin treatment, 12 of the 92 remaining patients (11.8%) transitioned to OHE within 1 year. The 1 year cumulative OHE transition rate was 14.5%. Among the 24 patients with CHE diagnosed by the NPT for whom NPT results could be evaluated at 4 and 12 weeks after starting treatment, 10 (41.6%) had recovered from CHE at 12 weeks. When the factors contributing to recovery from CHE were examined by multivariate analysis, an ammonia level <129 μg/dL was a significant factor. Rifaximin was thus significantly effective against both hyperammonemia and CHE in Japanese patients.
  • Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia.
    Michiko Takimoto-Sato; Toshinari Miyauchi; Masaru Suzuki; Hideyuki Ujiie; Toshifumi Nomura; Tomoo Ikari; Tomohiko Nakamura; Kei Takahashi; Machiko Matsumoto-Sasaki; Hirokazu Kimura; Hiroki Kimura; Yuichiro Matsui; Takashi Kitagataya; Ren Yamada; Kazuharu Suzuki; Akihisa Nakamura; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto; Naoko Yamaguchi; Noriyuki Otsuka; Utano Tomaru; Satoshi Konno
    Frontiers in genetics, 13, 870192, 870192, 2022年, [査読有り], [国際誌]
    英語, Background: Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP) is an extremely rare disease caused by mutations in FAM111B, and only approximately 30 cases have been reported worldwide. Some patients develop interstitial pneumonia, which may lead to progressive pulmonary fibrosis and poor prognosis. However, no effective treatment for interstitial pneumonia associated with POIKTMP has been reported. Here, we report an autopsy case of POIKTMP, wherein interstitial pneumonia was improved by corticosteroids. Case Presentation: A 44-year-old Japanese man was referred to our hospital due to poikiloderma, hypotrichosis, and interstitial pneumonia. He developed progressive poikiloderma and muscle weakness since infancy. He also had tendon contractures, short stature, liver cirrhosis, and interstitial pneumonia. Mutation analysis of FAM111B revealed a novel and de novo heterozygous missense mutation, c.1886T > G (p(Phe629Cys)), through which we were able to diagnose the patient with POIKTMP. 3 years after the POIKTMP diagnosis, interstitial pneumonia had worsened. After 2 weeks of administrating 40 mg/day of prednisolone, his symptoms and lung shadows improved. However, he subsequently developed severe hepatic encephalopathy and eventually died of respiratory failure due to bacterial pneumonia and pulmonary edema. Autopsy revealed an unclassifiable pattern of interstitial pneumonia, as well as the presence of fibrosis and fatty degeneration in several organs, including the liver, kidney, skeletal muscle, heart, pancreas, and thyroid. Conclusions: We report a case of POIKTMP in which interstitial pneumonia was improved by corticosteroids, suggesting that corticosteroids could be an option for the treatment of interstitial pneumonia associated with this disease.
  • Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Satoshi Abiko; Kenji Kinoshita; Shuichi Miyamoto; Ryo Sugiura; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    PloS one, 17, 1, e0261760, 2022年, [国際誌]
    英語, 研究論文(学術雑誌), For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6-12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population.
  • Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
    Takuya Sho; Kenichi Morikawa; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Mugumi Kimura; Masato Nakai; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    World journal of gastrointestinal oncology, 13, 12, 2076, 2087, 2021年12月15日, [国際誌]
    英語, 研究論文(学術雑誌), The phase III clinical trial of the novel molecular targeted agent (MTA) lenvatinib for patients with advanced hepatocellular carcinoma (HCC) (REFLECT trial) found that lenvatinib was non-inferior to sorafenib in overall survival. Recently, the efficacy of multiple MTAs, including lenvatinib, in practice has been reported, and therapeutic strategies for Barcelona Clinic Liver Cancer (BCLC) intermediate stage HCC are undergoing major changes. Based on these results, lenvatinib could be recommended for patients with transcatheter arterial chemoembolization (TACE)-refractory, ALBI grade 1, within the up-to-seven criteria in the BCLC intermediate stage. Lenvatinib provides a more favorable outcome than TACE, even in cases with large or multinodular HCC beyond the up-to-seven criteria with Child-Pugh grade A. When patients meet the definitions of TACE-refractory or TACE-unsuitable, switching to systemic chemotherapy, including lenvatinib, is for favorable for preserving liver function. If initial treatment, including MTA, has a significant therapeutic effect and downstaging of HCC is obtained, additional TACE or surgical resection should be considered. Lenvatinib also has a therapeutic effect for poorly differentiated type and non-simple nodular type HCC thanks to the survival-prolonging effect of this drug. Furthermore, a significant therapeutic effect is expected in tumors with more than 50% liver involvement or main portal vein invasion, which have traditionally been considered to have a poor prognosis in patients. This suggests that at the start of lenvatinib treatment, HCC patients with ALBI grade 1 may be able to maintain liver functional reserve.
  • Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
    Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Taku Shigesawa; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 51, 9, 979, 989, 2021年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a real-world setting, with a focus on patients who did not meet the IMbrave150 eligibility criteria. METHODS: In this multicenter study, patients with unresectable HCC treated with atezolizumab plus bevacizumab between October 2020 and May 2021 were screened. In patients who did not meet IMbrave150 eligibility criteria, treatment responses and safety at 6 and 12 weeks were evaluated. RESULTS: Atezolizumab plus bevacizumab was initiated in 64 patients, including 46 patients (71.9%) who did not meet IMbrave150 eligibility criteria. Most of these patients had a history of systemic therapy (44/46). The objective response rate and disease control rate observed using Response Evaluation Criteria in Solid Tumors 1.1 were 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively; these rates were similar between patients who met and did not meet the IMbrave150 criteria. Ten patients experienced progressive disease (PD) at 6 weeks. Portal vein tumor thrombosis was significantly associated with PD (p = 0.039); none of the 15 patients with hepatitis B virus-related HCC experienced PD (p = 0.050). The most common adverse events of grade 3 or higher were aspartate aminotransferase elevation (n = 8, 13.8%) and the safety profile was similar between patients who met and did not meet the IMbrave150 criteria. CONCLUSION: Most patients treated with atezolizumab plus bevacizumab did not meet the IMbrave150 criteria; however, the combination therapy showed good safety and efficacy at the early treatment phase.
  • Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals.
    Yoshimasa Tokuchi; Goki Suda; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Masatsugu Ohara; Ren Yamada; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
    Scientific reports, 11, 1, 16616, 16616, 2021年08月16日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were recruited into the study. Patients who achieved sustained virological response (SVR); and had complete clinical information, preserved serum samples at baseline and SVR48, and skeletal muscle mass evaluations based on the psoas muscle mass index (PMI) on computed tomography at baseline and ≥ 12 months were included. Altogether, 70.7% of patients (41/58) showed increased PMI after DAA therapy, and mean relative PMI was significantly higher after DAA therapy than at baseline. There were no significant associations between baseline clinical factors routinely examined in clinical practice and increased PMI. Among factors reported to be associated with skeletal muscle loss in patients with chronic liver disease, serum zinc levels and total and free carnitine levels increased significantly after DAA therapy and only changes in serum free carnitine levels were significantly associated with an increased PMI (r = 0305, P = 0.020). In conclusion, increased skeletal muscle mass after successful HCV eradication by DAAs was significantly associated with increased serum-free carnitine levels. L-carnitine supplementation may be beneficial in patients with low skeletal muscle mass after DAA.
  • Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas.
    Yusuke Uchinami; Norio Katoh; Daisuke Abo; Hiroshi Taguchi; Koichi Yasuda; Kentaro Nishioka; Takeshi Soyama; Ryo Morita; Naoki Miyamoto; Ryusuke Suzuki; Takuya Sho; Masato Nakai; Koji Ogawa; Tatsuhiko Kakisaka; Tatsuya Orimo; Toshiya Kamiyama; Shinichi Shimizu; Hidefumi Aoyama
    Hepatology research : the official journal of the Japan Society of Hepatology, 51, 8, 870, 879, 2021年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: To report the outcomes of stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinoma patients. METHODS: From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter ≤52 mm were treated by stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. No patient with a Child-Pugh Score ≥9 was included, and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with an α/β ratio of 10 (BED10 ), the median dose in BED10 at the reference point was 76.8 Gy (range 60-122.5 Gy). Overall survival (OS) and local control rates were assessed using the Kaplan-Meier method. RESULTS: With a median follow-up period of 24.6 months (range 0.9-118.4 months), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI] 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1, and 61.7% in patients with grade ≥2a. In the multivariate analysis, the mALBI grade (=1 vs. ≥2a) was a significant factor for OS (p = 0.028, 95% CI 1.11-6.18). The 1-year and 2-year local control rates were 100% (100-100%) and 92.0% (77.5-97.5%). The local control rates were significantly higher in the BED10 ≥100 Gy group than in the BED10 <100 Gy group (2-year 100% vs. 86.5%, p = 0.049) at the reference point. CONCLUSION: This retrospective study of stereotactic body radiotherapy using real-time tumor-tracking radiotherapy for hepatocellular carcinoma showed favorable outcomes with lower incidence of toxicities, especially in patients treated with BED10 ≥100 Gy to the reference point.
  • Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
    Akinori Kubo; Goki Suda; Megumi Kimura; Osamu Maehara; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
    Cancers, 13, 14, 2021年07月20日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC; however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to lenvatinib, and CTNNB-1 mutation frequency in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. In 52 patients with unresectable HCC treated with lenvatinib, the prevalence of iso-high intensity in the hepatobiliary phase of EOB-MRI was 13%. All patients had multiple HCCs, and 3 patients had multiple HCCs with iso-high intensity in the hepatobiliary phase of EOB-MRI. Lenvatinib response to progression-free survival and overall survival were similar between patients with or without iso-high intensity in the hepatobiliary phase of EOB-MRI. Seven patients (three and four patients who had unresectable HCC with or without iso-high intensity in the hepatobiliary phase of EOB-MRI, respectively) underwent genetic analyses. Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study's findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI.
  • Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia.
    Sonoe Yoshida; Goki Suda; Masatsugu Ohara; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Megumi Kimura; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Osamu Maehara; Shunsuke Ohnishi; Naoya Sakamoto
    Nutrients, 13, 7, 2021年07月14日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Renal dysfunction and sarcopenia are important prognostic factors in patients with chronic liver disease (CLD). Muscle atrophy can cause the overestimation of renal function based on serum creatinine. However, the frequency of overestimated renal function in Japanese patients with CLD and its relationship with sarcopenia are unclear. In present study, we evaluated the frequency of overestimated renal function, defined as a >20% higher eGFR using creatinine than using cystatin C, in 307 patients with CLD as well as its relationship with indicators of sarcopenia. In total, 24.8% of patients had overestimated renal function. In a multivariate regression analysis, liver cirrhosis (p = 0.004) and psoas muscle mass index (p = 0.049) were significantly associated with overestimated renal function. Loss of skeletal muscle mass was significantly more frequent in both male and female patients with overestimated renal function than without. In males, the loss of muscle strength and rate of sarcopenia, defined as loss of muscle mass and strength, were significantly higher in patients with than without overestimated renal function. The high frequency of overestimated renal function in Japanese patients suggests that indicators of renal function should be carefully considered; furthermore, monitoring and interventions for both renal function and sarcopenia are needed in patients with CLD.
  • FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.
    Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Taku Shigesawa; Gouki Kanbe; Megumi Kimura; Masaya Sugiyama; Masashi Mizokami; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Naoto Okubo; Shunsuke Ohnishi; Hiroshi Takeda; Naoya Sakamoto
    Cancer biology & therapy, 22, 5-6, 372, 380, 2021年06月03日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Fibroblast growth factors (FGFs) and their receptors (FGFRs) are important for signaling to maintain cancer stem-like cells (CSCs) in esophageal squamous cell carcinoma (ESCC). However, which FGF receptor, 1, 2, 3, 4, and L1, is essential or whether FGFRs have distinct different roles in ESCC-CSCs is still in question. This study shows that FGFR2, particularly the IIIb isoform, is highly expressed in non-CSCs. Non-CSCs have an epithelial phenotype, and such cells are more differentiated in ESCC. Further, FGFR2 induces keratinocyte differentiation through AKT but not MAPK signaling and diminishes CSC populations. Conversely, knockdown of FGFR2 induces epithelial-mesenchymal transition (EMT) and enriches CSC populations in ESCC. Finally, data analysis using The Cancer Genome Atlas (TCGA) dataset shows that expression of FGFR2 significantly correlated with cancer cell differentiation in clinical ESCC samples. The present study shows that each FGFR has a distinct role and FGFR2-AKT signaling is a key driver of keratinocyte differentiation in ESCC. Activation of FGFR2-AKT signaling could be a future therapeutic option targeting CSC in ESCC.
  • Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
    Yoshimasa Tokuchi; Goki Suda; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Masatsugu Ohara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    Journal of viral hepatitis, 28, 5, 755, 763, 2021年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Hepatitis C virus (HCV) infection can cause renal dysfunction, expected to improve upon HCV eradication. However, adverse effects of HCV eradication using direct-acting antiviral agents (DAAs) on renal function have been recently reported. This retrospective study aimed to evaluate renal function with glomerular filtration rate (eGFR) estimated using creatinine (eGFRcre) and cystatin C (eGFRcys). Complete clinical information and preserved serum samples were collected from 207 patients with HCV infection treated with interferon-free DAA at baseline and SVR48 (SVR48). Patients who underwent paired computed tomography (CT) at baseline and ≥12 months after DAA were evaluated for changes in skeletal muscle mass using the psoas muscle mass index (PMI). eGFRcre significantly worsened at SVR48, while eGFRcys was similar at baseline and SVR48. At baseline, eGFRcre was significantly higher than eGFRcys; eGFRcre and eGFRcys were similar at SVR48. Multivariate analysis revealed that the presence of liver cirrhosis and low-albumin level, as well as cirrhosis and age, was significantly associated with the overestimation of renal function by eGFRcre at baseline and SVR48, respectively. In the 57 patients who underwent paired CT at baseline and ≥12 months after DAA, relative values of PMI significantly increased after DAA. After DAA, in patients with increased PMI (65% 37/57), eGFRcre significantly worsened but did not change in patients without increased PMI. eGFRcre significantly worsened after DAAs; however, this might not reflect accurate changes in renal function, partially because of changes in skeletal muscle mass. eGFRcys did not change after DAAs, and it is a potential alternative to eGFRcre.
  • Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
    Naoki Kawagishi; Goki Suda; Megumi Kimura; Osamu Maehara; Ren Yamada; Yoshimasa Tokuchi; Akinori Kubo; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Masatsugu Ohara; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Yusuke Kudo; Mutsumi Nishida; Naoya Sakamoto
    Scientific reports, 11, 1, 9207, 9207, 2021年04月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associated with non-regression after treatment with direct-acting-antivirals (DAAs). Patients treated with DAAs who underwent transient elastography at baseline and 24 and 96 weeks after DAA therapy were included. Baseline and post-treatment serum Ang2 levels were measured. Liver fibrosis stages were defined based on LSM. Multivariate regression was used to evaluate factors associated with non-regression of liver fibrosis between various time points. In total, 110 patients were included. Of these, 11% showed non-regression of LSM-based fibrosis stage at 96 weeks after DAA therapy. In multivariate analysis, advanced liver fibrosis stage and high baseline Ang2 levels were significantly associated with non-regression at 96 weeks. In patients with advanced liver fibrosis (F3/4), baseline Ang2 levels were associated with non-regression of liver fibrosis stage. Between SVR24 and SVR96, post-treatment Ang2 levels and controlled attenuation parameter values at SVR24 were significantly associated with non-regression of liver fibrosis stage in patients with F3/4. Thus, serum Ang2 levels are an important target for monitoring and therapy.
  • Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
    Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
    Journal of gastroenterology, 56, 2, 168, 180, 2021年02月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Entecavir and tenofovir-disoproxil-fumarate are first-line nucleos(t)ide analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term administration can impact extrahepatic organs. Herein, we sought to examine the effect of NA on lipid metabolism while also characterizing the associated mechanism. METHODS: A retrospective study was performed on HBV patients administered entecavir or tenofovir-disoproxil-fumarate. Patient clinical information, as well as their preserved serum samples obtained at baseline and 6-12 months after treatment initiation, were analyzed. A 1:1 propensity score matching was applied to the assignment of tenofovir-disoproxil-fumarate or entecavir treatment. Changes in serum cholesterol, including oxidized-LDL, were analyzed. Subsequently, in vitro analysis elucidated the mechanism associated with the effect of NAs on lipid metabolism. RESULTS: Administration of tenofovir-disoproxil-fumarate, not entecavir, to chronic HBV patients, decreased serum cholesterol levels, including non-HDL and oxidized-LDL, which are strongly associated with arteriosclerosis. In vitro analysis revealed that tenofovir-disoproxil-fumarate reduced supernatant cholesterol, and upregulated the scavenger receptor, CD36, in hepatocytes. Meanwhile, silencing of hepatic CD36 increased supernatant cholesterol and negated the cholesterol-reducing effect of tenofovir-disoproxil-fumarate in HepG2-cells. Reporter, microarray, and RT-PCR analyses further revealed that tenofovir-disoproxil-fumarate treatment activates PPAR-α-mediated signaling, and upregulates PPAR-α target genes, including CPT1 and CD36. Alternatively, silencing of PPAR-α reversed the effects of tenofovir-disoproxil-fumarate on CD36. CONCLUSIONS: Tenofovir-disoproxil-fumarate modulates lipid metabolism by upregulating hepatic CD36 via PPAR-α activation. Since dyslipidemia could be associated with arteriosclerosis and hepatocarcinogenesis, these discoveries provide novel insights into anti-HBV therapies, as well as the associated extrahepatic effects of NA.
  • Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
    Taku Shigesawa; Goki Suda; Megumi Kimura; Osamu Maehara; Yoshimasa Tokuchi; Akinori Kubo; Ren Yamada; Ken Furuya; Masaru Baba; Takashi Kitagataya; Kazuharu Suzuki; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    PloS one, 16, 3, e0247728, 2021年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), A deteriorated liver functional reserve during systemic therapy for unresectable hepatocellular carcinoma (HCC) causes poor patient outcomes. We aimed to identify predictive factors associated with the deterioration of Child-Pugh score at 8 weeks after lenvatinib initiation. Patients with adequate clinical data and baseline preserved serum samples available were included. Baseline fibroblast growth factor (FGF)19 and 21, angiopoietin (ANG)2, and vascular endothelial growth factor (VEGF) levels were evaluated. Thirty-seven patients were included, and 6, 15, 14, and 2 experienced complete response, partial response, stable disease, and progressive disease, respectively. Twenty-four (65%) and 13 (35%) patients showed a maintained/improved and deteriorated Child-Pugh-score, respectively. While baseline clinical data, treatment response, and laboratory data were similar between these two patient groups, baseline ANG2 and VEGF levels were significantly higher (P = 0.0017) and lower (P = 0.0231), respectively, in patients with deteriorated Child-Pugh score than in those without. Based on receiver operating characteristic curve analysis, cut-off values for ANG2 and VEGF were found to be 3,108 pg/mL and 514.9 pg/mL, respectively. Among patients with low VEGF and high ANG2, 89% (8/9) exhibited a deteriorated Child-Pugh score, whereas none of the patients (0/9) with high VEGF and low ANG2 did. The deterioration of the Child-Pugh score in patients with unresectable HCC who are treated with lenvatinib may be predictable based on combined baseline serum ANG2 and VEGF levels.
  • Durable response without recurrence to Tolvaptan improves long-term survival.
    Masato Nakai; Goki Suda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masatsugu Ohara; Machiko Umemura; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    Journal of gastroenterology, 55, 12, 1150, 1161, 2020年12月, [査読有り], [筆頭著者], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Decompensated liver cirrhosis patients with refractory ascites or pleural effusion have a poor prognosis. Tolvaptan has been used for treating water retention associated with cirrhosis. However, despite the short-term response, water retention recurrence is still observed in some cases. This study aimed to clarify the water retention recurrence rate and the relationship between long-term response without recurrence and prognosis. METHODS: Altogether, 100 patients with decompensated cirrhosis treated with tolvaptan were retrospectively analyzed. Recurrence was evaluated according to the criteria of the EASL clinical practice guideline. The recurrence rate and prognosis of non-responders, patients with recurrence, and long-term responders were analyzed. The baseline factors related to short-term response, recurrence, and long-term response were also evaluated. RESULTS: Approximately 31.0% of the short-term responders had recurrence. Although there was no significant difference in the prognosis by short-term response (p = 0.07), the long-term responders had a significantly better prognosis than those with recurrence and non-responders (p < 0.01). Low CRP levels and high urinary Na/K ratios were significant factors related to short-term response, and the presence of acute kidney injury was also a factor related to non-response. The low CRP level (relapse: < 1.10 mg/dl, long-term response: < 0.94 mg/dl) was identified as a factor related to recurrence and long-term response. CONCLUSION: The long-term responders without recurrence had a significantly better prognosis. CRP was a useful predictor for long-term response, whereas renal function parameters were useful predictors for short-term response. Inflammation control may be important for long-term response and prognosis in cirrhosis patients with water retention.
  • Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.
    Goki Suda; Koji Ogawa; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Masatsugu Ohara; Yoshimasa Tokuchi; Akinori Kubo; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 50, 10, 1196, 1200, 2020年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: Coronavirus disease 2019 (COVID-19) is a serious public health concern, with unclarified prevalence in Japan. Concomitant liver disease could increase the severity of COVID-19 disease, and chronic liver disease patients sometimes require frequent admission and gastrointestinal endoscopy. Thus, clarifying the prevalence of asymptomatic COVID-19 in outpatients with liver disease is essential for preventing nosocomial infections. We aimed to clarify the time-dependent changes in COVID-19 seroprevalence in liver disease outpatients, who were asymptomatic for COVID-19, in an area of Japan experiencing a second wave of COVID-19. METHODS: We included the preserved sera of 100, 300, and 300 consecutive liver disease outpatients, who were asymptomatic for COVID-19, from May 2019, March 2020, and May 2020, respectively. The sera were analyzed immunochromatographically to detect immunoglobulin G against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (KURABO) and by Elecsys Anti-SARS-CoV-2-assay (Roche Diagnostics). RESULTS: Analysis of 100 cases from May 2019, before COVID-19 became pandemic, revealed that the specificity of immunochromatographic tests and Elecsys were 98% (95% confidence interval [CI], 93-99.8%) and 100% (95% CI, 97-100%), respectively. Analysis of 300 cases from March 2020 revealed a seroprevalence of 0.3% (1/300; 95% CI, 0-1.8%) for COVID-19 by Elecsys Anti-SARS-CoV-2 assay. Analysis of 300 cases from May 2020 revealed a seroprevalence of 0% (0/300; 95% CI, 0-1.0%). CONCLUSIONS: The Elecsys Anti-SARS-CoV-2 assay has high specificity. The cumulative seroprevalence of COVID-19 by the Elecsys Anti-SARS-CoV-2 assay in outpatients with liver disease in Sapporo, who were asymptomatic for COVID-19, was 0.17% (1/600; 95% CI, 0.0-0.9%) until May 2020.
  • Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease
    Masatsugu Ohara; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    JCSM Rapid Communications, 3, 2, 103, 114, Wiley, 2020年07月
    研究論文(学術雑誌)
  • Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin
    Tatsuhiko Sakamoto; Yoshitaka Saito; Masaki Kobayashi; Takehiro Yamada; Yoh Takekuma; Masato Nakai; Koji Ogawa; Ken Iseki; Mitsuru Sugawara
    Supportive Care in Cancer, 28, 7, 3251, 3257, 2020年07月01日
    研究論文(学術雑誌)
  • Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
    Takuya Sho; Goki Suda; Koji Ogawa; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Jun Ito; Yoshiya Yamamoto; Tomoe Kobayashi; Takashi Meguro; Akiyoshi Saga; Takuto Miyagishima; Katsumi Terasita; Tomofumi Takagi; Toshiya Kamiyama; Akinobu Taketomi; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 50, 8, 966, 977, 2020年06月20日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: This study aimed to determine the efficacy and safety of lenvatinib for patients with unresectable hepatocellular carcinoma (HCC) who did not meet REFLECT eligibility criteria (phase 3 clinical trial). METHODS: In this multicenter retrospective study, patients with unresectable HCC treated with lenvatinib between 2018 and 2019 and had adequate clinical data were included. Objective-response-rate (ORR), progression-free-survival (PFS), and safety were evaluated according to meeting or not meeting the REFLECT eligibility criteria and according to the criteria of the REFLECT trial. RESULTS: Of the 105 patients included, 61% (64/105) did not meet the REFLECT eligibility criteria. Safety and median PFS of lenvatinib were similar between the patients who did and those who did not meet the criteria. Among the patients who did not meet the criteria, 28, 27, 14, 6, 7, and 5 had a history of tyrosine kinase inhibitor (TKI) treatment, Child-Pugh score B, HCC in ≥50% of the liver, reduced platelet count, bile duct invasion, and main portal vein invasion. The efficacy and safety of lenvatinib for patients with or without Child-Pugh-score B or HCC in ≥50% of the liver were similar. Although treatment outcome was not significantly different, patients with TKI treatment history tended to have longer median PFS, whereas those with main portal vein invasion tended to have shorter median PFS. CONCLUSION: Lenvatinib was effective for patients who did not meet the REFLECT inclusion criteria. However, the treatment outcome may vary according to several factors, such as a history of TKI treatment and tumor invasion.
  • Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR 1-3 signaling, but not FGFR4 signaling.
    Taku Shigesawa; Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Megumi Kimura; Tomoe Shimazaki; Koji Yamamoto; Ren Yamada; Takashi Kitagataya; Akihisa Nakamura; Kazuharu Suzuki; Masatsugu Ohara; Naoki Kawagishi; Machiko Umemura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Masaya Sugiyama; Masashi Mizokami; Hiroshi Takeda; Naoya Sakamoto
    Carcinogenesis, 42, 1, 58, 69, 2020年05月25日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), In hepatocellular carcinoma (HCC), a subset of cells defined by high CD44 and CD133 expression has been reported to possess cancer stem-like cell (CSC) characteristics and to be associated with a poor prognosis. Since the approval of the multi-kinase inhibitor, lenvatinib, for patients with unresectable HCC, two such inhibitors (sorafenib and lenvatinib) have been employed as first-line systemic chemotherapeutics for these patients. Based on differences in the kinase-affinity profiles between these two drugs, evidence has suggested that both exert different effects on HCC, although these differences are not fully characterized. In this study, using in vitro and a preclinical in vivo xenograft mouse model, we showed that lenvatinib alone (not sorafenib or the cytotoxic agent, 5-fluorouracil) diminished CD44High/CD133High CSCs in HCC. Furthermore, western blotting and RT-PCR analysis revealed that the expression of fibroblast growth factor receptor (FGFR)-1 to 4 differed between CD44High/CD133High CSCs and control cells. Analysis of the effects of selective FGFR inhibitors and FGFR small interfering RNAs on CSCs in HCC revealed that lenvatinib diminished CSCs in HCC by inhibiting FGFR1-3 signaling, however, FGFR4 signaling was not impacted. Finally, we showed that FGF2 and FGF19 were involved in maintaining CD44High/CD133High CSCs in HCC, potentially, via FGFR1-3. The findings provide novel mechanistic insights into the effects of lenvatinib on CSCs in HCC and provide clues for developing effective targeted therapies against CSCs in HCC.
  • Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
    Taku Shigesawa; Goki Suda; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    JGH OPEN, 4, 5, 880, 888, 2020年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
    Masatsugu Ohara; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Tomoe Kobayashi; Minoru Uebayashi; Ryo Takagi; Isao Yokota; Tsuyoshi Shimamura; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 50, 6, 715, 725, 2020年03月23日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), This study aimed to determine the optimal psoas muscle mass index (PMI) cut-off values for diagnosis of skeletal muscle mass loss. METHODS: We evaluated PMI in two groups of normal controls: a medical check-up group and a liver donation candidate group. We analyzed two novel PMI cut-off values, one based on the mean - two standard deviations (2SD) and one based on the lower 5%. Skeletal muscle mass index (SMI) evaluations using computed tomography (sliceOmatic; TomoVision) and bioelectrical impedance analysis and PMI evaluation were undertaken simultaneously. We analyzed the correlation between our PMI cut-off values and the Japan Society of Hepatology-defined SMI cut-off values. The prevalence of skeletal muscle mass loss in patients with liver disease was assessed using the novel PMI cut-off values. RESULTS: In 504 normal controls aged ≤50 years, the PMI cut-off values based on mean -2SD and the lower 5% were set at 3.30 cm2 /m2 for men and 1.69 cm2 /m2 for women and 3.74 cm2 /m2 for men and 2.29 cm2 /m2 for women, respectively. The PMI cut-off values based on the lower 5% alone showed that skeletal muscle mass loss increased with age. Furthermore, they correlated well with Japan Society of Hepatology-defined SMI (sliceOmatic) cut-off values and showed a significantly higher prevalence of skeletal muscle mass loss in patients with liver cirrhosis than those without liver cirrhosis. CONCLUSIONS: We propose the following PMI cut-off values: 3.74 cm2 /m2 for male individuals and 2.29 cm2 /m2 for female individuals. These cut-off values can facilitate accurate diagnosis and management of sarcopenia in patients with chronic liver disease.
  • Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara-Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
    Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, 2020年03月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis.
  • High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
    Naoki Kawagishi; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Yusuke Kudo; Mutsumi Nishida; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 2020年02月05日, [査読有り], [国際誌]
    英語, AIM: Factors associated with improvement of liver fibrosis after successful hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting antiviral agents (DAAs) have been not clarified well. Angiopoietin-2 (Ang2) is reported to be associated with vascular leak and inflammation observed in patients with advanced liver fibrosis. METHODS: In this retrospective study, patients treated with IFN-free DAAs who underwent transient elastography before and at 24-weeks post-treatment and achieved sustained viral response were enrolled. Baseline serum Ang2 was measured, and its relationship with other clinical factors was analyzed. Liver fibrosis stage was defined based on liver stiffness according to a previous report. Predictive factors for regression of liver fibrosis stage after DAA therapy were evaluated. RESULTS: Overall, 116 patients were analyzed. Baseline serum Ang2 levels were significantly associated with liver stiffness, spleen index, and liver stiffness-based liver fibrosis stage. Moreover, 75% of patients experienced regression of liver fibrosis stage after DAA therapy. Multivariate analysis revealed that advanced liver fibrosis stage and Ang2 levels were significantly associated with regression of liver fibrosis stage after DAA therapy. In patients with advanced liver fibrosis (F3/4), baseline Ang2 level alone could predict regression of liver fibrosis stage. A baseline Ang2 cut-off value (354 pg/ML) could predict regression of liver fibrosis stage after DAA therapy with high accuracy (sensitivity 0.882, specificity 0.733). CONCLUSIONS: Evaluation of serum Ang2 levels before DAA therapy is important. Our results provide a novel mechanistic insight into non-regression of liver stiffness after DAA therapy. Long-term and larger studies are required.
  • Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting
    Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Tomoe Kobayashi; Takashi Meguro; Akiyoshi Saga; Takuto Miyagishima; Hideki Yokoo; Toshiya Kamiyama; Akinobu Taketomi; Naoya Sakamoto
    JGH OPEN, 4, 1, 54, 60, 2020年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
    Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Tomoe Kobayashi; Takashi Meguro; Akiyoshi Saga; Takuto Miyagishima; Hideki Yokoo; Toshiya Kamiyama; Akinobu Taketomi; Naoya Sakamoto
    JGH open : an open access journal of gastroenterology and hepatology, 4, 1, 54, 60, 2020年02月, [査読有り], [国際誌]
    英語
  • Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
    Koji Ogawa; Takashi Kobayashi; Jun-Ichi Furukawa; Hisatoshi Hanamatsu; Akihisa Nakamura; Kazuharu Suzuki; Naoki Kawagishi; Masatsugu Ohara; Machiko Umemura; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Masaru Baba; Ken Furuya; Katsumi Terashita; Tomoe Kobayashi; Manabu Onodera; Takahiro Horimoto; Keisuke Shinada; Seiji Tsunematsu; Izumi Tsunematsu; Takashi Meguro; Tomoko Mitsuhashi; Megumi Hato; Kenichi Higashino; Yasuro Shinohara; Naoya Sakamoto
    Scientific reports, 10, 1, 321, 321, 2020年01月15日, [査読有り], [国際誌]
    英語, Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) that may lead to liver cirrhosis or hepatocellular carcinoma. Here, we examined the diagnostic utility of tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin (AAT-A3F), a non-invasive glycobiomarker identified in a previous study of NASH diagnosis. This study included 131 biopsy-proven Japanese patients with NAFLD. We evaluated the utility of AAT-A3F in NASH diagnosis, and conducted genetic analysis to analyse the mechanism of AAT-A3F elevation in NASH. Serum AAT-A3F concentrations were significantly higher in NASH patients than in NAFL patients, and in patients with fibrosis, lobular inflammation, and ballooning. Hepatic FUT6 gene expression was significantly higher in NASH than in NAFL. IL-6 expression levels were significantly higher in NASH than in NAFL and showed a positive correlation with FUT6 expression levels. The serum-AAT-A3F levels strongly correlated with hepatic FUT6 expression levels. AAT-A3F levels increased with fibrosis, pathological inflammation, and ballooning in patients with NAFLD and may be useful for non-invasive diagnosis of NASH from the early stages of fibrosis.
  • Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
    Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 49, 11, 1294, 1304, 2019年11月, [査読有り], [国際誌]
    英語, AIM: Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are first-line nucleos(t)ide analogues for hepatitis B virus (HBV)-infected patients. However, consecutive TDF treatment causes renal dysfunction, and the safety and efficacy of TAF have not been established in severe renal dysfunction patients, including hemodialysis patients. The efficacy and safety of ETV in these populations has not been clarified. The study aimed to clarify this. METHODS: In this retrospective multicenter study, between 2006 and 2018, a total of 567 HBV-infected patients treated with ETV monotherapy were screened. Patients were included if >20 years old, treated with ETV monotherapy for >1 year, and had proper clinical information. The efficacy of ETV and changes in renal function were evaluated according to renal function. RESULTS: A total of 273 patients were included: 9.2% (25/273), 1.8% (5/273), and 3.7% (10/273) had chronic kidney disease (CKD) stage G3, CKD stage G4/5, and were on hemodialysis, respectively. Overall, 84.2%, 94.0%, and 96.2% of patients experienced serum HBV-DNA disappearance at 1, 2, and 3 years, respectively, after treatment initiation. In patients with CKD stage G3-5, estimated glomerular filtration rate tended to restore with time, which was in contrast to patients without renal dysfunction. The rate of disappearance in serum HBV-DNA, alanine transaminase normalization, and virological breakthrough was similar between patients with or without renal dysfunction. ETV showed high efficacy for all 10 hemodialysis patients without virological breakthrough. CONCLUSIONS: Entecavir for HBV-infected patients with severe renal dysfunction, including hemodialysis patients, is highly effective and does not affect renal function.
  • TRI-ANTENNARY TRI-SIALYLATED MONO-FUCOSYLATED GLYCAN OF ALPHA-1 ANTITRYPSIN AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS
    Takashi Kobayashi; Koji Ogawa; Jun-Ichi Furukawa; Hisatoshi Hanamatsu; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Megumi Hato; Kenichi Higashino; Yasuro Shinohara; Naoya Sakamoto
    HEPATOLOGY, 70, 1079A, 1079A, 2019年10月
    英語
  • ENTECAVIR TREATMENT OF HEPATITIS B VIRUS-INFECTED PATIENTS WITH SEVERE RENAL IMPAIRMENT, INCLUDING THOSE ON HEMODIALYSIS
    Kazuharu Suzuki; Goki Suda; Taku Shigesawa; Akihisa Nakamura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    HEPATOLOGY, 70, 314A, 314A, 2019年10月
    英語
  • Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of α2,3-Linked Sialic Acid Residues.
    Hanamatsu H; Nishikaze T; Tsumoto H; Ogawa K; Kobayashi T; Yokota I; Morikawa K; Suda G; Sho T; Nakai M; Miura N; Higashino K; Sekiya S; Iwamoto S; Miura Y; Furukawa JI; Tanaka K; Sakamoto N
    Analytical chemistry, 91, 21, 13343, 13348, 2019年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Sialic acids form the terminal sugars in glycan chains on glycoproteins via α2,3, α2,6, or α2,8 linkages, and structural isomers of sialyl linkages play various functional roles in cell recognition and other physiological processes. We recently developed a novel procedure based on sialic acid linkage-specific alkylamidation via lactone ring opening (aminolysis-SALSA). Herein, we have investigated an isotope labeling of α2,3-linked sialic acid residues (iSALSA) using amine hydrochloride salts. One limitation of SALSA using amine hydrochloride salts may be solved by adding only tert-butylamine (t-BA) as an acid scavenger, and comparative and quantitative glycomic analyses can be performed using iSALSA. We also developed quantitative glycomic analysis using dual isotope-labeled glycans by derivatizing with aminooxy-functionalized tryptophanylarginine methyl ester (aoWR) and iSALSA at the reducing and nonreducing end, respectively. Furthermore, we demonstrate that the amount of α2,3-linked sialoglycans in serum are altered during liver fibrosis using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) and liquid chromatography MS (LC/MS) analyses. We revealed that the ratio of A33,6,6 to A3F3,6,6 was gradually decreased along with liver fibrosis progression. Therefore, these glycan alterations are potential diagnostic markers of nonalcoholic steatohepatitis (NASH) fibrosis progression.
  • Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Goki Suda; Chitomi Hasebe; Masami Abe; Masayuki Kurosaki; Jun Itakura; Namiki Izumi; Yoshihito Uchida; Satoshi Mochida; Hiroaki Haga; Yoshiyuki Ueno; Kazumichi Abe; Atsushi Takahashi; Hiromasa Ohira; Yoko Tsukuda; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Tomoe Kobayashi; Jun Inoue; Katsumi Terasita; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    Journal of gastroenterology, 54, 7, 641, 649, 2019年07月, [査読有り], [国内誌]
    英語, BACKGROUND: Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentasvir (G/P) for hemodialysis patients showed high efficacy and safety; however, the number of GT2 HCV-infected patients, especially Asian patients, was limited and most of them were treated with a 12-week regimen. In this prospective multicenter study, we aimed to investigate the efficacy and safety of G/P in Japanese hemodialysis patients with GT2 HCV infection. METHODS: Twenty-seven Japanese hemodialysis patients with GT2 HCV infection who were started on with 8- or 12-week G/P regimen between November 2017 and June 2018 were included and followed up for around 12 weeks after treatment completion. RESULTS: Among the 27 included patients, 13 non-liver cirrhosis (LC) and direct-acting antivirals (DAAs)-naïve patients were treated with 8 weeks of G/P and 14 patients with LC (n = 13) or history of failure of DAAs (n = 1) were treated with a 12-week regimen. The overall sustained virological response at 12 weeks after treatment completion (SVR 12) was 96.3% (26/27). All patients with 8 weeks of treatment achieved SVR12. Two patients discontinued the therapy at 2 and 11 weeks after treatment initiation. The patient who discontinued at 2 weeks due to pruritus alone failed to respond to G/P. No patients experienced lethal adverse events during the therapy, and the most common adverse event was pruritus. CONCLUSIONS: An 8- or 12-week G/P regimen is highly effective and safe in GT2 HCV-infected hemodialysis patients.
  • Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs.
    Suda G; Kimura M; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Kawagishi N; Nakai M; Sho T; Maehara O; Shimazaki T; Morikawa K; Natsuizaka M; Ogawa K; Sakamoto N
    Hepatology research : the official journal of the Japan Society of Hepatology, 49, 11, 1275, 1285, Wiley, 2019年07月, [査読有り]
    研究論文(学術雑誌)
  • Correlation between Liver Elasticity by Ultrasound Elastography and Liver Functional Reserve.
    Sugiura R; Kuwatani M; Nishida M; Hirata K; Sano I; Kato S; Kawakubo K; Nakai M; Sho T; Suda G; Morikawa K; Ogawa K; Sakamoto N
    Ultrasound in medicine & biology, 2019年07月, [査読有り]
  • Quantifying Protein-Specific N-glycome Profiles by Focused Protein- and Immunoprecipitation-Glycomics.
    Kobayashi T; Ogawa K; Furukawa JI; Hanamatsu H; Hato M; Yoshinaga T; Morikawa K; Suda G; Sho T; Nakai M; Higashi-No K; Numata Y; Shinohara Y; Sakamoto N
    Journal of proteome research, 2019年07月, [査読有り]
  • Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
    Izumi T; Sho T; Morikawa K; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Kawagishi N; Umemura M; Shimazaki T; Kimura M; Nakai M; Suda G; Natsuizaka M; Ogawa K; Kudo Y; Nishida M; Ono K; Baba M; Furuya K; Sakamoto N
    Hepatology research : the official journal of the Japan Society of Hepatology, 49, 10, 1207, 1217, Wiley, 2019年06月, [査読有り]
    研究論文(学術雑誌)
  • Long-term effect of nucleos (t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients
    Morikawa Kenichi; Umemura Machiko; Ogawa Koji; Shigesawa Taku; Suzuki Kazuharu; Nakamura Akihisa; Ohara Masatsugu; Kawagishi Naoki; Shimazaki Tomoe; Kimura Megumi; Izumi Takaaki; Nakai Masato; Sho Takuya; Suda Goki; Natsuizaka Mitsuteru; Ono Kota; Murata Kazumoto; Sugiyama Masaya; Masashi Mizokami; Sakamoto Naoya
    JOURNAL OF HEPATOLOGY, 70, E477, 2019年04月, [査読有り]
  • The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
    Suda G; Nakai M; Sho T; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Baba M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N; NORTE Study Group
    Internal medicine (Tokyo, Japan), 58, 7, 943, 947, Japanese Society of Internal Medicine, 2019年04月, [査読有り]
    研究論文(学術雑誌)
  • Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay
    Koji Ogawa; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Naoya Sakamoto
    Acta Hepatologica Japonica, 60, 11, 397, 404, Japan Society of Hepatology, 2019年
    日本語, 研究論文(学術雑誌)
  • Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    Goki Suda; Masayuki Kurosaki; Jun Itakura; Namiki Izumi; Yoshihito Uchida; Satoshi Mochida; Chitomi Hasebe; Masami Abe; Hiroaki Haga; Yoshiyuki Ueno; Ikuto Masakane; Kazumichi Abe; Atsushi Takahashi; Hiromasa Ohira; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Tomoe Kobayashi; Atsuhiko Kawakami; Kenichi Kumagai; Katsumi Terasita; Masatsugu Ohara; Naoki Kawagishi; Machiko Umemura; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    Journal of gastroenterology, 54, 1, 78, 86, 2019年01月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is high and results in a poor prognosis. Thus, safer and more effective treatment regimens are required. In this prospective multicenter study, we investigated the efficacy and safety of the novel HCV-NS5A-inhibitor, elbasvir, and protease inhibitor, grazoprevir in Japanese hemodialysis patients with genotype 1b HCV infection. METHODS: This study is registered at the UMIN Clinical Trials Registry as UMIN00002578. A total of 23 Japanese dialysis patients with genotype 1b HCV infection who were treated with elbasvir and grazoprevir between January 2017 and March 2018 and followed for more than 12 weeks after treatment completion were included. We evaluated the sustained virologic response at 12 weeks after treatment completion (SVR12) and safety during treatment. RESULTS: Of the 23 patients, 7 had advanced liver fibrosis and 2 had a signature resistance-associated variant of NS5A (NS5A RAVs)-L31M/V or Y93H at baseline. All patients completed therapy, and 96.7% (22/23) of the patients achieved SVR12. All patients with advanced liver fibrosis and signature NS5A RAVs at baseline achieved SVR12 with a high safety profile. No patient experienced lethal or severe adverse events during therapy, and the most common adverse event was anemia. One patient, who was a non-responder to this therapy, had a history of failure with daclatasvir and asunaprevir therapies and had NS5A RAVs of A92K at baseline, but not signature NS5A RAVs. CONCLUSIONS: Grazoprevir and elbasvir combination is highly effective and safe for hemodialysis patients with genotype 1b HCV infection.
  • Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
    Sho T; Suda G; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Izumi T; Kawagishi N; Baba M; Nakai M; Natsuizka M; Morikawa K; Ogawa K; Sakamoto N; NORTE Study Group
    Internal medicine (Tokyo, Japan), 58, 6, 797, 802, 2018年11月, [査読有り]
  • Higher Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein (M2BPGi) Not M2BP and Pre-Sarcopenia Are Prognostic and Recurrence Markers of Primary Hepatocellular Carcinoma Treated By RFA in HCV-Negative and HCV-Eradicated Patients.
    Nakai Masato; Suda Goki; Ogawa Koji; Suzuki Kazuharu; Nakamura Akihisa; Ohara Masatsugu; Kawagishi Naoki; Umemura Machiko; Sho Takuya; Morikawa Kenichi; Sakamoto Naoya
    HEPATOLOGY, 68, 843A, 844A, 2018年10月, [査読有り]
  • Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus.
    Nakamura H; Fujieda Y; Yasuda S; Nakai M; Atsumi T
    Annals of internal medicine, 169, 5, 352, 353, 2018年09月, [査読有り]
  • L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.
    Ohara M; Ogawa K; Suda G; Kimura M; Maehara O; Shimazaki T; Suzuki K; Nakamura A; Umemura M; Izumi T; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ohnishi S; Sakamoto N
    Hepatology communications, 2, 8, 906, 918, Wiley, 2018年08月, [査読有り]
    研究論文(学術雑誌)
  • Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
    Takuya Sho; Goki Suda; Atsushi Nagasaka; Yoshiya Yamamoto; Ken Furuya; Kenichi Kumagai; Minoru Uebayashi; Katsumi Terashita; Tomoe Kobayashi; Izumi Tsunematsu; Manabu Onodera; Takashi Meguro; Megumi Kimura; Jun Ito; Machiko Umemura; Takaaki Izumi; Naoki Kawagishi; Masatsugu Ohara; Yuji Ono; Masato Nakai; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 48, 7, 529, 538, 2018年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: The safety and efficacy of sofosbuvir (SOF) and ribavirin (RBV) have not been well clarified in patients with renal dysfunction because clinical trials have not included such patients. We evaluated the safety and efficacy of SOF and RBV for genotype 2 hepatitis C virus (HCV)-infected patients with renal dysfunction. METHODS: The study included genotype 2 HCV-infected patients who received SOF and RBV between July 2014 and May 2017. The sustained virologic response (SVR) after the treatment and safety during the therapy were evaluated according to renal function. RESULTS: A total of 231 patients were included in this study. The median age was 62 years old, and 45.9% (106/231) were men. Of the 231 patients, 191 (82.8%) and 40 (17.2%) were classified as having chronic kidney disease (CKD) stages G1/2 and G3, respectively. The overall SVR rate was 97% (224/231). The SVR rates in patients with CKD stages G1, 2, G3a, and G3b were 98.1%, 98.6%, 87.9%, and 100%, respectively, and this therapy was tolerated. Multivariate analysis indicated that renal dysfunction was significantly associated with a non-SVR (odds ratio, 6.963; 95% confidence interval, 1.494-32.41; P = 0.013). The patients with renal dysfunction were older, had advanced liver fibrosis, lower baseline platelet and hemoglobin levels, and a higher rate of RBV dose reduction. CONCLUSIONS: Sofosbuvir and RBV therapy is highly effective and safe for genotype 2 HCV-infected Japanese patients. However, attention should be paid to baseline renal function when SOF- and RBV-containing regimens are used for patients with renal dysfunction.
  • Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
    Goki Suda; Jun Ito; Atsushi Nagasaka; Yoshiya Yamamoto; Ken Furuya; Munenori Okamoto; Katsumi Terashita; Tomoe Kobayashi; Izumi Tsunematsu; Junichi Yoshida; Takashi Meguro; Masatsugu Ohara; Naoki Kawagishi; Megumi Kimura; Machiko Umemura; Takaaki Izumi; Yoko Tsukuda; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 48, 3, E146-E154, E154, 2018年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The Japan Society of Hepatology guidelines indicate that hepatitis C virus (HCV) protease inhibitor combination therapy with simeprevir (SMV), pegylated-interferon (Peg-IFN), and ribavirin (RBV) is a therapeutic option for patients who fail to respond to a direct direct-acting antiviral-containing regimen. However, treatment outcomes have room for improvement. Fluvastatin (FLV) add-on treatment in Peg-IFN and RBV combination therapy for HCV-infected patients significantly improved the sustained virologic response (SVR), but the add-on effect of FLV on SMV combination therapy is not well understood. METHODS: This was a prospective, randomized, multicenter study in which a total of 61 HCV genotype 1b-infected patients were recruited and 60 eligible patients were randomly allocated to two groups that received 12 weeks of SMV/Peg-IFN/RBV followed by 12 weeks of Peg-IFN/RBV with or without 24 weeks of FLV. The SVR rate and adverse events were compared between the two groups. RESULTS: Thirty-one patients were allocated to the FLV add-on group and 29 patients were allocated to the control group. Baseline clinical factors, including median age, baseline platelet count, alanine aminotransferase level, HCV RNA titer, Fibrosis-4 index, and rate of IL28B minor genotype, were all similar between the two groups. The rapid virologic response, end-of-treatment response rates, SVR rates at 24 weeks after treatment, and safety profiles were also similar between the two groups. CONCLUSIONS: This prospective, randomized, multicenter study indicated that FLV had no add-on effect when given with SMV/Peg-IFN/RBV combination therapy for genotype 1b HCV-infected patients.
  • Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.
    Masato Nakai; Koji Ogawa; Rei Takeda; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Machiko Umemura; Jun Ito; Takuya Sho; Goki Suda; Kenichi Morikawa; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology, 48, 3, E311-E319, E319, 2018年02月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), AIM: Water retention, hepatic ascites, and peripheral edema are significant problems in patients with liver cirrhosis (LC). Although furosemide and spironolactone are commonly used as treatment, they are often insufficient to treat hyponatremia and renal insufficiency in patients with LC. Tolvaptan (TVP) could provide an effective treatment alternative. However, predictive factors of a therapeutic response to TVP are unclear. Our aim was to examine clinical predictors of the response to TVP in patients with LC and water retention. METHODS: Fifty-two patients were treated with TVP, with therapeutic effects judged by a decrease in body weight (≥2 kg) and increase in urinary volume (≥500 mL) within 7 days. Blood biochemical tests were carried out at baseline and post-treatment, including serum soluble CD14 (sCD14) and urinary aquaporin 2 (AQP2) levels. Clinical and laboratory predictive factors of a TVP response were evaluated by univariate and multivariate analyses. RESULTS: The overall response to TVP was 55.8%. On univariate analyses, serum C-reactive protein (CRP) level, the neutrophil-to-lymphocyte ratio, urinary blood urea nitrogen, and urinary AQP2 were predictors of the TVP response, with only serum CRP retained on multivariate analysis. A higher serum sCD14 level was strongly associated with a non-response to TVP. A decrease in urinary AQP2 to undetectable level was associated with a response. CONCLUSION: Tolvaptan provides a rapid and strong effect to improve water retention in patients with LC. Baseline serum sCD14 and CRP levels are useful predictors of a response to TVP, with a decrease in urinary AQP2 during treatment indicating an early response.
  • Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
    PloS one, 13, 12, e0209615, e0209615, Public Library of Science (PLoS), 2018年, [査読有り]
    研究論文(学術雑誌)
  • Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    Goki Suda; Norihiro Furusyo; Hidenori Toyoda; Yoshiiku Kawakami; Hiroki Ikeda; Michihiro Suzuki; Keiko Arataki; Nami Mori; Keiji Tsuji; Yoshio Katamura; Koichi Takaguchi; Toru Ishikawa; Kunihiko Tsuji; Noritomo Shimada; Atsushi Hiraoka; Sho Yamsaki; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Mineo Kudo; Atsushi Nagasaka; Ken Furuya; Yoshiya Yamamoto; Kanji Kato; Yoshiyuki Ueno; Etsuko Iio; Yasuhito Tanaka; Masayuki Kurosaki; Takashi Kumada; Kazuaki Chayama; Naoya Sakamoto
    Journal of gastroenterology, 53, 1, 119, 128, 2018年01月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Hepatitis C virus (HCV) infection is common in hemodialysis patients and worsens their prognosis, while antiviral therapy options are limited. Recently, clinical trial and real-world, small-scale studies have reported excellent responses to direct-acting antivirals in patients with advanced chronic kidney diseases. However, real-world, large-scale data were lacking. This large multicenter analysis included HCV-infected hemodialysis patients receiving combination therapy with a nonstructural protein 5A (NS5A) inhibitor, daclatasvir (DCV), and a protease inhibitor, asunaprevir (ASV). METHODS: Twenty-three centers in Japan participated in this study of 123 hemodialysis patients with genotype 1 HCV infection, who received DCV/ASV combination therapy between November 2014 and March 2016. We collected and analyzed data relating to treatment outcome, baseline clinical information, laboratory measurements (during and after the treatment), and adverse events. RESULTS: Thirty-nine patients (31.7%) had advanced liver fibrosis, 12 (9.8%) had histories of hepatocellular carcinoma (HCC), and 18 (14.6%) had baseline resistance-associated variants (RAVs) of NS5A. The overall sustained virological response (SVR)12 rate was 95.9% (118/123). Notably, all patients with HCC and 94.4% (17/18) of those with NS5A RAVs achieved SVR12. Significant factors associated with non-SVR were advanced fibrosis and the interleukin-28B non-TT genotype at rs8099917. Four patients (3.3%) discontinued therapy because of adverse events including elevated serum alanine transaminase levels (n = 2), rash (n = 1), and HCC (n = 1); all of these achieved SVR12. CONCLUSIONS: This real-world, nationwide study revealed that DCV/ASV combination therapy was safe and highly effective for hemodialysis patients with genotype 1 HCV infections. This study was registered at the UMIN Clinical Trials Registry (UMIN000024227).
  • Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C
    N. Kawagishi; G. Suda; M. Onozawa; M. Kimura; O. Maehara; M. Ohara; T. Izumi; M. Umemura; J. Ito; M. Nakai; T. Sho; M. Natsuizaka; K. Morikawa; K. Ogawa; N. Sakamoto
    JOURNAL OF VIRAL HEPATITIS, 24, 12, 1098, 1106, 2017年12月
    英語, 研究論文(学術雑誌)
  • Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection
    Naoki Kawagishi; Goki Suda; Masahiro Onozawa; Megumi Kimura; Osamu Maehara; Jun Ito; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    JOURNAL OF HEPATOLOGY, 67, 5, 1106, 1108, 2017年11月, [査読有り]
    英語
  • Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma
    Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Shunsuke Ohnishi; Yoshito Komatsu; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Tomoe Shimazaki; Megumi Kimura; Ayaka Asano; Yoshiyuki Fujimoto; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Kelly A. Whelan; Hiroshi Nakagawa; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
    CARCINOGENESIS, 38, 11, 1073, 1083, 2017年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment
    Goki Suda; Atsushi Nagasaka; Yoshiya Yamamoto; Ken Furuya; Kenichi Kumagai; Mineo Kudo; Katsumi Terashita; Tomoe Kobayashi; Izumi Tsunematsu; Junichi Yoshida; Takashi Meguro; Megumi Kimura; Jun Ito; Machiko Umemura; Takaaki Izumi; Seiji Tsunematsu; Fumiyuki Sato; Yoko Tsukuda; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    HEPATOLOGY RESEARCH, 47, 11, 1127, 1136, 2017年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy
    Goki Suda; Koji Ogawa; Yoshiya Yamamoto; Masaki Katagiri; Ken Furuya; Kenichi Kumagai; Jun Konno; Megumi Kimura; Naoki Kawagishi; Masatsugu Ohara; Machiko Umemura; Jun Ito; Takaaki Izumi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Akihito Tsubota; Noritomo Shimada; Etsuko Iio; Yasuhito Tanaka; Naoya Sakamoto
    JOURNAL OF GASTROENTEROLOGY, 52, 10, 1122, 1129, 2017年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
    Takuya Sho; Mitsuru Nakanishi; Kenichi Morikawa; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Machiko Umemura; Jun Ito; Masato Nakai; Goki Suda; Koji Ogawa; Makoto Chuma; Takashi Meguro; Michio Nakamura; Atsushi Nagasaka; Hiromasa Horimoto; Yoshiya Yamamoto; Naoya Sakamoto
    Drugs in R&D, 17, 3, 381, 388, 2017年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND AND AIMS: Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. Combination therapy with sorafenib and other cytotoxic agents for HCC may result in additive anticancer activity. The purpose of this phase I study was to investigate the safety and tolerability of combination therapy with sorafenib and 5-fluorouracil (5-FU) and to determine the optimum dose of 5-FU for a phase II trial. METHODS: This phase I study used a conventional 3 + 3 dose-escalation design. The primary endpoint was to determine the maximum tolerated dose (MTD) of 5-FU in combination with sorafenib and to determine the recommended dosage (RD) for phase II. The secondary endpoints evaluated were toxicity and the tumor response rate. All patients received 800 mg of sorafenib daily and three different dosages of 5-FU (250, 350, and 450 mg/m2/day) for 20 days by intravenous infusion in 1 month as one cycle. RESULTS: Twelve patients with advanced HCC were evaluated. The MTD of 5-FU in combination with sorafenib was 450 mg/m2/day, and 350 mg/m2/day was selected as the RD for a phase II study. Thrombocytopenia, stomatitis, and hand-foot skin reaction were observed as grade 3 adverse events. Nine patients achieved stable disease (75%), and three patients (25%) were judged to have progressive disease. The disease control rate was 75%. CONCLUSIONS: Combination therapy with sorafenib and 5-FU appears to be well tolerated and may have the potential to be an option for advanced HCC.
  • ウイルソン病における各診断ガイドラインの有用性の検討
    中井 正人; 森川 賢一; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉
    日本消化器病学会雑誌, 114, 5, 839, 845, (一財)日本消化器病学会, 2017年05月, [査読有り], [筆頭著者]
    日本語
  • Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Tsunematsu S; Suda G; Yamasaki K; Kimura M; Takaaki I; Umemura M; Ito J; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Kamiyama T; Taketomi A; Sakamoto N
    Hepatology research : the official journal of the Japan Society of Hepatology, 47, 6, 533, 541, 2017年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Anti-Adipogenic and Antiviral Effects of L-Carnitine on Hepatitis C Virus Infection
    Yoko Tsukuda; Goki Suda; Seiji Tsunematsu; Jun Ito; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Takuya Sho; Osamu Maehara; Tomoe Shimazaki; Megumi Kimura; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Makoto Chuma; Naoya Sakamoto
    JOURNAL OF MEDICAL VIROLOGY, 89, 5, 857, 866, 2017年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    Tsunematsu S; Suda G; Yamasaki K; Kimura M; Izumi T; Umemura M; Ito J; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Tanaka Y; Watashi K; Wakita T; Sakamoto N
    Journal of medical virology, 89, 2, 267, 275, 2017年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Hepatitis B virus infected cell slows down its cell cycle and proliferation by viral protein and replication
    K. Morikawa; T. Shimazaki; T. Izumi; M. Umemura; M. Nakai; G. Suda; N. Sakamoto
    JOURNAL OF HEPATOLOGY, 66, 1, S644, S644, 2017年
    英語
  • Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C
    N. Kawagishi; G. Suda; M. Onozawa; M. Kimura; O. Maehara; M. Ohara; T. Izumi; M. Umemura; J. Ito; M. Nakai; T. Sho; M. Natsuizka; K. Morikawa; K. Ogawa; N. Sakamoto
    JOURNAL OF HEPATOLOGY, 66, 1, S725, S726, 2017年
    英語
  • Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
    Goki Suda; Koji Ogawa; Megumi Kimura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
    Journal of clinical and translational hepatology, 4, 4, 320, 327, 2016年12月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Prevalence of hepatitis C virus (HCV) infection is high in patients with end-stage renal dysfunction, including patients undergoing hemodialysis (HD). The HCV infection itself can cause glomerulonephritis and puts individuals at increased risk of developing end-stage renal disease; fortunately, successful HCV eradication sometimes restore HCV-related renal dysfunction. Moreover, the prognosis of dialysis patients infected with HCV is significantly worse and the renal allograft survival in HCV-infected patients is also worse than in dialysis patients without HCV infection. If life prognosis is favorable, therefore, anti-HCV therapy is strongly recommended for HCV-infected patients with severe renal dysfunction. The standard therapy for HCV-infected patients with severe renal dysfunction has historically been interferon-based therapy. However, this therapy remains ineffective in achieving high, sustained viral response rates and the rate of adverse events and treatment discontinuation due to treatment-induced adverse events continues to be high in patients with severe renal dysfunction. Safe and effective anti-HCV therapies are urgently needed, and crucial, for patients with severe renal dysfunction. Recently, direct-acting antivirals (DAAs) that specifically target viral proteins have been developed, and these targets include the NS3, NS5A, and NS5B of HCV. Clinical trials have revealed high efficacy and safety of the DAA-based therapies, but patients with severe renal dysfunction were not included in the majority of these trials. However, several recent reports have shown high efficacy and safety for some regimens of DAA combination therapy for HCV-infected patients with severe renal dysfunction. In this review, we discuss novel treatments for HCV-infected patients with severe renal dysfunction and the pharmacokinetics of these drugs.
  • Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection
    Jun Ito; Goki Suda; Yoshiya Yamamoto; Atsushi Nagasaka; Ken Furuya; Kenichi Kumagai; Hideaki Kikuchi; Takuto Miyagishima; Tomoe Kobayashi; Megumi Kimura; Kazushi Yamasaki; Machiko Umemura; Takaaki Izumi; Seiji Tsunematsu; Fumiyuki Sato; Yoko Tsukuda; Katsumi Terashita; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    HEPATOLOGY RESEARCH, 46, 13, 1294, 1303, 2016年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficacy and tolerability of IFN-free direct acting antivirals therapy (daclatasvir and asunaprevir) in chronic hemodialysis patients with chronic hepatitis C
    Goki Suda; Koji Ogawa; Kenichi Morikawa; Masato Nakai; Naoya Sakamoto
    HEPATOLOGY, 64, 975A, 975A, 2016年10月, [査読有り]
    英語
  • Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
    Goki Suda; Mineo Kudo; Atsushi Nagasaka; Ken Furuya; Yoshiya Yamamoto; Tomoe Kobayashi; Keisuke Shinada; Miki Tateyama; Jun Konno; Yoko Tsukuda; Kazushi Yamasaki; Megumi Kimura; Machiko Umemura; Takaaki Izumi; Seiji Tsunematsu; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
    JOURNAL OF GASTROENTEROLOGY, 51, 7, 733, 740, 2016年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Dynamic Analysis Of Cellular Factors Modulated By Hepatitis B Virus Protein Expression And Replication
    Kenichi Morikawa; Tomoe Shimazaki; Takaaki Izumi; Machiko Umemura; Masato Nakai; Goki Suda; Darius Moradpour; Naoya Sakamoto
    HEPATOLOGY, 62, 1024A, 1024A, 2015年10月, [査読有り]
    英語
  • The decreased urinary aquaporin2 excretion is a predictive factor for the efficacy of Tolvaptan in patients with hepatic cirrhosis
    Nakai Masato; Itoh Jun; Sato Fumiyuki; Tsunematsu Seiji; Sho Takuya; Suda Goki; Morikawa Kenichi; Ogawa Koji; Sakamoto Naoya
    HEPATOLOGY, 62, 358A, 2015年10月, [査読有り], [筆頭著者]
  • Truncated Hepatitis B virus X protein up-regulates CD44+cancer stem like cells through LTBP1
    Suda Goki; Tsunematsu Seiji; Nakai Masato; Itoh Jun; Natsuizaka Mitsuteru; Morikawa Kenichi; Ogawa Koji; Sakamoto Naoya
    HEPATOLOGY, 62, 1157A, 2015年10月, [査読有り]
  • A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
    Maehara O; Sato F; Natsuizaka M; Asano A; Kubota Y; Itoh J; Tsunematsu S; Terashita K; Tsukuda Y; Nakai M; Sho T; Suda G; Morikawa K; Ogawa K; Chuma M; Nakagawa K; Ohnishi S; Komatsu Y; Whelan KA; Nakagawa H; Takeda H; Sakamoto N
    Cancer biology & therapy, 16, 10, 1453, 1461, 2015年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV)
    Masato Nakai; Hiroyuki Oshiumi; Kenji Funami; Masaaki Okamoto; Misako Matsumoto; Tsukasa Seya; Naoya Sakamoto
    SENSORS, 15, 10, 27160, 27173, 2015年10月, [査読有り], [筆頭著者]
    英語
  • Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions
    Goki Suda; Yoshiya Yamamoto; Astushi Nagasaka; Ken Furuya; Mineo Kudo; Yoshimichi Chuganji; Yoko Tsukuda; Seiji Tsunematsu; Fumiyuki Sato; Katsumi Terasita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuteru Natsuizaka; Kouji Ogawa; Shunsuke Ohnishi; Makoto Chuma; Yasuyuki Fujita; Riichiro Abe; Miki Taniguchi; Mina Nakagawa; Yasuhiro Asahina; Naoya Sakamoto
    HEPATOLOGY RESEARCH, 45, 8, 837, 845, 2015年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma
    Seiji Tsunematsu; Makoto Chuma; Toshiya Kamiyama; Noriyuki Miyamoto; Satoshi Yabusaki; Kanako Hatanaka; Tomoko Mitsuhashi; Hirofumi Kamachi; Hideki Yokoo; Tatsuhiko Kakisaka; Yousuke Tsuruga; Tatsuya Orimo; Kenji Wakayama; Jun Ito; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Yoko Tsukuda; Takuya Sho; Goki Suda; Kenichi Morikawa; Mitsuteru Natsuizaka; Mitsuru Nakanishi; Koji Ogawa; Akinobu Taketomi; Yoshihiro Matsuno; Naoya Sakamoto
    ABDOMINAL IMAGING, 40, 6, 1492, 1499, 2015年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • KLF5 Promotes Tumorigenicity of Hepatocellular Carcinoma by Upregulation of Cancer Stem-Like Cells
    Sato Fumiyuki; Natsuizaka Mitsuteru; Maehara Osamu; Asano Ayaka; Kubota Yoshimasa; Itoh Jun; Tsunematsu Seiji; Tsukuda Yoko; Terashita Katsumi; Nakai Masato; Sho Takuya; Suda Goki; Morikawa Kenichi; Ogawa Koji; Ohnishi Shunsuke; Sakamoto Naoya
    GASTROENTEROLOGY, 148, 4, S43, 2015年04月, [査読有り]
  • The J6JFH1 Strain of Hepatitis C Virus Infects Human B-Cells with Low Replication Efficacy
    Masato Nakai; Tsukasa Seya; Misako Matsumoto; Kunitada Shimotohno; Naoya Sakamoto; Hussein H. Aly
    VIRAL IMMUNOLOGY, 27, 6, 285, 294, 2014年08月, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions
    Goki Suda; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Naoya Sakamoto
    HEPATOLOGY, 60, 703A, 704A, 2014年
    英語
  • A pivotal role of KLF5 in regulation of cancer stem-like cells in hepatocellular carcinoma
    Mitsuteru Natsuizaka; Osamu Maehara; Fumiyuki Sato; Yoshimasa Kubota; Goki Suda; Jun Itoh; Seiji Tsunematsu; Yoko Tsukuda; Katsumi Terashita; Masato Nakai; Takuya Sho; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
    HEPATOLOGY, 60, 825A, 825A, 2014年, [査読有り]
    英語
  • Characterization of a lymphotropic HCV-J6JFH1 replication in human primary B cells
    Masato Nakai; Tsukasa Seya; Misako Matsumoto; Hussein H. Aly; Jun Itoh; Seiji Tsunematsu; Fumiyuki Sato; Yoko Tsukuda; Katsumi Terashita; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
    HEPATOLOGY, 60, 1083A, 1084A, 2014年, [査読有り]
    英語
  • Hepatosplenic Gamma-delta T-cell Lymphoma Associated with Epstein-Barr Virus
    Seiji Tsunematsu; Mitsuteru Natsuizaka; Hiromi Fujita; Noriyuki Otsuka; Katsumi Terashita; Fumiyuki Sato; Tomoe Kobayashi; Masato Nakai; Yoko Tsukuda; Hiromasa Horimoto; Takuya Sho; Goki Suda; Mitsuru Nakanishi; Satoshi Hashino; Makoto Chuma; Naoya Sakamoto
    INTERNAL MEDICINE, 53, 18, 2079, 2082, 2014年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C
    Tomoe Kobayashi; Shuhei Hige; Katsumi Terashita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuru Nakanishi; Koji Ogawa; Makoto Chuma; Naoya Sakamoto; Masahiro Asaka
    JOURNAL OF GASTROENTEROLOGY, 47, 11, 1228, 1237, 2012年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • ANEMIA AND THROMBOCYTOSIS INDUCED BY RIBAVIRIN MONOTHERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C
    Tomoe Kobayashi; Shuhei Hige; Masato Nakai; Katsumi Terashita; Hiromasa Horimoto; Takuya Sho; Mitsuru Nakanishi; Makoto Chuma
    HEPATOLOGY, 54, 872A, 873A, 2011年10月
    英語
  • Efficacy of therapy for advanced hepatocellular carcinoma: Intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation
    Makoto Chuma; Hiroshi Taguchi; Yoshiya Yamamoto; Shinichi Shimizu; Mitsuru Nakanishi; Koji Ogawa; Takuya Sho; Hiromasa Horimoto; Tomoe Kobayashi; Masato Nakai; Katsumi Terashita; Yusuke Sakuhara; Daisuke Abo; Yoko Tsukuda; Seiji Tsunematsu; Shuhei Hige; Mototsugu Kato; Hiroki Shirato; Masahiro Asaka
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26, 7, 1123, 1132, 2011年07月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
  • B型肝炎ウイルスキャリアに発症し悪性腫瘍の既往により診断に苦慮した肝血管筋脂肪腫の1例
    横山 大輔; 大原 正嗣; 中井 正人; 須田 剛生; 荘 拓也; 北潟谷 隆; 目野 晃光; 保浦 直弘; 北野 翔一; 田中 崇倫; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 138回・132回, 62, 62, 2026年03月
    日本消化器病学会-北海道支部, 日本語
  • 2026年改訂肝硬変ガイドラインの最新情報 2026年肝硬変ガイドライン改定のポイント 肝性脳症
    中井 正人; 北潟谷 隆, 日本消化器病学会雑誌, 123, 臨増総会, A190, A190, 2026年03月
    (一財)日本消化器病学会, 日本語
  • 2026年肝硬変ガイドライン改定のポイント~肝性脳症~
    中井正人; 北潟谷隆, 日本消化器病学会雑誌(Web), 123, 2026年
  • アテゾリズマブ+ベバシズマブ治療によるConversion前後の肝予備能および蛋白尿の変化
    荘拓也; 須田剛生; 北野翔一; 目野晃光; 保浦直弘; 北潟谷隆; 大原正嗣; 中井正人; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 33rd, 2026年
  • 切除不能進行肝細胞に対するアテゾリズマブ+ベバシズマブ治療と局所療法併用のインパクト
    荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 坂本 直哉, 肝臓, 66, Suppl.2, A640, A640, 2025年09月
    (一社)日本肝臓学会, 日本語
  • Bacterial translocationマーカーによる腹水を有する非代償性肝硬変の利尿剤反応性と予後予測
    中井 正人; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉, 肝臓, 66, Suppl.2, A658, A658, 2025年09月
    (一社)日本肝臓学会, 日本語
  • 実臨床における肝硬変診療ガイドラインの妥当性検証 不顕性肝性脳症を診断する適切な方法と課題 高齢者と非高齢者での検証
    中井 正人; 須田 剛生; 坂本 直哉, 肝臓, 66, Suppl.1, A47, A47, 2025年04月
    (一社)日本肝臓学会, 日本語
  • 肝硬変・門脈圧亢進症 病態解析と診療の進歩 肝硬変外来患者における活動量低下の実態
    平岡 淳; 原 なぎさ; 浪崎 正; 中井 正人; 坂本 直哉; 吉治 仁志, 日本消化器病学会雑誌, 122, 臨増総会, A219, A219, 2025年03月
    (一財)日本消化器病学会, 日本語
  • 切除不能進行肝細胞癌におけるアテゾリズマブ+ベバシズマブ併用療法の治療効果とTACE併用療法の意義
    荘拓也; 須田剛生; 田中崇倫; 北野翔一; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 32nd, 2025年
  • 慢性B型肝炎症例におけるCAMP-BとPAGE-Bによる発癌リスク評価の検討
    大原正嗣; 須田剛生; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 中井正人; 荘拓也; 坂本直哉, 日本消化器病学会雑誌(Web), 122, 2025年
  • CLINICAL IMPACT OF HARM REDUCTION IN PATIENTS WITH CHRONIC LIVER DISEASE AND ALCOHOL USE DISORDER BY BRIEF INTERVENTION IN A HEPATOLOGY OUTPATIENT UNIT
    Nagisa Hara; Atsushi Hiraoka; Masato Nakai; Makoto Shiraki; Tadashi Namisaki; Hisamitsu Miyaaki; Takuro Hisanaga; Hirokazu Takahashi; Hideko Ohama; Fujimasa Tada; Naoya Sakamoto; Kazuhiko Nakao; Taro Takami; Yuichiro Eguchi; Hitoshi Yoshiji, HEPATOLOGY, 80, S1106, S1106, 2024年10月
    英語, 研究発表ペーパー・要旨(国際会議)
  • アルコール関連肝疾患の現状と課題 AUDITを用いた慢性肝疾患患者のアルコール使用の実態と飲酒量低減指導の効果
    中井 正人; 須田 剛生; 坂本 直哉, 肝臓, 65, Suppl.3, A844, A844, 2024年10月
    (一社)日本肝臓学会, 日本語
  • 門脈圧亢進症治療最前線 肝硬変体液貯留におけるLeaky gutマーカーsoluble CD14のインパクト
    中井 正人; 須田 剛生; 坂本 直哉, 肝臓, 65, Suppl.2, A614, A614, 2024年09月
    (一社)日本肝臓学会, 日本語
  • 急性肝不全に対する移植スコアリングシステム High-flow hemodiafiltration時代の急性肝不全診療
    川村 典生; 嶋村 剛; 後藤 了一; 巖築 慶一; 渡辺 正明; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 武冨 紹信, 肝臓, 65, 5, 249, 249, 2024年05月
    (一社)日本肝臓学会, 日本語
  • 末梢血幹細胞移植前後で発症し,再活性化が疑われた急性E型肝炎の1例
    久保 彰則; 小川 浩司; 得地 祐匡; 重沢 拓; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 石田 勢津子; 坂本 直哉, 肝臓, 65, 5, 259, 259, 2024年05月
    (一社)日本肝臓学会, 日本語
  • 急性肝不全に対する移植スコアリングシステム High-flow hemodiafiltration時代の急性肝不全診療
    川村 典生; 嶋村 剛; 後藤 了一; 巖築 慶一; 渡辺 正明; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 武冨 紹信, 肝臓, 65, 5, 249, 249, 2024年05月
    (一社)日本肝臓学会, 日本語
  • 昏睡型亜急性型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
    松井 双葉; 後藤 了一; 川村 典生; 渡辺 正明; 金沢 亮; 津坂 隼也; 松居 剛志; 中井 正人; 荘 拓也; 小川 浩司; 嶋村 剛; 武冨 紹信, 日本外科学会定期学術集会抄録集, 124回, RS, 3, 2024年04月
    (一社)日本外科学会, 日本語
  • 当院において経皮経脾静脈アプローチによるIVRを施行した2例
    高柳 歩; 阿保 大介; 森田 亮; 高橋 文也; 木野田 直也; 加藤 大祐; 藤井 宝顕; 山崎 康之; 中西 喜嗣; 荘 拓也; 中井 正人; 平野 聡; 工藤 與亮, 日本インターベンショナルラジオロジー学会雑誌, 39, Suppl., 304, 304, 2024年04月
    (一社)日本インターベンショナルラジオロジー学会, 日本語
  • 消化器癌における薬物療法の超音波検査による治療効果判定 LEN-TACE療法の治療効果判定における造影USの役割
    荘 拓也; 北潟谷 隆; 大原 正嗣; 中井 正人; 須田 剛生; 坂本 直哉, 超音波医学, 51, Suppl., S200, S200, 2024年04月
    (公社)日本超音波医学会, 日本語
  • 昏睡型亜急性型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
    松井 双葉; 後藤 了一; 川村 典生; 渡辺 正明; 金沢 亮; 津坂 隼也; 松居 剛志; 中井 正人; 荘 拓也; 小川 浩司; 嶋村 剛; 武冨 紹信, 日本外科学会定期学術集会抄録集, 124回, RS, 3, 2024年04月
    (一社)日本外科学会, 日本語
  • 当院において経皮経脾静脈アプローチによるIVRを施行した2例
    高柳 歩; 阿保 大介; 森田 亮; 高橋 文也; 木野田 直也; 加藤 大祐; 藤井 宝顕; 山崎 康之; 中西 喜嗣; 荘 拓也; 中井 正人; 平野 聡; 工藤 與亮, 日本インターベンショナルラジオロジー学会雑誌, 39, Suppl., 304, 304, 2024年04月
    (一社)日本インターベンショナルラジオロジー学会, 日本語
  • 食道胃静脈瘤に対し経皮経脾静脈瘤塞栓術を施行した1例
    保浦 直弘; 大原 正嗣; めの 晃光; 甲谷 理紗子; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 阿保 大介; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 46, 46, 2024年03月
    日本消化器病学会-北海道支部, 日本語
  • 肝内胆管癌との鑑別に難渋した大腸癌遅発性肝転移再発の1例
    目野 晃光; 小川 浩司; 保浦 直弘; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 折茂 達也; 柿坂 達彦, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 47, 47, 2024年03月
    日本消化器病学会-北海道支部, 日本語
  • 非代償性肝硬変の課題克服を目指して 門脈圧亢進症合併HCV症例のSVR後の肝予備能,非代償化の検討
    中井 正人; 大原 正嗣; 北潟谷 隆; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 121, 臨増総会, A158, A158, 2024年03月
    (一財)日本消化器病学会, 日本語
  • 食道胃静脈瘤に対し経皮経脾静脈瘤塞栓術を施行した1例
    保浦 直弘; 大原 正嗣; めの 晃光; 甲谷 理紗子; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 阿保 大介; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 46, 46, 2024年03月
    日本消化器病学会-北海道支部, 日本語
  • 【チーム医療で取り組む肝胆膵疾患の栄養マネジメント】肝胆膵疾患に最適な栄養アセスメント法とは
    中井 正人; 大原 正嗣; 坂本 直哉, 肝胆膵, 88, 1, 7, 13, 2024年01月
    (株)アークメディア, 日本語
  • High-flow hemodiafiltration時代の急性肝不全診療
    川村典生; 嶋村剛; 後藤了一; 巖築慶一; 渡辺正明; 中井正人; 荘拓也; 森川賢一; 小川浩司; 武冨紹信; 武冨紹信, 肝臓, 65, 5, 2024年
  • 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の早期治療効果と安全性
    荘拓也; 須田剛生; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 29th, 2024年
  • LEN-TACE療法の治療効果判定における造影USの役割
    荘拓也; 北潟谷隆; 大原正嗣; 中井正人; 須田剛生; 坂本直哉, 超音波医学 Supplement, 51, 2024年
  • 門脈圧亢進症合併HCV症例のSVR後の肝予備能,非代償化の検討
    中井正人; 大原正嗣; 北潟谷隆; 荘拓也; 須田剛生; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 121, 2024年
  • 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の早期治療効果と安全性
    荘拓也; 須田剛生; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 得地祐匡; 山本義也; 坂本直哉, 肝胆膵, 89, 3, 422, 423, 2024年
    (株)アークメディア, 日本語
  • 高齢肝疾患患者における筋肉量評価法の検討
    大原正嗣; 須田剛生; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 細田峻一; 吉田苑永; 北潟谷隆; 中井正人; 荘拓也; 小川浩司; 坂本直哉, 肝臓, 65, Supplement 1, A361, A361, 2024年
    (一社)日本肝臓学会, 日本語
  • 慢性肝疾患患者の低栄養アセスメントを行うべき患者を適切に絞り込むスクリーニング方法の検討
    中井正人; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 荘拓也; 須田剛生; 小川浩司; 坂本直哉, 肝臓, 65, Supplement 1, A473, A473, 2024年
    (一社)日本肝臓学会, 日本語
  • 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の初期治療成績
    荘拓也; 須田剛生; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 山本義也; 坂本直哉, 肝臓, 65, Supplement 1, A449, A449, 2024年
    (一社)日本肝臓学会, 日本語
  • 北海道における肝炎ウイルス陽性者対策の課題
    大原正嗣; 小川浩司; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 中井正人; 荘拓也; 須田剛生; 坂本直哉, 肝臓, 65, Supplement 2, A687, A687, 2024年
    (一社)日本肝臓学会, 日本語
  • 切除不能肝細胞癌に対するレンバチニブ治療後のFGF21の変化と食欲不振の関連性について
    甲谷理紗子; 須田剛生; 大原正嗣; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 中井正人; 荘拓也; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 121, 2024年
  • 進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法中に自己免疫性脳炎を発症した1例
    北野翔一; 荘拓也; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 須田剛生; 坂本直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 135th-129th, 51, 51, 2024年
    日本消化器病学会-北海道支部, 日本語
  • 門脈圧亢進症症例における低栄養と適切なスクリーニング方法の検討
    中井正人; 北野翔一; 田中崇倫; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 荘拓也; 須田剛生; 坂本直哉, 日本門脈圧亢進症学会雑誌, 30, 3 (CD-ROM), 107, 107, 2024年
    (一社)日本門脈圧亢進症学会, 日本語
  • 切除不能進行肝細胞癌におけるICI-Rechallenge療法の治療効果と安全性の検討
    荘拓也; 須田剛生; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 小川浩司; 高木智史; 目黒高志; 馬場英; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 31st, 2024年
  • 【チーム医療で取り組む肝胆膵疾患の栄養マネジメント】肝胆膵疾患に最適な栄養アセスメント法とは
    中井 正人; 大原 正嗣; 坂本 直哉, 肝胆膵, 88, 1, 7, 13, 2024年01月
    (株)アークメディア, 日本語
  • アルコール性肝障害とハームリダクションの可能性 肝臓専門外来患者のアルコール摂取状況 AUDITを用いた飲酒摂取状況の評価
    平岡 淳; 浪崎 正; 中井 正人; 原 なぎさ; 華井 竜徳; 宮明 寿光; 中原 隆志; 平松 憲; 吉治 仁志, アルコールと医学生物学, 42, 8, 11, 2023年12月
    梵天書房, 日本語
  • 病態に応じた肝硬変症薬物治療の最適化 リファキシミンの高アンモニア血症/不顕性脳症への治療効果と肝予備能への影響
    中井 正人; 小川 浩司; 坂本 直哉, 肝臓, 64, Suppl.3, A757, A757, 2023年10月
    (一社)日本肝臓学会, 日本語
  • 北海道における肝炎医療コーディネーター養成研修会の実施状況の変遷に関する検討
    大原 正嗣; 小川 浩司; 長谷川 智子; 櫻井 菜々子; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉, 肝臓, 64, Suppl.3, A808, A808, 2023年10月
    (一社)日本肝臓学会, 日本語
  • IMbrave150基準外症例におけるアテゾリズマブ+ベバシズマブ併用療法の生存に寄与する因子の検討 多施設共同研究
    荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉, 日本消化器病学会雑誌, 120, 臨増大会, A813, A813, 2023年10月
    (一財)日本消化器病学会, 日本語
  • IMbrave150基準外症例におけるアテゾリズマブ+ベバシズマブ併用療法の生存に寄与する因子の検討 多施設共同研究
    荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉, 日本消化器病学会雑誌, 120, 臨増大会, A813, A813, 2023年10月
    (一財)日本消化器病学会, 日本語
  • 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Advanced stage肝細胞癌 Phase 3 HIMALAYA試験の結果とその解釈
    荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉, 肝胆膵, 87, 4, 439, 446, 2023年10月
    (株)アークメディア, 日本語
  • IMbrave150基準外進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
    荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 鈴木 和治; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉, 肝胆膵, 87, 4, 508, 509, 2023年10月
    (株)アークメディア, 日本語
  • 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Advanced stage肝細胞癌 Phase 3 HIMALAYA試験の結果とその解釈
    荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉, 肝胆膵, 87, 4, 439, 446, 2023年10月
    (株)アークメディア, 日本語
  • IMbrave150基準外進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
    荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 鈴木 和治; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉, 肝胆膵, 87, 4, 508, 509, 2023年10月
    (株)アークメディア, 日本語
  • 肝硬変診療ガイドライン改訂に向けて AKIマーカー尿NGALによる肝硬変症例におけるTolvaptan短期/長期効果,投与後AKIの予測
    中井 正人; 小川 浩司; 坂本 直哉, 肝臓, 64, Suppl.2, A574, A574, 2023年09月
    (一社)日本肝臓学会, 日本語
  • 肝癌患者におけるマニュアルトレース法による筋肉量と皮下脂肪CT値評価の有用性の検討
    大原 正嗣; 須田 剛生; 佐々木 貴志; 甲谷 理紗子; 細田 峻一; 吉田 苑永; 得地 祐匡; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉, 肝臓, 64, Suppl.2, A644, A644, 2023年09月
    (一社)日本肝臓学会, 日本語
  • 腹腔鏡下横隔膜縫合術、腹腔静脈シャント術により体液コントロールされた肝硬変の1例
    目野 晃光; 小川 浩司; 保浦 直弘; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 得地 祐匡; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 武藤 潤, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133回・127回, 40, 40, 2023年09月
    日本消化器病学会-北海道支部, 日本語
  • 肝肺症候群を合併したBudd-Chiari症候群の1例
    保浦 直弘; 目野 晃光; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133回・127回, 40, 40, 2023年09月
    日本消化器病学会-北海道支部, 日本語
  • 【超高齢社会における肝胆膵疾患診療】高齢者における肝硬変治療
    中井 正人; 吉田 苑永; 坂本 直哉, 肝胆膵, 86, 6, 697, 702, 2023年06月
    (株)アークメディア, 日本語
  • 肝疾患と生活習慣 AUDITを用いた本邦における慢性肝疾患患者のアルコール使用の実態調査
    中井 正人; 平岡 淳; 吉治 仁志, 肝臓, 64, Suppl.1, A137, A137, 2023年04月
    (一社)日本肝臓学会, 日本語
  • 肝硬変合併症の基礎と臨床 Stroop testで過小診断する症例の特徴から考えた不顕性脳症の診断
    中井 正人; 小川 浩司; 坂本 直哉, 肝臓, 64, Suppl.1, A196, A196, 2023年04月
    (一社)日本肝臓学会, 日本語
  • 肝硬変の成因と病態の推移 当科における肝硬変の成因分析
    小川 浩司; 甲谷 理紗子; 佐々木 貴志; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉, 肝臓, 64, Suppl.1, A237, A237, 2023年04月
    (一社)日本肝臓学会, 日本語
  • 【肝胆膵領域におけるアルコール医学の新潮流】日本におけるアルコール依存の現状と対策 治療目標の選択
    中井 正人; 坂本 直哉, 肝胆膵, 86, 4, 459, 463, 2023年04月
    (株)アークメディア, 日本語
  • 肝細胞腺腫との鑑別が困難であった限局性結節性過形成の1例
    吉田 苑永; 小川 浩司; 佐々木 貴志; 甲谷 理紗子; 細田 峻一; 久保 彰則; 得地 祐匡; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 42, 42, 2023年03月
    日本消化器病学会-北海道支部, 日本語
  • BCLCステージB2肝癌に対してアテゾリズマブ+ベバシズマブ併用療法と焼灼療法にてCancer Freeが得られた1症例
    細田 峻一; 荘 拓也; 佐々木 貴志; 甲谷 理紗子; 吉田 苑永; 得地 祐匡; 大原 正嗣; 中井 正人; 須田 剛生; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 46, 46, 2023年03月
    日本消化器病学会-北海道支部, 日本語
  • BavenoVI分類とYerdel分類を用いた肝疾患に伴う門脈血栓症に対するアンチトロンビンIII製剤の治療効果の検討
    中井 正人; 小川 浩司; 佐々木 貴志; 甲谷 理紗子; 吉田 苑永; 細田 俊一; 得地 祐匡; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉, 日本消化器病学会雑誌, 120, 臨増総会, A417, A417, 2023年03月
    (一財)日本消化器病学会, 日本語
  • 自己免疫性肝炎による昏睡型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
    松井双葉; 後藤了一; 川村典生; 渡辺正明; 金沢亮; 津坂隼也; 松居剛志; 中井正人; 荘拓也; 小川浩司; 嶋村剛; 武冨紹信; 武冨紹信, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133rd-127th, 37, 37, 2023年
    日本消化器病学会-北海道支部, 日本語
  • IMbrave150基準外症例におけるアテゾリズマブ+ベバシズマブ併用療法の生存に寄与する因子の検討-多施設共同研究-
    荘拓也; 須田剛生; 大原正嗣; 中井正人; 小川浩司; 出水孝章; 目黒高志; 中村晃久; 高木智史; 馬場英; 古家乾; 山本義也; 伊藤淳; 山田錬; 宮城島拓人; 坂本直哉, 日本消化器病学会雑誌(Web), 120, 2023年
  • 予後改善を視野に入れた肝硬変のマネージメント 肝硬変症例における息切れ評価とmodified MRC Gradeを用いたPoPH拾い上げの試み
    中井 正人; 荘 拓也; 坂本 直哉, 肝臓, 63, Suppl.3, A666, A666, 2022年10月
    (一社)日本肝臓学会, 日本語
  • 切除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
    荘 拓也; 出水 孝章; 目黒 高志; 中村 晃久; 上林 実; 高木 智史; 馬場 英; 古家 乾; 鈴木 和治; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 1, 39, 39, 2022年09月
    日本消化器病学会-北海道支部, 日本語
  • 肝硬変体液貯留に対するトルバプタン投与症例における尿NGAL測定の有用性
    中井 正人; 森川 賢一; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 大原 正嗣; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉, 肝臓, 63, Suppl.2, A592, A592, 2022年09月
    (一社)日本肝臓学会, 日本語
  • 肝血管筋脂肪腫の1切除例
    佐々木 貴志; 甲谷 理紗子; 細田 峻一; 吉田 苑永; 得地 祐匡; 久保 彰則; 大原 正嗣; 須田 剛生; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉; 相山 健; 武冨 紹信; 岡崎 ななせ; 松野 吉宏, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 40, 40, 2022年09月
    日本消化器病学会-北海道支部, 日本語
  • 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 免疫療法(単剤・複合療法)の効果は肝細胞癌のetiologyと関係するか
    小川 浩司; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉, 肝胆膵, 85, 3, 393, 398, 2022年09月
    (株)アークメディア, 日本語
  • 核酸アナログによるHBs抗原消失—Hepatitis B surface antigen (HBsAg) seroclearance by nucleos(t)ide analogs treatment—特集 B型肝炎診療の進歩
    山田 錬; 森川 賢一; 中村 晃久; 出水 孝章; 梅村 真知子; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉, 消化器・肝臓内科 = Gastroenterology & hepatology / 消化器・肝臓内科編集委員会 編, 12, 2, 184, 192, 2022年08月
    科学評論社, 日本語
  • B型肝炎治療オーバービュー—Overview of treatment for hepatitis B—特集 B型肝炎診療の進歩
    須田 剛生; 川岸 直樹; 大原 正嗣; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉, 消化器・肝臓内科 = Gastroenterology & hepatology / 消化器・肝臓内科編集委員会 編, 12, 2, 172, 174, 2022年08月
    科学評論社, 日本語
  • 【臓器線維化へのアプローチ-肝臓・膵臓のアンチエイジングを見据えて-】臓器線維化治療のニューウェーブ
    小川 浩司; 中井 正人; 坂本 直哉, アンチ・エイジング医学, 18, 3, 182, 185, 2022年06月
    (株)メディカルレビュー社, 日本語
  • 急性・慢性肝不全のマネジメント-予防・診断・治療 Covert脳症に対するリファキシミンの治療効果の検討
    中井 正人; 須田 剛生; 坂本 直哉, 肝臓, 63, Suppl.1, A50, A50, 2022年04月
    (一社)日本肝臓学会, 日本語
  • 肝硬変-合併症の管理(含む門脈圧亢進症) 肝硬変診療ガイドライン2020を踏まえた腹水Grade別の予後と利尿剤の治療効果
    中井 正人; 小川 浩司; 坂本 直哉, 肝臓, 63, Suppl.1, A61, A61, 2022年04月
    (一社)日本肝臓学会, 日本語
  • 再活性化が疑われた急性E型肝炎の1例
    久保 彰則; 小川 浩司; 吉田 苑永; 細田 峻一; 得地 祐匡; 山田 錬; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 石田 勢津子; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 55, 55, 2022年03月
    日本消化器病学会-北海道支部, 日本語
  • 若年女性に見られた肝細胞腺腫症の1例
    北潟谷 隆; 吉田 苑永; 細田 俊一; 久保 彰則; 得地 祐匡; 山田 錬; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 高桑 恵美; 中島 収, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 56, 56, 2022年03月
    日本消化器病学会-北海道支部, 日本語
  • 肝癌に対する新世代マイクロ波凝固療法の治療成績
    中井 正人; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 70, 70, 2022年03月
    日本消化器病学会-北海道支部, 日本語
  • 特集 肝不全・肝硬変に対する再生療法-最先端の今 4.開発中の肝再生医療(7)肝星細胞に対するビタミンAを介した肝線維化改善療法の開発
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 臨床消化器内科, 36, 13, 1690, 1694, 2021年11月20日
    日本メディカルセンター, 日本語
  • 【肝胆膵疾患におけるバイオマーカーの意義を探る】肝疾患のバイオマーカー NASHにおける新規糖鎖バイオマーカー(AAT-A3F)
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝胆膵, 83, 4, 527, 533, 2021年10月
    (株)アークメディア, 日本語
  • 当院における切除不能肝細胞癌に対するAtezolizumab+Bevacizumab併用療法の使用経験
    吉田 苑永; 荘 拓也; 久保 彰則; 得地 祐匡; 細田 峻一; 北潟谷 隆; 山田 錬; 中井 正人; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 129回・123回, 40, 40, 2021年09月
    日本消化器病学会-北海道支部, 日本語
  • Lenvatinib加療後にCRに至りconversion surgeryを施行した肝内多発転移を伴う肝細胞癌の1例
    細田 峻一; 中井 正人; 吉田 苑永; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 岡崎 ななせ; 大塚 拓也; 三橋 智子, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 129回・123回, 42, 42, 2021年09月
    日本消化器病学会-北海道支部, 日本語
  • Transient elastographyによるLSMと年齢を用いたSVR後肝発癌低リスク群の囲い込み
    中井 正人; 山本 義也; 馬場 英; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 古家 乾; 坂本 直哉, 肝臓, 62, Suppl.2, A543, A543, 2021年09月
    (一社)日本肝臓学会, 日本語
  • 除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療経験:多施設共同研究
    荘 拓也; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 62, Suppl.2, A550, A550, 2021年09月
    (一社)日本肝臓学会, 日本語
  • 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 アテゾリズマブ+ベバシズマブによるCR例の特徴
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝胆膵, 83, 2, 259, 263, 2021年08月
    (株)アークメディア, 日本語
  • 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 アテゾリズマブ+ベバシズマブによるCR例の特徴
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝胆膵, 83, 2, 259, 263, 2021年08月
    (株)アークメディア, 日本語
  • 【ガイドライン2020から読み解くNAFLD/NASH】診断 NAFLD/NASHの超音波診断
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝胆膵, 83, 1, 67, 73, 2021年07月
    (株)アークメディア, 日本語
  • 【ガイドライン2020から読み解くNAFLD/NASH】診断 NAFLD/NASHの超音波診断
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝胆膵, 83, 1, 67, 73, 2021年07月
    (株)アークメディア, 日本語
  • 部分的脾動脈塞栓術(PSE)、バルーン閉塞下逆行性経静脈的塞栓術(B-RTO)の肝予備能、線維化マーカー、予後への影響
    中井 正人; 小川 浩司; 坂本 直哉; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一, 肝臓, 62, Suppl.1, A332, A332, 2021年04月
    (一社)日本肝臓学会, 日本語
  • 胆嚢転移を来した原発性肝細胞癌再発の1例
    得地 祐匡; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 荘 拓也; 小川 浩司; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 57, 57, 2021年03月
    日本消化器病学会-北海道支部, 日本語
  • 経過観察中に増大傾向がみられ、肝切除術に至った肝原発神経内分泌腫瘍の1例
    久保 彰則; 小川 浩司; 得地 祐匡; 山田 錬; 北潟谷 隆; 重沢 拓; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 58, 58, 2021年03月
    日本消化器病学会-北海道支部, 日本語
  • 肝機能障害を契機に診断された肝ヘモクロマトーシスの一例
    吉田 苑永; 中井 正人; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 67, 67, 2021年03月
    日本消化器病学会-北海道支部, 日本語
  • 肝疾患患者における筋肉量の経時変化の評価はBIA法に比べCT画像を用いた方法が有用である
    大原正嗣; 須田剛生; 重沢拓; 鈴木和治; 中村晃久; 川岸直樹; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 62, Supplement 1, 2021年
  • 血行異常 肝内動静脈短絡(A-V shunt)
    小川浩司; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 日本臨床, 2021年
  • 【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】カボザンチニブ CELESTIAL試験の総括とサブ解析
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝胆膵, 81, 5, 986, 992, 2020年11月
    (株)アークメディア, 日本語
  • 当院における門脈血栓症に対するアンチトロンビンIII製剤の使用成績
    北潟谷 隆; 小川 浩司; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 44, 44, 2020年10月
    日本消化器病学会-北海道支部, 日本語
  • ソホスブビル/ベルパタスビル投与によりSVR12が得られたC型非代償性肝硬変の1例
    山田 錬; 小川 浩司; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 45, 45, 2020年10月
    日本消化器病学会-北海道支部, 日本語
  • 進行肝細胞癌に対するREFLECT内/外におけるレンバチニブの治療効果と安全性の検討
    荘 拓也; 須田 剛生; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 117, 臨増総会, A253, A253, 2020年07月
    (一財)日本消化器病学会, 日本語
  • 部分的脾動脈塞栓術(PSE)により肝予備能は改善するか
    中井 正人; 小川 浩司; 北潟谷 隆; 山田 錬; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会雑誌, 117, 臨増総会, A367, A367, 2020年07月
    (一財)日本消化器病学会, 日本語
  • 大規模健常人データ(肝移植ドナー・検診受験者)を用いた低骨格筋量に対する最適psoas muscle mass index cut-off値検討と肝疾患患者における評価
    須田 剛生; 大原 正嗣; 小川 浩司; 荘 拓也; 中井 正人; 森川 賢一; 坂本 直哉, 肝臓, 61, Suppl.1, A474, A474, 2020年04月
    (一社)日本肝臓学会, 日本語
  • NAFLD患者におけるMRエラストグラフィ診断能の検討
    山田 錬; 小川 浩司; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 61, Suppl.1, A495, A495, 2020年04月
    (一社)日本肝臓学会, 日本語
  • 進行肝細胞癌に対するレンバチニブ治療成績からみた適格使用時期の検討 多施設共同研究
    荘 拓也; 須田 剛生; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 川岸 直樹; 宮城島 拓人; 馬場 英; 古家 乾; 山本 義也; 小林 智絵; 目黒 高志; 高木 智史; 神山 俊哉; 武冨 紹信; 坂本 直哉, 肝臓, 61, Suppl.1, A334, A334, 2020年04月
    (一社)日本肝臓学会, 日本語
  • トルバプタン奏効後の再燃と炎症および尿L-FABP値の関連
    中井正人; 北潟谷隆; 山田錬; 重沢拓; 鈴木和治; 中村晃久; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 61, Supplement 1, 2020年
  • 肝性脳症の疫学
    中井正人; 小川浩司; 久保彰則; 得地祐匡; 北潟谷隆; 山田錬; 重沢拓; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 日本門脈圧亢進症学会雑誌, 26, 3, 2020年
  • HCC既往の無いC型肝炎SVR後の初発肝発癌の囲い込み因子としての肝弾性度の有用性
    中井正人; 山本義也; 馬場英; 古家乾; 北潟谷隆; 山田錬; 重沢拓; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 61, Supplement 2, 2020年
  • 免疫チェックポイント阻害剤関連肝炎の頻度,予測因子,臨床経過の検討
    北潟谷隆; 須田剛生; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 61, Supplement 2, 2020年
  • 安定同位体を用いたSALSA法による比較質量分析法の開発
    花松久寿; 西風隆司; 津元裕樹; 小川浩司; 横田育子; 森川賢一; 須田剛生; 荘拓也; 中井正人; 三浦信明; 関谷禎規; 岩本慎一; 三浦ゆり; 田中耕一; 坂本直哉; 古川潤一, 日本糖質学会年会要旨集, 39th, 2020年
  • 【肝胆膵の線維化up-to-date】肝臓の線維化 臨床・病理 新たな肝線維化マーカーの開発状況
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 79, 5, 891, 896, 2019年11月
    (株)アークメディア, 日本語
  • CLIA法を用いたPIVKA-IIの臨床的有用性の評価
    小川 浩司; 鈴木 和治; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 60, 11, 397, 404, 2019年11月
    (一社)日本肝臓学会, 日本語
  • 進行肝細胞癌に対するレンバチニブの奏功に寄与する因子と予備能変化についての検討
    山田 錬; 荘 拓也; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 60, Suppl.3, A946, A946, 2019年11月
    (一社)日本肝臓学会, 日本語
  • C型肝炎患者の血清Angiopoietin-2値はDAAs治療後の肝線維化非改善例を予測する
    川岸 直樹; 須田 剛生; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.2, A653, A653, 2019年10月
    (一社)日本肝臓学会, 日本語
  • カルニチンは肝硬変患者における筋肉量減少を抑制する
    大原 正嗣; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 川岸 直樹; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.2, A677, A677, 2019年10月
    (一社)日本肝臓学会, 日本語
  • 進行肝細胞癌に対するレンバチニブ投与症例からみた適格使用時期の検討
    荘 拓也; 須田 剛生; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.2, A705, A705, 2019年10月
    (一社)日本肝臓学会, 日本語
  • 【進化する肝細胞癌の薬物療法-2019 Update(Part 2)】切除・ablation後のアジュバント試験 ニボルマブによる根治治療後の再発抑制試験(CheckMate 9DX trial)
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 79, 3, 461, 465, 2019年09月
    (株)アークメディア, 日本語
  • 増大傾向を認めた肝血管筋脂肪腫の一切除例
    北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 折茂 達也; 神山 俊哉; 武冨 紹信; 杉野 弘和; 三橋 智子, 日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 46, 46, 2019年09月
    日本消化器病学会-北海道支部, 日本語
  • 急速な経過をたどった肉腫様肝癌の1例
    山田 錬; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 清水 亜衣; 三橋 智子, 日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 59, 59, 2019年09月
    日本消化器病学会-北海道支部, 日本語
  • 門亢症を伴う肝硬変に対する薬物療法の進歩〜腹水・脳症・血栓など〜 リファキシミン投与前後でのNPT改善効果、Bacterial translocationマーカーの検討
    中井 正人; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本門脈圧亢進症学会雑誌, 25, 3, 70, 70, 2019年09月
    (一社)日本門脈圧亢進症学会, 日本語
  • 肝静脈-下大静脈ステント留置にて改善した4型Budd-Chiari症候群の一例
    鈴木 和治; 中井 正人; 阿保 大介; 北潟谷 隆; 山田 錬; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 吉野 裕紀; 曽山 武士; 坂本 直哉, 日本門脈圧亢進症学会雑誌, 25, 3, 154, 154, 2019年09月
    (一社)日本門脈圧亢進症学会, 日本語
  • リファキシミン投与によるNPT改善効果とカルニチン製剤との比較
    中井正人; 重沢拓; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 60, Supplement 1, A523, A523, 2019年04月20日
    (一社)日本肝臓学会, 日本語
  • リファキシミン投与によるNPT改善効果とカルニチン製剤との比較
    中井 正人; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.1, A523, A523, 2019年04月
    (一社)日本肝臓学会, 日本語
  • 【B型肝炎治療におけるアンメットニーズ】肝線維化を戻すことは可能か
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, Progress in Medicine, 39, 4, 405, 408, 2019年04月
    (株)ライフ・サイエンス, 日本語
  • 【B型肝炎治療におけるアンメットニーズ】肝線維化を戻すことは可能か
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, Progress in Medicine, 39, 4, 405, 408, 2019年04月
    (株)ライフ・サイエンス, 日本語
  • 【肝性脳症治療の変遷】肝性脳症治療の最近の考え方 肝性脳症治療の流れと各薬剤の位置づけ
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 78, 3, 379, 384, 2019年03月
    (株)アークメディア, 日本語
  • 当院におけるE型急性肝不全4例の検討
    重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会プログラム・抄録集, 124回, 45, 45, 2019年03月
    日本消化器病学会-北海道支部, 日本語
  • 肝細胞癌に対してレンバニチニブ導入後破壊性甲状腺炎を呈した一例
    久々湊 雅; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会プログラム・抄録集, 124回, 60, 60, 2019年03月
    日本消化器病学会-北海道支部, 日本語
  • 肝硬変様の形態を呈した肝サルコイドーシスの一例
    中村 晃久; 重沢 拓; 鈴木 和治; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会プログラム・抄録集, 124回, 62, 62, 2019年03月
    日本消化器病学会-北海道支部, 日本語
  • 肝疾患患者における筋肉量測定方法別の経時的変化
    大原 正嗣; 重沢 拓; 中村 晃久; 鈴木 和治; 梅村 真知子; 川岸 直樹; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A372, A372, 2019年03月
    (一財)日本消化器病学会, 日本語
  • 進行肝細胞癌に対するレンバチニブの4週/8週における治療効果と安全性の検討
    荘 拓也; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A415, A415, 2019年03月
    (一財)日本消化器病学会, 日本語
  • 肝疾患患者における筋肉量測定方法別の経時的変化
    大原 正嗣; 重沢 拓; 中村 晃久; 鈴木 和治; 梅村 真知子; 川岸 直樹; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A372, A372, 2019年03月
    (一財)日本消化器病学会, 日本語
  • 進行肝細胞癌に対するレンバチニブの4週/8週における治療効果と安全性の検討
    荘 拓也; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A415, A415, 2019年03月
    (一財)日本消化器病学会, 日本語
  • 炎症性筋線維芽細胞性腫瘍に対しステロイド治療で長期の病勢コントロールが得られた1例
    國崎 守; 朝比奈 肇; 水柿 秀紀; 菊地 英毅; 榊原 純; 品川 尚文; 清水 亜衣; 松野 吉宏; 樋田 泰浩; 加賀 基知三; 中井 正人; 菅原 恵理; 西原 広史, 肺癌, 59, 1, 109, 109, 2019年02月
    (NPO)日本肺癌学会, 日本語
  • 肝疾患患者における筋肉量測定方法別の経時的変化
    大原正嗣; 重沢拓; 中村晃久; 鈴木和治; 梅村真知子; 川岸直樹; 中井正人; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 116, 2019年
  • 進行肝細胞癌に対するレンバチニブの4週/8週における治療効果と安全性の検討
    荘拓也; 須田剛生; 重沢拓; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 中井正人; 森川賢一; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 116, 2019年
  • FPGおよびIPG法による標的タンパク質におけるN-結合型糖鎖解析法の開発
    花松久寿; 小林隆史; 小川浩司; 羽藤愛美; 吉永知世; 森川賢一; 須田剛生; 荘拓也; 中井正人; 東野賢一; 沼田義人; 篠原康郎; 坂本直哉; 古川潤一, 日本糖質学会年会要旨集, 38th, 2019年
  • 進行肝細胞癌に対するレンバチニブの初期治療経験
    荘拓也; 須田剛生; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 中井正人; 森川賢一; 小川浩司; 坂本直哉, Liver Cancer Journal, 10, Suppl.2, 55‐56, 56, 2018年12月10日
    (株)メディカルレビュー社, 日本語
  • 進行肝細胞癌に対するレンバチニブの初期治療経験
    荘 拓也; 須田 剛生; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, The Liver Cancer Journal, 10, Suppl.2, 55, 56, 2018年12月
    (株)メディカルレビュー社, 日本語
  • Sorafenib不応進行肝細胞癌におけるRegorafenibの初期使用経験
    中村晃久; 中井正人; 重沢拓; 鈴木和治; 大原正嗣; 川岸直樹; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 3, A931, A931, 2018年11月25日
    (一社)日本肝臓学会, 日本語
  • 当院における肝細胞癌に対するラジオ波焼灼療法(RFA)の検討
    山本 義也; 中井 正人; 江藤 和範; 小松 康之; 小川 浩司; 山本 文泰; 畑中 一映; 片桐 雅樹; 成瀬 宏仁, 道南医学会ジャーナル, 増刊号, 26, 28, 2018年11月
    当院では肝細胞癌に対するRFAの適応を「肝障害度がAもしくはBで腫瘍径3cm以下、腫瘍個数3個以内、脈管侵襲のない症例」としている。2000~2006年にRFAを施行した肝細胞癌は92例128結節で、最大腫瘍径の内訳は、20mm以下が78結節、21~30mm以下が33結節、31~50mm以下が11結節、50mm超が6結節であった。今回、腫瘍径毎の局所再発率について調査した。結果、20mm以下群は10.3%、21~30mm以下群は15.2%、31~50mm以下群は27.3%、50mm超群は66.7%であり、腫瘍径の増大とともに局所再発率は上昇していた。RFAに先行してTAEを併施した場合と併施しなかった場合の局所再発率について調査した結果、20mm以下群では併施あり6.1%/併施なし13.3%、21~30mm以下群では併施あり11.5%/なし28.6%、30mm超群では併施あり37.5%/なし100%であり、各群とも併施ありで局所再発率は低い傾向にあった。入院期間の延長を要したり予後に大きく影響したと思われる重篤な合併症を5例に認め、内訳は肝梗塞2例、肝不全1例、十二指腸穿孔1例、横隔膜ヘルニア1例であった。, 道南医学会, 日本語
  • 炎症性筋線維芽細胞性腫瘍に対しステロイド治療で長期の病勢コントロールが得られた一例
    國崎守; 朝比奈肇; 朝比奈肇; 水柿秀紀; 菊地英毅; 榊原純; 清水亜衣; 松野吉宏; 樋田泰浩; 加賀基知三; 中井正人; 菅原恵理; 西原広史; 品川尚文, 日本肺癌学会総会号, 59th, 6, 733, 733, 2018年10月25日
    (NPO)日本肺癌学会, 日本語
  • 核酸アナログによるウイルス制御下での肝発癌の検討
    小川浩司; 重沢拓; 中村晃久; 鈴木和治; 川岸直樹; 大原正嗣; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝臓, 59, Supplement 2, A659, A659, 2018年09月20日
    (一社)日本肝臓学会, 日本語
  • 高発癌リスク群HIV/HCV重複感染例に対するHCV治療
    荘拓也; 須田剛生; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 中井正人; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 2, A707, A707, 2018年09月20日
    (一社)日本肝臓学会, 日本語
  • 肝硬変症に伴う高アンモニア血症に対するリファキシミンの効果,安全性の検討
    中井正人; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 2, A721, A721, 2018年09月20日
    (一社)日本肝臓学会, 日本語
  • HCV肝炎治療高齢化時代における,HCV排除後LDL‐C上昇の動脈硬化リスクの検討
    川岸直樹; 須田剛生; 鈴木和治; 中村晃久; 大原正嗣; 梅村真知子; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 2, A665, A665, 2018年09月20日
    (一社)日本肝臓学会, 日本語
  • 【急速に変貌する肝細胞癌の薬物療法2018 Update】免疫チェックポイント阻害剤同士のコンビネーション治療 ソラフェニブvsアテゾリズマブ+ベバシズマブの第III相試験(IMbrave150試験)
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 77, 2, 486, 490, 2018年08月
    (株)アークメディア, 日本語
  • 【急速に変貌する肝細胞癌の薬物療法2018 Update】 免疫チェックポイント阻害剤同士のコンビネーション治療 ソラフェニブvsアテゾリズマブ+ベバシズマブの第III相試験(IMbrave150試験)
    小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 77, 2, 486, 490, 2018年08月
    (株)アークメディア, 日本語
  • 長期生存を目指した分子標的治療ほか 進行肝細胞癌に対するソラフェニブ治療不応例の検討
    中村晃久; 小川浩司; 鈴木和治; 大原正嗣; 川岸直樹; 出水孝章; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, Liver Cancer Journal, Suppl.1, 75‐76, 76, 2018年06月10日
    (株)メディカルレビュー社, 日本語
  • 進行肝細胞癌に対するソラフェニブ治療不応例の検討
    中村 晃久; 小川 浩司; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, The Liver Cancer Journal, Suppl.1, 75, 76, 2018年06月
    (株)メディカルレビュー社, 日本語
  • NASH/NAFLDの新知見 画像診断 Transient elastography
    小川浩司; 中井正人; 荘拓也; 須田剛生; 森川賢一; 西田睦; 坂本直哉, 肝胆膵, 76, 4, 662‐667, 667, 2018年04月28日
    (株)アークメディア, 日本語
  • 肝硬変症の成因別実態
    小川浩司; 鈴木和治; 中村晃久; 川岸直樹; 大原正嗣; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝臓, 59, Supplement 1, A272, 2018年04月20日
    日本語
  • HBV感染者に対する核酸アナログ投与の脂質代謝に及ぼす影響の検討
    鈴木和治; 須田剛生; 中村晃久; 大原正嗣; 川岸直樹; 出水孝章; 梅村真知子; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 1, A486, A486, 2018年04月20日
    (一社)日本肝臓学会, 日本語
  • DAAsによるHCV排除後の肝脂肪化・脂質代謝変化の包括的検討
    川岸直樹; 鈴木和治; 中村晃久; 大原正嗣; 梅村真知子; 出水孝章; 中井正人; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 1, A387, A387, 2018年04月20日
    (一社)日本肝臓学会, 日本語
  • 【肝癌-診断・治療の最新知見-】SVR後の発がん予測因子
    中井 正人; 坂本 直哉, 日本臨床, 76, 2, 330, 336, 2018年02月
    (株)日本臨床社, 日本語
  • 肝臓の栄養管理 肝硬変患者に対するカルニチン投与による筋肉量への影響
    大原 正嗣; 須田 剛生; 小川 浩司; 鈴木 和治; 中村 晃久; 川岸 直樹; 梅村 真知子; 出水 孝章; 中井 正人; 荘 拓也; 森川 賢一; 坂本 直哉, 日本病態栄養学会誌, 21, Suppl., S, 38, 2018年01月
    (一社)日本病態栄養学会, 日本語
  • エピルビシンを用いた肝動脈化学塞栓術(TACE )施行時の制吐薬による消化器症状の予防効果の評価
    坂本達彦; 齋藤佳敬; 小林正紀; 山田武宏; 笠師久美子; 中井正人; 小川浩司; 井関 健, 日本医療薬学会第27回年会講演要旨集, 27, 2017年11月
    研究発表ペーパー・要旨(全国大会,その他学術会議)
  • 肝硬変患者における血中亜鉛の検討
    小川 浩司; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.3, A779, A779, 2017年11月
    (一社)日本肝臓学会, 日本語
  • 慢性肝疾患患者のそう痒症状に対するナルフラフィンの治療効果の検討
    鈴木 和治; 中井 正人; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A788, A788, 2017年11月
    (一社)日本肝臓学会, 日本語
  • C型肝炎のDAAs治療における脂質、糖代謝の変化の検討
    川岸 直樹; 鈴木 和治; 中村 晃久; 大原 正嗣; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A813, A813, 2017年11月
    (一社)日本肝臓学会, 日本語
  • 肝硬変患者における血中亜鉛の検討
    小川 浩司; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.3, A779, A779, 2017年11月
    (一社)日本肝臓学会, 日本語
  • 慢性肝疾患患者のそう痒症状に対するナルフラフィンの治療効果の検討
    鈴木 和治; 中井 正人; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A788, A788, 2017年11月
    (一社)日本肝臓学会, 日本語
  • C型肝炎のDAAs治療における脂質、糖代謝の変化の検討
    川岸 直樹; 鈴木 和治; 中村 晃久; 大原 正嗣; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A813, A813, 2017年11月
    (一社)日本肝臓学会, 日本語
  • ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果と非著効例における薬剤耐性ウイルスの検討
    荘 拓也; 須田 剛生; 大原 正嗣; 出水 孝章; 川岸 直樹; 中井 正人; 森川 賢一; 伊藤 淳; 山本 義也; 小野 雄司; 永坂 敦; 寺下 勝巳; 小林 智絵; 古家 乾; 坂本 直哉, 肝臓, 58, Suppl.2, A575, A575, 2017年09月
    (一社)日本肝臓学会, 日本語
  • DAA治療非著効により獲得される耐性変異の検討
    伊藤 淳; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.2, A589, A589, 2017年09月
    (一社)日本肝臓学会, 日本語
  • 肝硬変患者における筋肉量測定方法の検討
    大原 正嗣; 鈴木 和治; 中村 晃久; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.2, A633, A633, 2017年09月
    (一社)日本肝臓学会, 日本語
  • 核酸アナログ製剤によるHBs抗原の低下作用
    小川 浩司; 中村 晃久; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.2, A616, A616, 2017年09月
    (一社)日本肝臓学会, 日本語
  • NBNC肝癌の臨床的特徴
    小川 浩司; 中村 晃久; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.2, A604, A604, 2017年09月
    (一社)日本肝臓学会, 日本語
  • ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果と非著効例における薬剤耐性ウイルスの検討
    荘 拓也; 須田 剛生; 大原 正嗣; 出水 孝章; 川岸 直樹; 中井 正人; 森川 賢一; 伊藤 淳; 山本 義也; 小野 雄司; 永坂 敦; 寺下 勝巳; 小林 智絵; 古家 乾; 坂本 直哉, 肝臓, 58, Suppl.2, A575, A575, 2017年09月
    (一社)日本肝臓学会, 日本語
  • DAA治療非著効により獲得される耐性変異の検討
    伊藤 淳; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.2, A589, A589, 2017年09月
    (一社)日本肝臓学会, 日本語
  • NBNC肝癌の臨床的特徴
    小川 浩司; 中村 晃久; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.2, A604, A604, 2017年09月
    (一社)日本肝臓学会, 日本語
  • 核酸アナログ製剤によるHBs抗原の低下作用
    小川 浩司; 中村 晃久; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.2, A616, A616, 2017年09月
    (一社)日本肝臓学会, 日本語
  • 肝硬変患者における筋肉量測定方法の検討
    大原 正嗣; 鈴木 和治; 中村 晃久; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.2, A633, A633, 2017年09月
    (一社)日本肝臓学会, 日本語
  • RFA/TACE前後のM2BPGiの変化とRFA後再発予測因子としてのM2BPGiの有用性
    中井 正人; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 伊藤 淳; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.1, A352, A352, 2017年04月
    (一社)日本肝臓学会, 日本語
  • 肝炎ウイルス陽性者アラートシステム導入後の改善効果
    小川 浩司; 川岸 直樹; 大原 正嗣; 出水 孝章; 梅村 真知子; 伊藤 淳; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会雑誌, 114, 臨増総会, A340, A340, 2017年03月
    (一財)日本消化器病学会, 日本語
  • 肝硬変を理解する―分子機構から実臨床に至るまで―治療 抗ウイルス治療(C型肝硬変)
    中井正人; 須田剛生; 坂本直哉, 肝胆膵, 73, 6, 1093‐1099, 1099, 2016年12月28日
    (株)アークメディア, 日本語
  • 【肝硬変を理解する-分子機構から実臨床に至るまで-】 治療 抗ウイルス治療(C型肝硬変)
    中井 正人; 須田 剛生; 坂本 直哉, 肝・胆・膵, 73, 6, 1093, 1099, 2016年12月, [筆頭著者]
    (株)アークメディア, 日本語
  • 高齢者ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果・安全性の検討
    荘 拓也; 須田 剛生; 大原 正嗣; 出水 孝章; 梅村 真知子; 川岸 直樹; 伊藤 淳; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 57, Suppl.3, A776, A776, 2016年10月
    (一社)日本肝臓学会, 日本語
  • 核酸アナログ製剤によるHBs抗原の低下作用
    小川 浩司; 大原 正嗣; 川岸 直樹; 梅村 真知子; 出水 孝章; 伊藤 淳; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 57, Suppl.2, A530, A530, 2016年09月
    (一社)日本肝臓学会, 日本語
  • ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果の検討
    荘 拓也; 山本 義也; 永坂 敦; 古家 乾; 吉田 純一; 常松 泉; 伊藤 淳; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会雑誌, 113, 臨増大会, A742, A742, 2016年09月
    (一財)日本消化器病学会, 日本語
  • 進行肝細胞癌におけるSorafenib+5-FU併用療法の検討
    荘 拓也; 小川 浩司; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, The Liver Cancer Journal, 8, 1, 58, 59, 2016年06月
    (株)メディカルレビュー社, 日本語
  • 日本におけるB型肝炎キャリアの実態とその診療
    中井 正人; 小川 浩司; 坂本 直哉, 消化器の臨床, 19, 3, 181, 186, 2016年06月, [筆頭著者]
    (株)ヴァンメディカル, 日本語
  • 【肝不全-その常識は正しいか?-】 慢性肝不全 その常識は正しいか? ウイルス性慢性肝不全に対する抗ウイルス治療は有用である
    中井 正人; 須田 剛生; 坂本 直哉, 救急・集中治療, 28, 5-6, 377, 381, 2016年05月, [筆頭著者]
    (株)総合医学社, 日本語
  • C型慢性肝疾患に対するダクラタスビル/アスナプレビル併用療法による肝線維化指標の改善効果
    小川 浩司; 出水 孝章; 梅村 真知子; 伊藤 淳; 佐藤 史幸; 常松 聖司; 中井 正人; 荘 卓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会雑誌, 113, 臨増総会, A312, A312, 2016年03月
    (一財)日本消化器病学会, 日本語
  • 肝移植後C型肝炎患者に対するダクラタスビル・アスナプレビル併用療法の検討
    小川 浩司; 梅村 真知子; 出水 孝章; 伊藤 淳; 佐藤 史幸; 常松 聖司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉; 嶋村 剛, 肝臓, 56, Suppl.3, A981, A981, 2015年11月
    (一社)日本肝臓学会, 日本語
  • 肝細胞癌におけるKLF5による癌幹細胞制御機構
    佐藤 史幸; 夏井坂 光輝; 前原 経; 浅野 彩華; 久保田 良政; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 大西 俊介; 坂本 直哉, 肝臓, 56, Suppl.3, A1002, A1002, 2015年11月
    (一社)日本肝臓学会, 日本語
  • 肝癌・非肝癌症例における肝弾性値の検討
    荘 拓也; 小川 浩司; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 56, Suppl.3, A1010, A1010, 2015年11月
    (一社)日本肝臓学会, 日本語
  • 単純性脂肪肝と非アルコール性脂肪性肝炎の臨床的検討
    寺下 勝巳; 小川 浩司; 伊藤 淳; 佐藤 史幸; 常松 聖司; 佃 曜子; 中井 正人; 荘 拓也; 須田 剛気; 森川 健一; 坂本 直哉, 肝臓, 56, Suppl.2, A756, A756, 2015年09月
    (一社)日本肝臓学会, 日本語
  • B型慢性肝炎に対するテノホビル(TDF)の初期使用経験と短期効果の検討
    中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.2, A760, A760, 2015年09月
    (一社)日本肝臓学会, 日本語
  • 非消化器系診療科における院内肝炎ウイルス陽性者の動向調査
    小川 浩司; 伊藤 淳; 常松 聖司; 佐藤 史幸; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 56, Suppl.2, A788, A788, 2015年09月
    (一社)日本肝臓学会, 日本語
  • NS3、NS5AおよびNS5B阻害剤耐性変異とシメプレビル3剤併用療法における治療効果の検討
    伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 荘 拓也; 須田 剛生; 夏井坂 光輝; 森川 賢一; 小川 浩司; 永坂 敦; 古家 乾; 宮城島 拓人; 坂本 直哉, 肝臓, 56, Suppl.1, A247, A247, 2015年04月
    (一社)日本肝臓学会, 日本語
  • 当科におけるC型肝炎SVR後の肝発癌症例の検討 発癌率と危険因子
    中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 森川 賢一; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.1, A262, A262, 2015年04月
    (一社)日本肝臓学会, 日本語
  • 肝動注化学療法における早期治療効果予測因子に関する検討
    常松 聖司; 須田 剛生; 伊藤 淳; 佐藤 史幸; 寺下 勝巳; 佃 曜子; 中井 正人; 荘 拓也; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.1, A285, A285, 2015年04月
    (一社)日本肝臓学会, 日本語
  • C型肝炎ウイルスの粒子形成・分泌機構の解明と関与する細胞性因子の解析
    森川 賢一; 島崎 とも江; 伊藤 淳; 常松 聖司; 佐藤 史幸; 寺下 勝巳; 佃 曜子; 中井 正人; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.1, A318, A318, 2015年04月
    (一社)日本肝臓学会, 日本語
  • 各種肝疾患における肝弾性度の検討
    荘 拓也; 小川 浩司; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 須田 剛生; 森川 賢一; 夏井坂 光輝; 坂本 直哉, 肝臓, 56, Suppl.1, A360, A360, 2015年04月
    (一社)日本肝臓学会, 日本語
  • ヒト初代B細胞におけるHCVcc感染
    中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; フセイン・ハッサン・アリ; 松本 美佐子; 瀬谷 司; 坂本 直哉, 日本消化器病学会雑誌, 112, 臨増総会, A354, A354, 2015年03月
    (一財)日本消化器病学会, 日本語
  • エラストを臨床に活かす 当科におけるフィブロスキャン活用の現状
    荘 拓也; 小川 浩司; 伊藤 淳; 佃 曜子; 寺下 勝巳; 中井 正人; 坂本 直哉; 工藤 悠輔; 西田 睦, 超音波医学, 42, 1, 83, 83, 2015年01月
    (一社)日本超音波医学会, 日本語
  • 当院におけるフォンタン術後患者の肝合併症の現状
    荘 拓也; 小川 浩司; 伊藤 淳; 佐藤 史幸; 常松 聖司; 佃 曜子; 寺下 勝巳; 中井 正人; 須田 剛生; 夏井坂 光輝; 坂本 直哉; 泉 岳; 武田 充人; 有賀 正, 肝臓, 55, Suppl.3, A855, A855, 2014年10月
    (一社)日本肝臓学会, 日本語
  • L-カルニチンのC型肝炎ウイルス増殖抑制効果に関する研究
    佃 曜子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; 中馬 誠; 坂本 直哉, 日本消化器病学会雑誌, 111, 臨増大会, A916, A916, 2014年09月
    (一財)日本消化器病学会, 日本語
  • 非代償性肝硬変に伴う胸腹水および肝腎症候群に対するトルバプタン使用例の検討
    中井 正人; 伊藤 淳; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 55, Suppl.2, A670, A670, 2014年09月
    (一社)日本肝臓学会, 日本語
  • 当科におけるHCV/HIV重複感染症の現状と抗HCV療法
    荘 拓也; 中馬 誠; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 堀本 啓大; 須田 剛生; 夏井坂 光輝; 藤本 勝也; 遠藤 知之; 豊嶋 崇徳; 坂本 直哉, 肝臓, 55, Suppl.1, A213, A213, 2014年04月
    (一社)日本肝臓学会, 日本語
  • L-カルニチンのC型肝炎ウイルス増殖抑制効果に関する研究
    佃 曜子; 伊藤 淳; 佐藤 史幸; 常松 聖司; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 須田 剛生; 夏井坂 光輝; 中馬 誠; 坂本 直哉, 肝臓, 55, Suppl.1, A240, A240, 2014年04月
    (一社)日本肝臓学会, 日本語
  • L-カルニチンのC型肝炎ウイルス増殖抑制効果に関する研究
    佃 曜子; 須田 剛生; 佐藤 史幸; 常松 聖司; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 夏井坂 光輝; 中馬 誠; 坂本 直哉, 日本消化器病学会雑誌, 111, 臨増総会, A306, A306, 2014年03月
    (一財)日本消化器病学会, 日本語
  • 低分化型肝細胞癌と肝内胆管癌の画像所見からの鑑別
    荘 拓也; 中馬 誠; 常松 聖司; 佐藤 史幸; 寺下 勝巳; 佃 曜子; 中井 正人; 堀本 啓大; 須田 剛生; 夏井坂 光輝; 横尾 英樹; 神山 俊哉; 武富 紹信; 坂本 直哉, 肝臓, 54, Suppl.3, A860, A860, 2013年11月
    (一社)日本肝臓学会, 日本語
  • 分子標的薬と殺細胞性薬剤併用による治療効果増強の検証 高度進行肝癌に対する5-FU+ソラフェニブ併用療法の臨床第I相試験
    荘 拓也; 中西 満; 中馬 誠; 中村 路夫; 永坂 敦; 小川 浩司; 山本 義也; 目黒 高志; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 小林 智絵; 夏井坂 光輝; 髭 修平; 坂本 直哉, The Liver Cancer Journal, 5, 2, 142, 143, 2013年06月
    (株)メディカルレビュー社, 日本語
  • 高度進行肝癌に対する5-FU+ソラフェニブ併用療法の臨床第I相試験 分子標的薬と殺細胞性薬剤併用による治療効果増強の検証
    中西 満; 中馬 誠; 髭 修平; 中村 路夫; 小川 浩司; 常松 聖司; 佃 曜子; 寺下 勝巳; 中井 正人; 小林 智絵; 荘 拓也; 山本 義也; 永坂 敦; 目黒 高志; 坂本 直哉, 肝臓, 53, Suppl.1, A406, A406, 2012年04月
    (一社)日本肝臓学会, 日本語
  • C型肝炎患者に対するリバビリン単独投与における貧血と血小板増加効果
    小林 智絵; 髭 修平; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 中西 満; 小川 浩司; 中馬 誠, 日本消化器病学会雑誌, 109, 臨増総会, A313, A313, 2012年03月
    (一財)日本消化器病学会, 日本語
  • 肝細胞癌に対するラジオ波焼灼療法後の同亜区域内、亜区域外再発と生命予後の検討
    荘 拓也; 中馬 誠; 中西 満; 堀本 啓大; 中井 正人; 小林 智絵; 寺下 勝巳; 髭 修平; 浅香 正博, 肝臓, 52, Suppl.2, A664, A664, 2011年09月
    (一社)日本肝臓学会, 日本語
  • Precore/Core promoter変異とB型肝炎の病態および抗HBV治療
    中井 正人; 小林 智絵; 荘 拓也; 中西 満; 中馬 誠; 髭 修平, 肝臓, 52, Suppl.1, A292, A292, 2011年04月
    (一社)日本肝臓学会, 日本語
  • 検査値の読み方 C型肝炎のペグIFN/リバビリン併用治療効果、副作用に関連するヒト遺伝子多型-IL28BとITPA遺伝子変異
    髭 修平; 小林 智絵; 中井 正人; 荘 拓也; 中西 満; 中馬 誠, 臨床消化器内科, 26, 5, 611, 615, 2011年04月
    (株)日本メディカルセンター, 日本語
  • 【B型肝炎治療の最新戦略】 B型肝炎に対するIFN/核酸アナログ製剤の有効性
    髭 修平; 中馬 誠; 中井 正人; 小林 智絵; 荘 拓也; 中西 満; 浅香 正博, 消化器内科, 52, 1, 108, 114, 2011年01月
    (有)科学評論社, 日本語
  • HBV関連肝細胞癌サーベイランスにおけるHBコア関連抗原の有用性
    中西 満; 中馬 誠; 髭 修平; 小林 智絵; 中井 正人; 荘 拓也; 浅香 正博, 肝臓, 52, 6, 387, 389, 2011年
    (一社)日本肝臓学会, 英語
  • 非B非C型肝細胞癌の臨床的検討
    荘 拓也; 中馬 誠; 中井 正人; 小林 智絵; 中西 満; 山本 義也; 髭 修平; 浅香 正博, 肝臓, 51, Suppl.2, A560, A560, 2010年09月
    (一社)日本肝臓学会, 日本語
  • Sonazoid造影超音波にて経過観察し得た肝炎症性偽腫瘍の1例
    中村 俊一; 岡崎 真悟; 野瀬 弘之; 大野 竜一; 東 弘志; 中井 正人; 宮下 憲暢, 超音波医学, 37, 4, 537, 537, 2010年07月
    (一社)日本超音波医学会, 日本語
  • Eating Disorderを背景とした急性胃拡張による胃腸管壊死の一例
    高橋 秀和; 中井 正人; 廣田 ジョージョ; 宮下 憲暢; 小西 康平; 横山 仁; 筋浦 立成; 内田 多久實; 藤永 明, 北海道農村医学会雑誌, 42, 29, 34, 2010年03月
    症例は15歳の女子で、中学1年生頃より不登校となり、リストカットや大量服薬による自殺を図るようになった。食事を食べては下剤を内服し、拒食・過食を繰り返し、病院で加療されたが継続して通院しなくなった。夕食を大量に摂取後、普段は食後に嘔吐していたが嘔吐できず、腹痛が増強し救急搬送された。LDH、アミラーゼ、Cr、血糖の軽度な上昇を認めるのみで、腹部単純X線で著明な胃拡張を認め、free air様に見えた。腹部CTで食物で満たされた胃が腹部全体に占める著明な胃拡張を認め、骨盤腔にまで達していた。腹腔内および後腹膜臓器は胃により圧排され変位し、下大静脈や腹部大動脈は拡張した胃によって圧迫されていた。肝臓には造影ムラが認められ、血流障害の存在が示唆されたが明らかなfree air像は認めなかった。大量の食事摂取による急性胃拡張と診断し、救急外来で18FrのNGチューブを挿入し、1L胃内のドレナージを施行し、症状は軽快した。経過観察のため入院し、翌朝腹部症状が再燃し、内視鏡でドレナージを試みたが固形物が多く、吸引できず断念した。胃内には多量の残渣があり観察は不十分であったが、粘膜は白色調で壊死が疑われた。経鼻内視鏡を経口的に胃内へ挿入し、これを内筒として胃洗浄用チューブを経口的に挿入し胃内容物を5L排液した。大量の輸液を施行したが無尿状態となり、LDH、CKなどの組織逸脱酵素上昇を認めたが乳酸値上昇を伴う著明な代謝性代謝性アシドーシスを認めた。血液透析の施行を考えたが血圧が低いためできず、大量輸液、DIC治療、γ-グロブリン投与など内科的集学治療を行ったが反応せず翌日死亡した。, 北海道農村医学会, 日本語
  • 小腸癌転移病巣にTS-1+CPT-11療法が奏効した1例
    畑中 一映; 林 秀幸; 中井 正人; 井上 弘行; 小川 浩司; 山本 文泰; 山本 義也; 片桐 雅樹; 成瀬 宏仁; 原 豊; 工藤 和洋; 高橋 一人, 函館医学誌, 33, 1, 19, 22, 2009年10月
    小腸癌術約1年後、腫瘍マーカーCA19-9の上昇、続いて肝S5、下大静脈周囲リンパ節、骨盤腔内に転移所見がみられた50歳代男性症例について検討した。術後補助化学療法としてテガフール・ウラシル(UFT)内服治療を行っていたが、抗癌剤感受性試験でテガフール・ギメラシル・オテラシルカリウム(TS-1)およびイリノテカン(CPT-11)が高感受性を示したことより、全身化学療法としてTS-1+CPT-11併用療法を開始した。経過中、Grade 1の脱毛、Grade 3の好中球数減少を認めたが他に重篤な有害事象はみられなかった。6コース(4週/コース)終了時点のCTで測定可能病変は消失し、PETでも集積を認めず、Complete response(CR)と判定した。小腸癌再発病変に対し、効果の高い治療法として選択肢の1つになりうる可能性が示された。, 市立函館病院, 日本語
  • C型慢性肝炎に対するインターフェロン療法著効7年後に発症した細胆管癌成分に富む混合型肝癌の1例
    山本 義也; 林 秀幸; 中井 正人; 井上 弘行; 小川 浩司; 山本 文泰; 畑中 一映; 片桐 雅樹; 成瀬 宏仁; 吉田 淳; 鈴木 伸作; 倉内 宣明; 木村 純; 工藤 和洋; 下山 則彦, 函館医学誌, 33, 1, 11, 14, 2009年10月
    上腹部痛を主訴とするC型慢性肝炎の71歳男性について検討した。7年前インターフェロン(IFN)治療を受け、Sustained virological response(SVR)と判定されていた。腹部超音波検査、腹部造影CT検査、CTAP/CTHAで肝細胞癌と診断し、肝S6亜区域切除術を行った。腫瘍は25×25mm大で、褐色調で膨張性発育を呈する部分と白色調で硬い領域が存在した。肉眼上褐色調の領域はmid trabecular patternを示し、Edmondson II型の中分化型肝細胞癌で、Cytokeratin(CK)8/81、HEP-PAR1、CK7が陽性、CK19、粘液染色は陰性であった。白色調の領域はantler patternを示し、細胆管癌様で、CK8/81、CK7が陽性、HEP-PAR1、CK19、粘液染色は陰性であった。粘液産生を伴う典型的肝内胆管癌成分は認められないものの、肝細胞癌、胆管系の癌の両方が明瞭に区分されて存在し、混合型肝癌であった。, 市立函館病院, 日本語
  • 十二指腸乳頭部異所性膵の1例
    佐藤 木の実; 倉内 宣明; 吉田 淳; 向井 信貴; 工藤 和洋; 下山 則彦; 中井 正人; 成瀬 宏仁; 脇屋 太一; 青柳 武史; 笠島 浩行; 原 豊; 鈴木 伸作; 遠山 茂; 木村 純, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 21回, 411, 411, 2009年06月
    (一社)日本肝胆膵外科学会, 日本語
  • 診断が困難であった十二指腸乳頭部異所性膵の1例
    佐藤 木の実; 倉内 宣明; 鈴木 伸作; 吉田 淳; 丸山 将輝; 向井 信貴; 成瀬 宏仁; 中井 正人; 下山 則彦; 工藤 和洋, 北海道外科雑誌, 54, 1, 52, 53, 2009年06月
    北海道外科学会, 日本語
  • 当院における消化管内分泌細胞癌の検討
    畑中一映; 林秀幸; 中井正人; 井上弘行; 小川浩司; 山本文泰; 山本義也; 片桐雅樹; 成瀬宏仁; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 106, A356, 2009年03月20日
    日本語
  • 集学的治療により長期無再発生存中のリンパ節転移を有した肝細胞癌の二例
    山本 義也; 林 秀幸; 中井 正人; 井上 弘行; 小川 浩司; 山本 文泰; 畑中 一映; 片桐 雅樹; 成瀬 宏仁; 吉田 淳; 鈴木 伸作; 倉内 宣明; 木村 純; 工藤 和洋; 下山 則彦; 浅香 正博, 日本消化器病学会雑誌, 106, 臨増総会, A419, A419, 2009年03月
    (一財)日本消化器病学会, 日本語
  • 十二指腸癌の4例
    片桐 雅樹; 林 秀幸; 中井 正人; 井上 弘行; 小川 浩司; 山本 文泰; 畑中 一映; 山本 義也; 成瀬 宏仁; 原 豊; 遠山 茂; 木村 純; 工藤 和洋; 下山 則彦; 浅香 正博, 日本消化器病学会雑誌, 106, 臨増総会, A453, A453, 2009年03月
    (一財)日本消化器病学会, 日本語
  • 内科における内視鏡的胃粘膜切開剥離術(ESD)のまとめ
    片桐 雅樹; 林 秀幸; 井上 弘行; 中井 正人; 小川 浩司; 山本 文泰; 畑中 一映; 山本 義也; 成瀬 宏仁; 工藤 和洋; 下山 則彦, 道南医学会大会並びに総会プログラム・抄録集, 61回, 55, 55, 2008年11月
    道南医学会, 日本語
  • 集学的治療が奏功した胃小細胞癌の1例
    中井 正人; 小川 浩司; 江藤 和範; 山本 文泰; 畑中 一映; 山本 義也; 片桐 雅樹; 成瀬 宏仁; 原 豊; 工藤 和洋; 下山 則彦, 函館医学誌, 32, 1, 23, 27, 2008年10月
    上腹部痛と全身倦怠感を主訴とした50歳代男性症例について検討した。心窩部に圧痛を認め、炎症反応の軽度上昇、高度貧血がみられた。癌胎児性抗原(CEA)、CA 19-9は正常範囲であったが、NSEは高値であった。GIF・上部消化管造影では、胃前提部後壁を中心とする巨大な潰瘍底を伴う2型腫瘍を認めた。生検では、N/C比が高くクロマチンに富み、核の切れ込み像をもつ異型度の高い細胞の集塊を認めた。免疫染色はAE1/AE3陽性、synaptophisin(+)、chromogranin A(+)、NCAM(+)であった。胃小細胞癌、T4N3H0P0M0のcStage IVと診断した。シスプラチン(CDDP)+塩酸イリノテカン(CPT-11)、TS-1+CDDP、カルボプラチン(CBDCA)+エトポシド(VP-16)といった全身化学療法、放射線療法、姑息的手術を行った。これらには一定の効果を認めたが、腹腔内残存原発巣の増大、転移巣の増悪から全身状態が悪化し、第410病日に死亡した。胃小細胞癌の原発巣に対しても、積極的な放射線療法にて一定の効果が期待できる症例が存在することが示唆された。, 市立函館病院, 日本語
  • 小腸癌転移病変にIRISが奏効した1例
    畑中 一映; 林 秀幸; 中井 正人; 井上 弘行; 小川 浩司; 山本 文泰; 山本 義也; 片桐 雅樹; 成瀬 宏仁; 工藤 和洋; 坂田 幸雄; 辻 龍一; 小松 嘉人, 日本癌治療学会誌, 43, 2, 935, 935, 2008年10月
    (一社)日本癌治療学会, 日本語
  • 腹腔鏡下肝生検にて診断し得た肝硬化性血管腫の1例
    吉田 淳; 倉内 宣明; 鈴木 伸作; 青柳 武史; 向井 信貴; 丸山 将輝; 工藤 大輔; 笠島 浩行; 原 豊; 遠山 茂; 中井 正人; 山本 義也; 成瀬 宏仁; 木村 純, 日本臨床外科学会雑誌, 69, 3, 712, 712, 2008年03月
    日本臨床外科学会, 日本語
  • 胃前庭部小彎幽門輪より十二指腸球部に達した早期胃癌にESDを施行した1例
    片桐 雅樹; 中井 正人; 江藤 和範; 小松 康之; 小川 浩司; 山本 文泰; 畑中 一映; 山本 義也; 成瀬 宏仁; 工藤 和洋; 下山 則彦, 道南医学会大会並びに総会プログラム・抄録集, 60回, 28, 28, 2007年11月
    道南医学会, 日本語
  • 硬化性胆管炎を伴った自己免疫性膵炎の一例
    中井 正人; 永坂 敦; 藤澤 孝志; 才川 大介; 荘 拓也; 横山 仁; 佐野 公昭; 西川 秀司; 樋口 晶文, 市立札幌病院医誌, 67, 1, 59, 65, 2007年09月
    市立札幌病院, 日本語
  • 悪性腹膜中皮腫の3例
    畑中 一映; 中井 正人; 小松 康之; 江藤 和範; 小川 浩司; 山本 文泰; 山本 義也; 片桐 雅樹; 成瀬 宏仁; 下山 則彦; 小松 嘉人, 日本癌治療学会誌, 42, 2, 827, 827, 2007年09月
    (一社)日本癌治療学会, 日本語
  • 【透析患者における難治性感染症 最新の診断と治療】 難治性MRSA感染症 外科領域
    佐野 秀一; 武田 圭佐; 中井 正人; 斉藤 容子; 石角 鈴華; 山田 純一, 臨床透析, 22, 2, 167, 174, 2006年02月
    (株)日本メディカルセンター, 日本語
  • 術前診断が困難であった腸間膜血腫の1例
    才川 大介; 斉藤 琢巳; 庄中 達也; 鈴木 美櫻; 中井 正人; 馬場 基; 武田 圭佐; 大川 由美; 田口 和典; 三澤 一仁; 佐野 秀一, 市立札幌病院医誌, 65, 2, 285, 286, 2005年12月
    75歳男.下腹部不快感を主訴に受診し,右下腹部に可動性良好な腫瘤を触知した.腹部超音波,CT,MRIにて確定診断できなかったが,悪性腫瘍が否定できず開腹術を行った.術中所見は回盲部に腫瘤を触れ,虫垂原発の悪性腫瘍が強く疑われた.回盲部切除およびD3郭清を行った.摘出標本は充実性腫瘍で回腸間膜に局在し,病理学的には,陳旧変性した出血層の周辺に膠原繊維の発達した結合織に覆われており,器質化した血腫の所見であった, 市立札幌病院, 日本語
  • 食道裂孔ヘルニアを伴った胃噴門部GISTの一例
    中井 正人; 武田 圭佐; 原田 亮; 馬場 基; 三澤 一仁; 才川 大介; 鈴木 美櫻; 庄中 達也; 斉藤 琢巳; 大川 由美; 田口 和典; 佐野 秀一, 市立札幌病院医誌, 65, 2, 283, 284, 2005年12月
    72歳男.嚥下困難と吃逆を主訴に受診し,上部消化管内視鏡にて腫瘍を認めたため精査目的で入院となった.20年ほど前から胸やけを自覚し,健診にて食道裂孔ヘルニアを指摘されていた.画像診断および生検では確定診断には至らなかったが,肉眼上胃噴門部の悪性腫瘍と考え,胃全摘術を行った.病理組織学的所見より,c-kit陰性の消化管間葉系腫瘍と診断した, 市立札幌病院, 日本語
  • 腹膜原発と考えられる癌の2症例
    武田 圭佐; 中井 正人; 馬場 基; 原田 亮; 鈴木 美櫻; 才川 大介; 庄中 達也; 斉藤 琢己; 大川 由美; 田口 和典; 三澤 一仁; 佐野 秀一, 北海道外科雑誌, 50, 2, 171, 171, 2005年12月
    北海道外科学会, 日本語
  • 術前診断が困難であった腸間膜血腫の1例
    才川 大介; 庄中 達也; 鈴木 美櫻; 中井 正人; 馬場 基; 斉藤 琢己; 武田 圭佐; 大川 由美; 田口 和典; 三澤 一仁; 佐野 秀一, 北海道外科雑誌, 50, 2, 154, 154, 2005年12月
    北海道外科学会, 日本語
■ 書籍等出版物
■ 講演・口頭発表等
  • 当院において経皮経脾静脈アプローチによるIVRを施行した2例
    高柳 歩; 阿保 大介; 森田 亮; 高橋 文也; 木野田 直也; 加藤 大祐; 藤井 宝顕; 山崎 康之; 中西 喜嗣; 荘 拓也; 中井 正人; 平野 聡; 工藤 與亮
    日本インターベンショナルラジオロジー学会雑誌, 2024年04月, (一社)日本インターベンショナルラジオロジー学会, 日本語
    2024年04月 - 2024年04月
  • 昏睡型亜急性型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
    松井 双葉; 後藤 了一; 川村 典生; 渡辺 正明; 金沢 亮; 津坂 隼也; 松居 剛志; 中井 正人; 荘 拓也; 小川 浩司; 嶋村 剛; 武冨 紹信
    日本外科学会定期学術集会抄録集, 2024年04月, (一社)日本外科学会, 日本語
    2024年04月 - 2024年04月
  • 食道胃静脈瘤に対し経皮経脾静脈瘤塞栓術を施行した1例
    保浦 直弘; 大原 正嗣; めの 晃光; 甲谷 理紗子; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 阿保 大介; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2024年03月, 日本消化器病学会-北海道支部, 日本語
    2024年03月 - 2024年03月
  • 北海道における肝炎医療コーディネーター養成研修会の実施状況の変遷に関する検討
    大原 正嗣; 小川 浩司; 長谷川 智子; 櫻井 菜々子; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉
    肝臓, 2023年10月, (一社)日本肝臓学会, 日本語
    2023年10月 - 2023年10月
  • IMbrave150基準外症例におけるアテゾリズマブ+ベバシズマブ併用療法の生存に寄与する因子の検討 多施設共同研究
    荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉
    日本消化器病学会雑誌, 2023年10月, (一財)日本消化器病学会, 日本語
    2023年10月 - 2023年10月
  • 肝肺症候群を合併したBudd-Chiari症候群の1例
    保浦 直弘; 目野 晃光; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2023年09月, 日本消化器病学会-北海道支部, 日本語
    2023年09月 - 2023年09月
  • 腹腔鏡下横隔膜縫合術、腹腔静脈シャント術により体液コントロールされた肝硬変の1例
    目野 晃光; 小川 浩司; 保浦 直弘; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 得地 祐匡; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 武藤 潤
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2023年09月, 日本消化器病学会-北海道支部, 日本語
    2023年09月 - 2023年09月
  • 肝癌患者におけるマニュアルトレース法による筋肉量と皮下脂肪CT値評価の有用性の検討
    大原 正嗣; 須田 剛生; 佐々木 貴志; 甲谷 理紗子; 細田 峻一; 吉田 苑永; 得地 祐匡; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉
    肝臓, 2023年09月, (一社)日本肝臓学会, 日本語
    2023年09月 - 2023年09月
  • 肝細胞腺腫との鑑別が困難であった限局性結節性過形成の1例
    吉田 苑永; 小川 浩司; 佐々木 貴志; 甲谷 理紗子; 細田 峻一; 久保 彰則; 得地 祐匡; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2023年03月, 日本消化器病学会-北海道支部, 日本語
    2023年03月 - 2023年03月
  • BCLCステージB2肝癌に対してアテゾリズマブ+ベバシズマブ併用療法と焼灼療法にてCancer Freeが得られた1症例
    細田 峻一; 荘 拓也; 佐々木 貴志; 甲谷 理紗子; 吉田 苑永; 得地 祐匡; 大原 正嗣; 中井 正人; 須田 剛生; 小川 浩司; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2023年03月, 日本消化器病学会-北海道支部, 日本語
    2023年03月 - 2023年03月
  • BavenoVI分類とYerdel分類を用いた肝疾患に伴う門脈血栓症に対するアンチトロンビンIII製剤の治療効果の検討
    中井 正人; 小川 浩司; 佐々木 貴志; 甲谷 理紗子; 吉田 苑永; 細田 俊一; 得地 祐匡; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉
    日本消化器病学会雑誌, 2023年03月, (一財)日本消化器病学会, 日本語
    2023年03月 - 2023年03月
  • 切除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
    荘 拓也; 出水 孝章; 目黒 高志; 中村 晃久; 上林 実; 高木 智史; 馬場 英; 古家 乾; 鈴木 和治; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年09月, 日本消化器病学会-北海道支部, 日本語
    2022年09月 - 2022年09月
  • 肝血管筋脂肪腫の1切除例
    佐々木 貴志; 甲谷 理紗子; 細田 峻一; 吉田 苑永; 得地 祐匡; 久保 彰則; 大原 正嗣; 須田 剛生; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉; 相山 健; 武冨 紹信; 岡崎 ななせ; 松野 吉宏
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年09月, 日本消化器病学会-北海道支部, 日本語
    2022年09月 - 2022年09月
  • 肝硬変体液貯留に対するトルバプタン投与症例における尿NGAL測定の有用性
    中井 正人; 森川 賢一; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 大原 正嗣; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉
    肝臓, 2022年09月, (一社)日本肝臓学会, 日本語
    2022年09月 - 2022年09月
  • 再活性化が疑われた急性E型肝炎の1例
    久保 彰則; 小川 浩司; 吉田 苑永; 細田 峻一; 得地 祐匡; 山田 錬; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 石田 勢津子; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年03月, 日本消化器病学会-北海道支部, 日本語
    2022年03月 - 2022年03月
  • 若年女性に見られた肝細胞腺腫症の1例
    北潟谷 隆; 吉田 苑永; 細田 俊一; 久保 彰則; 得地 祐匡; 山田 錬; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 高桑 恵美; 中島 収
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年03月, 日本消化器病学会-北海道支部, 日本語
    2022年03月 - 2022年03月
  • 肝癌に対する新世代マイクロ波凝固療法の治療成績
    中井 正人; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年03月, 日本消化器病学会-北海道支部, 日本語
    2022年03月 - 2022年03月
  • 当院における切除不能肝細胞癌に対するAtezolizumab+Bevacizumab併用療法の使用経験
    吉田 苑永; 荘 拓也; 久保 彰則; 得地 祐匡; 細田 峻一; 北潟谷 隆; 山田 錬; 中井 正人; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2021年09月, 日本消化器病学会-北海道支部, 日本語
    2021年09月 - 2021年09月
  • Lenvatinib加療後にCRに至りconversion surgeryを施行した肝内多発転移を伴う肝細胞癌の1例
    細田 峻一; 中井 正人; 吉田 苑永; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 岡崎 ななせ; 大塚 拓也; 三橋 智子
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2021年09月, 日本消化器病学会-北海道支部, 日本語
    2021年09月 - 2021年09月
  • Transient elastographyによるLSMと年齢を用いたSVR後肝発癌低リスク群の囲い込み
    中井 正人; 山本 義也; 馬場 英; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 古家 乾; 坂本 直哉
    肝臓, 2021年09月, (一社)日本肝臓学会, 日本語
    2021年09月 - 2021年09月
  • 除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療経験:多施設共同研究
    荘 拓也; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2021年09月, (一社)日本肝臓学会, 日本語
    2021年09月 - 2021年09月
  • 部分的脾動脈塞栓術(PSE)、バルーン閉塞下逆行性経静脈的塞栓術(B-RTO)の肝予備能、線維化マーカー、予後への影響
    中井 正人; 小川 浩司; 坂本 直哉; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一
    肝臓, 2021年04月, (一社)日本肝臓学会, 日本語
    2021年04月 - 2021年04月
  • 肝機能障害を契機に診断された肝ヘモクロマトーシスの一例
    吉田 苑永; 中井 正人; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2021年03月, 日本消化器病学会-北海道支部, 日本語
    2021年03月 - 2021年03月
  • 経過観察中に増大傾向がみられ、肝切除術に至った肝原発神経内分泌腫瘍の1例
    久保 彰則; 小川 浩司; 得地 祐匡; 山田 錬; 北潟谷 隆; 重沢 拓; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2021年03月, 日本消化器病学会-北海道支部, 日本語
    2021年03月 - 2021年03月
  • 胆嚢転移を来した原発性肝細胞癌再発の1例
    得地 祐匡; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 荘 拓也; 小川 浩司; 森川 賢一; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2021年03月, 日本消化器病学会-北海道支部, 日本語
    2021年03月 - 2021年03月
  • 肝性脳症〜わが国における現状と課題〜 肝性脳症の疫学
    中井 正人; 小川 浩司; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
    日本門脈圧亢進症学会雑誌, 2020年10月, (一社)日本門脈圧亢進症学会, 日本語
    2020年10月 - 2020年10月
  • HCC既往の無いC型肝炎SVR後の初発肝発癌の囲い込み因子としての肝弾性度の有用性
    中井 正人; 山本 義也; 馬場 英; 古家 乾; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2020年09月, (一社)日本肝臓学会, 日本語
    2020年09月 - 2020年09月
  • 免疫チェックポイント阻害剤関連肝炎の頻度、予測因子、臨床経過の検討
    北潟谷 隆; 須田 剛生; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2020年09月, (一社)日本肝臓学会, 日本語
    2020年09月 - 2020年09月
  • トルバプタン奏効後の再燃と炎症および尿L-FABP値の関連
    中井 正人; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2020年04月, (一社)日本肝臓学会, 日本語
    2020年04月 - 2020年04月
  • C型肝炎患者の血清Angiopoietin-2値はDAAs治療後の肝線維化非改善例を予測する
    川岸 直樹; 須田 剛生; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2019年10月, (一社)日本肝臓学会, 日本語
    2019年10月 - 2019年10月
  • カルニチンは肝硬変患者における筋肉量減少を抑制する
    大原 正嗣; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 川岸 直樹; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2019年10月, (一社)日本肝臓学会, 日本語
    2019年10月 - 2019年10月
  • 進行肝細胞癌に対するレンバチニブ投与症例からみた適格使用時期の検討
    荘 拓也; 須田 剛生; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2019年10月, (一社)日本肝臓学会, 日本語
    2019年10月 - 2019年10月
  • RFA/TACE前後のM2BPGiの変化とRFA後再発予測因子としてのM2BPGiの有用性
    中井 正人; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 伊藤 淳; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2017年04月, 日本語
  • 各種抗HCV治療に伴う肝線維化マーカー変化とSVR後の肝発癌予測因子としてのM2BPGi
    中井 正人; 小川 浩司; 坂本 直哉
    肝臓, 2016年04月, 日本語
  • 肝硬変治療の進歩 肝性腹水・浮腫に対するトルバプタンの効果と尿中アクアポリン2の関係
    中井 正人; 小川 浩司; 坂本 直哉
    肝臓, 2015年11月, 日本語
  • B型慢性肝炎に対するテノホビル(TDF)の初期使用経験と短期効果の検討
    中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
    肝臓, 2015年09月, 日本語
  • 当科におけるC型肝炎SVR後の肝発癌症例の検討 発癌率と危険因子
    中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 森川 賢一; 夏井坂 光輝; 小川 浩司; 坂本 直哉
    肝臓, 2015年04月, 日本語
  • ヒト初代B細胞におけるHCVcc感染
    中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; フセイン・ハッサン・アリ; 松本 美佐子; 瀬谷 司; 坂本 直哉
    日本消化器病学会雑誌, 2015年03月, 日本語
  • 非代償性肝硬変に伴う胸腹水および肝腎症候群に対するトルバプタン使用例の検討
    中井 正人; 伊藤 淳; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; 坂本 直哉
    肝臓, 2014年09月, 日本語
  • Precore/Core promoter変異とB型肝炎の病態および抗HBV治療
    中井 正人; 小林 智絵; 荘 拓也; 中西 満; 中馬 誠; 髭 修平
    肝臓, 2011年04月, 日本語
  • B型肝炎診療の現在・未来 HBe抗体陽性B型肝炎に対する核酸アナログ中止条件の検討
    中井 正人; 髭 修平; 中馬 誠
    肝臓, 2010年10月, 日本語
■ 主な担当授業
  • 医学総論, 2024年, 博士後期課程, 医学研究科
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ 共同研究・競争的資金等の研究課題
  • 腸管滅菌/プロバイオティクスによる難治性腹水に対する新規治療方法の探索
    科学研究費助成事業
    2022年04月01日 - 2025年03月31日
    中井 正人
    日本学術振興会, 若手研究, 北海道大学, 22K15954
  • HBV感染における自然免疫系センサー分子の探索
    科学研究費助成事業
    2016年04月01日 - 2020年03月31日
    中井 正人
    HBV急性感染時のHBV-DNAに対する核酸認識や自然免疫機構は不明な点が多く、慢性感染では免疫寛容状態が成立し、HBV完全閉鎖2本鎖DNAが核内に残存し完全排除は困難である。本研究では細胞内DNAセンサー分子のHBV感染、HBV-DNA複製に対する影響と免疫応答に関して検討した。
    DNAセンサー分子のうち、特にDDX41に着目し、各種肝細胞株における発現を解析した。DDX41を恒常的ノックダウンしたNTCP-C4-HepG2細胞を作成し、HBVウイルス感染を行った場合、HBV-DNA,RNAがコントロールと比較して早期に増加した。DDX41がHBVの増殖を肝細胞内にて抑制する結果が示唆された。
    日本学術振興会, 若手研究(B), 北海道大学, 16K19324